

IN THE UNITED STATES DISTRICT COURT FOR THE
MIDDLE DISTRICT OF TENNESSEE
NASHVILLE DIVISION

RUTH SMITH, Individually and as Widow for the)	
Use and Benefit of Herself and the Next Kin of)	
Richard Smith, Deceased,)	
)	
Plaintiff,)	Civil No. 3:05-0444
)	Judge Aleta A. Trauger
v.)	(Dist. Of MA No.
)	1:05-cv-11515PBS)
PFIZER, INC., <i>et al.</i> ,)	
)	
Defendants.)	

DEFENDANTS' TRIAL EXHIBIT LIST

Defendants, Pfizer Inc ("Pfizer") and Warner-Lambert Company LLC ("Warner-Lambert") (collectively, "Defendants"), by and through their undersigned counsel, hereby list the exhibits which may be offered at trial. Defendants submit these exhibits conditionally and without waiver of their right to object on grounds of relevancy, prejudice, or any other ground to the subject matter of the exhibits, and reserve their right to use any or all of these exhibits as rebuttal evidence in the event that their objections to Plaintiff's evidence are overruled. In submitting this exhibit list, Defendants specifically reserve the right to: 1) withdraw at any time any exhibit identified on this list; 2) supplement and/or amend this list in the event that additional relevant materials are produced in this action or are discovered subsequent to the date of service of this list; 3) supplement and/or amend this list to use additional exhibits at trial as required for authentication, rebuttal or impeachment and/or as necessitated by evidence presented by Plaintiff; 4) supplement and/or amend this list to add exhibits related to and including depositions that have not yet been taken or with regard to which a deposition transcript is not yet available; 5) supplement and/or amend this list in response to the Court's rulings on pretrial

motions or other evidentiary matters; and 6) supplement and/or amend this list as otherwise permitted by this Court. Finally, Defendants reserve their right to use any document listed on Plaintiff's exhibit list, as well as to use demonstratives at trial to support witness testimony.

Smith v. Pfizer Inc., et al., Middle District of Tennessee Civil No. 3:05-0444 Defendants' Trial Exhibit List		
EX. NO.	DESCRIPTION	DATE
D-1	Richard Smith's National Health Laboratories Medical Records.	
D-2	Richard Smith's Wood, Christopher L. DDS, Dental Records.	
D-3	Richard Smith's Berklacich, Frank M. MD, Medical Records.	
D-4	Richard Smith's Action Quick Corporation, Medical Records.	
D-5	Richard Smith's Baptist Hospital, Medical Records.	
D-6	Richard Smith's Blue Cross and Blue Shield of Tennessee, Insurance Records.	
D-7	Richard Smith's Cardiology Group of Middle Tennessee, Medical Records.	
D-8	Richard Smith's Centennial Medical Center, Medical Records.	
D-9	Richard Smith's Centers for Medicare and Medicaid Services, Insurance Records.	
D-10	Richard Smith's Colon & Rectal Surgery Associates, Medical Records.	
D-11	Richard Smith's Dyer, David N. MD, Medical Records.	
D-12	Richard Smith's Eckerd Drugs, Pharmacy Records.	
D-13	Richard Smith's Hampf, Carl MD, Medical Records.	
D-14	Richard Smith's Harwell, William B., Jr. MD, Medical Records.	
D-15	Richard Smith's Heart & Vascular Clinic, Medical Records.	

D-16	Richard Smith's Heritage Medical Associates, Medical Records.	
D-17	Richard Smith's Loden Vision Center, Optometry Records.	
D-18	Richard Smith's Nashville Orthopedic Associates, Medical Records.	
D-19	Richard Smith's Neurological Surgeons, Medical Records.	
D-20	Richard Smith's Neurosurgical Associates, Medical Records.	
D-21	Richard Smith's Otolaryngology Associates of Tennessee, Medical Records.	
D-22	Richard Smith's Outpatient Diagnostic Center, Medical Records.	
D-23	Richard Smith's Premier Radiology, Medical Records.	
D-24	Richard Smith's Saint Thomas Hospital, Medical Records.	
D-25	Richard Smith's Southern Sports Medicine records.	
D-26	Richard Smith's Spalding & Nesbitt Urology Clinic, Medical Records.	
D-27	Richard Smith's Specialized Assays, Medical Records.	
D-28	Richard Smith's Tennessee Orthopedic Alliance, Medical Records.	
D-29	Richard Smith's University Medical Center, Medical Records.	
D-30	Richard Smith's Vanderbilt University Medical Center, Medical Records.	
D-31	Richard Smith's Willowbrook Home Care Agencies, Medical Records.	
D-32	Richard Smith's Woods, Christopher L. DDS, Dental Records.	
D-33	Richard Smith's Plaintiff Produced Records.	
D-34	Richard Smith's Associated Urologists of Nashville records.	
D-35	Richard Smith's Powers Chiropractic Clinic records.	

D-36	Richard Smith's CVS records.	
D-37	Richard Smith's Elite Sports Medicine records.	
D-38	Richard Smith's Midstate Cardiology records.	
D-39	Richard Smith's Nashville Internal Medicine Associates records.	
D-40	Richard Smith's Rite Aid records.	
D-41	Richard Smith's Schull, David, M.D. records.	
D-42	Richard Smith's Premier Orthopedics and Sports Medicine records.	
D-43	Richard Smith's Stasko, Thomas records.	
D-44	Richard Smith's Urology Associates records.	
D-45	Richard Smith's Mohs Micrographic Surgery and Dermatology records.	
D-46	Richard Smith's Walgreen's records.	
D-47	Richard Smith's McCombs, Paul, M.D. records.	
D-48	Richard Smith's Medicare records.	
D-200	Richard Smith's W-2 Forms.	
D-201	Richard Smith's Nashville Office Machines, Employment Records.	
D-202	Richard Smith's IRS Tax Return Records.	
D-203	Metropolitan Nashville Police Department, Records.	
D-204	Autopsy Records.	
D-205	Plaintiff's Response to Defendants' First Set of Interrogatories.	
D-206	Death Certificate.	

D-207	Suicide Note.	
D-208	Obituary.	
D-209	Letters Testamentary.	
D-210	Letter from M. Richer to A. Seaton re: additional Information.	2/16/2007
D-211	Berkklacich, Frank M.D. - Medical Records marked at deposition.	
D-212	Medical Examination Report marked at the deposition of Gary Wayne Biggs.	
D-213	Gary Wayne Biggs Notes.	
D-214	Gary Wayne Biggs Investigation Fee Schedule.	
D-215	Photograph of Dresser Top with Suicide Note.	
D-216	Photograph of Dresser Top without Suicide Note.	
D-217	Photograph of Suicide Note - Close Up.	
D-218	Metropolitan Police Department Report by Danny Satterfield marked at the deposition of Gary Wayne Biggs.	
D-219	C.V. - Curriculum Vitae of James Cato, M.D.	
D-220	Medical records marked at the deposition of James Cato, M.D.	
D-221	C.V. - Curriculum Vitae of Carl Hampf, M.D.	
D-222	Notice to Take Deposition of Carl Hampf, M.D.	
D-223	Invoice to Richard Smith from Carl Hampf, M.D.	
D-224	Medical records marked at the deposition of Carl Hampf, M.D.	
D-225	Medical records marked at the deposition of Pamela Krancer, APN	
D-226	Suicide Note.	

D-227	C.V. - Curriculum Vitae of Feng Li, M.D., J.D., Ph.D.	
D-228	Medical records marked at the deposition of Feng Li, M.D., J.D., Ph.D.	
D-229	C.V. - Curriculum Vitae of Edward Mackey, M.D.	
D-230	Medical records marked at the deposition of Edward Mackey, M.D.	
D-231	Medical records marked at the deposition of Paul R. McCombs, III M.D.	
D-232	McCombs, Paul R. III (M.D.) Deposition - Ex. 3.	
D-233	Police records marked at the deposition of Danny Satterfield.	
D-234	Photograph of Suicide Note - Close Up.	
D-235	Medical records marked at the deposition of Danny Satterfield.	
D-236	Medical records marked at the deposition of Ruth Smith.	
D-237	Page from Questionnaire marked at the deposition of Ruth Smith.	
D-238	Pharmacy records marked at the deposition of Ruth Smith.	
D-239	Pharmacy records marked at the deposition of Ruth Smith.	
D-240	Medical records marked at the deposition of Ruth Smith.	
D-241	Medical records marked at the deposition of Ruth Smith.	
D-242	Expert from Plaintiff's Response to First Set of Interrogatories marked at the deposition of Ruth Smith.	
D-243	Pharmacy records marked at the deposition of Ruth Smith.	
D-244	Medical records marked at the deposition of Ruth Smith.	
D-245	Medical records marked at the deposition of Cindy Smith-Charlton.	
D-246	Medical records marked at the deposition of Stewart Stowers.	

D-247	C.V. - Curriculum Vitae of Stewart Stowers.	
D-248	Dental records marked at the deposition of Chris L. Wood.	
D-249	Samples of Neurontin or other medications or containers in possession of the Smith family.	
D-250	Photographs of Neurontin or other medications or containers in possession of the Smith Family to be taken at a future date upon agreement of the parties.	
D-252	Transcript of 911 call.	
D-253	Douglas Jacobs, M.D. Expert Report.	11/10/2008
D-254	Peter M. Donofrio, M.D. Expert Report.	11/10/2008
D-255	Peter M. Donofrio, M.D. C.V.	
D-256	Robert P. Granacher, M.D., M.B.A. Expert Report.	
D-257	Robert P. Granacher, M.D., M.B.A. C.V.	12/16/2004
D-258	Richard Smith's Church of Christ at Trinity Lane records.	
D-259	Richard Smith's Gilroy Church of Christ records.	
D-260	Richard Smith's Jackson Park Church of Christ records.	
D-261	Peter D. Donofrio, M.D. Notes.	
D-262	Peter D. Donofrio, M.D. Notes.	
D-263	A 52-Year-Old Suicidal Man by Douglas G. Jacobs JAMA, 2000;283(20);2693-2699.	
D-264	List of Documents reviewed by Douglas G.Jacobs, M.D.	
D-265	Medical Chronology of Richard Smith.	
D-266	Smith: 911 Call Tape Transcript marked at the deposition of Douglas G.Jacobs, M.D.	

J-300	Suicide Over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients (Blumenthal, S., et al. American Psychiatric Press, Inc.).	1990
J-301	Comprehensive Textbook of Suicidology (Ronald W. Maris, et al.).	2000
J-302	Reference Guide on Epidemiology (Green, M., et al. Reference Manual on Scientific Evidence, 2nd ed., 2000).	2000
J-303	Schatzberg, Alan F. M.D., et al., Textbook of Psychopharmacology, 736-739 (Am. Psych. Pub. 3rd ed. 2004) (2000).	2000
J-304	Schatzberg, AF and Nemeroff, C. eds. Textbook of Psychopharmacology, 3rd ed. APA Press, Washington, 2004.	2004
J-305	DSM IV.	2001
J-306	Modern Epidemiology 3rd Edition by Greenland and Rotham.	1998
J-307	Daniel Klein and Alexander Tabarrok, "Who Certifies Off-Label," Regulation 60-63 (Summer 2004).	Summer 2004
J-308	Acosta GB, Losada MEO, Rubio MC (1993): Area-dependent changes in GABAergic function after acute and chronic cold stress. Neuroscience Letters 154:175-178.	1993
J-309	Acosta GB, Rubio MC (1994): GABAA receptors mediate the changes produced by stress on GABA function and locomotor activity. Neuroscience Letters 176:29-31.	1994
J-310	Ahmad SR, Goetsch RA, Marks NS. Chapter 9, Spontaneous reporting in the United States. In: Pharmacoepidemiology. 4th Edition. Strom Bed. Wiley & Sons. England. 2005.	2005
J-311	Ahn HS, Choi JS, Choi BH, Kim MJ, Rhie DJ, Yoon SH, et al (2005): Inhibition of the cloned delayed rectifier K ⁺ channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 133:1007-1019.	2005
J-312	Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, et al (2006): Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319:323-331.	2006
J-313	Ahn SH, Park HW, Lee BS, et al. Gabapentin Effect on Neuropathic Pain Compared Among Patients with Spinal Cord Injury and Different Durations of Symptoms. Spine. 2003; 28(4):341-47.	2003
J-314	Ahrens B et al. Excess cardiovascular and suicide mortality of affective disorders may be reduced by lithium prophylaxis. J Affect Disorder 1995; 33:67-75.	1995
J-315	Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE, Jr., Jones EG (1995): Gene expression for glutamic acid decarboxylase is reduced without loss of	1995

	neurons in prefrontal cortex of schizophrenics [see comments]. Archives of General Psychiatr.	
J-316	Almenoff, JS., LaCroix, KK., Yuen, NA., Fram, D., DuMouchel, W. Comparative performance of two quantitative safety signaling methods: implications for use in a pharmacovigilance department. Drug Safety 2006; 29(10):875-887.	2006
J-317	Alsheikh-Ali, A., Ambrose, M., Kuvin, J., Karas, R. The Safety of Rosuvastatin as Used in Common Clinical Practice: A Postmarketing Analysis. Circulation 2005; 111(23):3051-3057.	2005
J-318	Altshuler L. et al. Temporal lobe epilepsy, temporal lobe epilepsy, temporal lobectomy and major depression. J Neuropsychiatry Clin Neurosci 1999; 11 :436-43.	1999
J-319	Altshuler LL, et al.: Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1:61-5, 1999.	1999
J-320	American Academy of Pain Medicine and the American Pain Society. Consensus Statement: The Use of Opioids for the Treatment of Chronic Pain. 1997.	1997
J-321	American Psychiatric Association TFoE (1990): The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging,. Convulsive Therapy 6:85-120.	1990
J-322	American Psychiatric Association. APA Practice Guidelines for the Assessment and Treatment of Patients with Suicidal Behaviors. American Journal of Psychiatry 2004; 160 (11).	2004
J-323	American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Practice Guidelines for Chronic Pain Management. Anesthesiology. 1997; 86:995-1004.	1997
J-324	Andrews N, Loomis S, Blake R, Ferrigan L, Singh L, McKnight AT. Effect of Gabapentin-like compounds on development and maintenance of morphine-induced conditioned place preference. Psychopharmacology 2001;157(4):381-387.	2001
J-325	Angehagen M, Ben-Menachem E, Shank R, Ronnback L, Hansson E. Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. 2004;88:320-325.	2004
J-326	Angst J, Angst F, Stassen HH. Suicide risk in patients with major depressive disorder. J Clin Psychiatry. 1999;60 Suppl 2:57-62.	1999
J-327	Appendix 5, Pfizer Safety and Risk Management Literature Review: Gabapentin Use Among Persons with a History of Psychotic Disorder bearing the bates range	2005

	Pfizer_Regulatory_000260.	
J-328	Apter A, Laufer N, Bar-Sever M, Har-Even D, Ofek H, Weizman A. Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric “inpatients. <i>Biol Psychiatry</i> . 1999 Aug 15;46(4):532-41.	1999
J-329	Arikkath J, Campbell KP. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. <i>Curr Opin Neurobiol</i> 2003; 13(3):298-307.	2003
J-330	Aronson JK, Hauben M. Anecdotes that provide definitive evidence. <i>BMJ</i> 2006; 333:1267-9.	2006
J-331	Arseneault, L., et al. Causal Association Between Cannabis and Psychosis: Examination of the Evidence, 2 Focus 270 (2007).	2007
J-332	Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of Gabapentin on the Different Components of Peripheral and Central Neuropathic Pain Syndromes: A Pilot Study. <i>Eur. Neural</i> . 1998; 40: 191-200.	1998
J-333	Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000): Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. <i>Biological Psychiatry</i> 47:305-313.	2000
J-334	Azbill RD, Mu X, Springer JE (2000): Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. <i>Brain Res</i> 871:175-180.	2000
J-335	Azoulay, Pierre, “Do Pharmaceutical Sales Respond to Scientific Evidence?” <i>Journal of Economics & Management Strategy</i> , Volume 11, No.4, Winter 2002.	2002
J-336	Baastrup, C. and N. B. Finnerup (2008). “Pharmacological management of neuropathic pain following spinal cord injury.” <i>CNS Drugs</i> 22(6): 455-75.	2008
J-337	Backonja M, Beydoun A, Edwards KR, et. al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus. <i>JAMA</i> . December 2, 1998; 280(21): 1831-1836.	1998
J-338	Backonja M. Gabapentin Monotherapy for the Symptomatic Treatment of Painful Neuropathy: a Multicenter, Double-Blind, Placebo-controlled Trial in Patients with Diabetes. <i>Epilepsia</i> . 1999; 40 (Suppl. 6):S57-S59.	1999
J-339	Bailey HR, Beck DE, Billingham RP, Binderow SR, Gottesman L, Hull TL, Larach SW, Margolin DA, Milsom JW, Potenti FM, Rafferty JF, Riff DS, Sands LR, Senagore A, Stamos MJ, Yee LF, Young-Fadok TM, Gibbons RD; Fissure Study Group. A study to determine the nitroglycerin	2002

	ointment dose and dosing interval that best promote the healing of chronic anal fissures. Dis Colon Rectum 2002 Sep; 45(9):1192-9.	
J-340	Baker K, Barkhuizen A. Pharmacologic Treatment of Fibromyalgia. Current Pain and Headache Reports. 2005; 9:301-306.	2005
J-341	Balazsa T, Biro J, Gullai N, Ledent C, Sperlagh B. CB(1)-cannabinoid receptors are involved in the modulation of non-synaptic [(3)h]serotonin release from the rat hippocampus. Neurochem Int 2007.	2007
J-342	Baldessarini RJ, et al. Decreased Risk of Suicides and Attempts During Long-Term Lithium Treatment: A Meta-Analytic Review. Bipolar Disorder 2006; 8:625-639.	2006
J-343	Baldessarini RJ, Pompili M, Tondo L. Suicide in Bipolar Disorder: Risks and Management. CNS Spectr 2006; 11(6):465-471.	2006
J-344	Baldessarini, RJ., Tondo, L. Suicide risk and treatments for patients with bipolar disorder. JAMA 2003; 290:1517-1519.	2003
J-345	Baldessarini, Ross J., "Lithium Treatment and Suicide Risk in Major Affective Disorders: Update and New Findings," Journal of Clinical Psychiatry, 2003:64.	2003
J-346	Baldessarini, Ross, et al., "Treating the Suicidal Patient with Bipolar Disorder Reducing Suicide Risk with Lithium," Annals New York Academy of Sciences, pp.24-43.	
J-347	Ballantyne, J.C. and J. Mao (2003). "Opioid therapy for chronic pain." N Engl J Med 349(20): 1943-53.	2003
J-348	Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 2005; 179(1):218-229.	2005
J-349	Bandini F, Castello E, Mazzella L, Mancardi GL, Solaro C. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis? Journal of Neurology, Neurosurgery, and Psychiatry 20.	2001
J-350	Baraclough, B. "Suicide and Epilepsy" in Epilepsy and Psychiatry, ed. Reynold, EH. and Trimble, MR Churchill Livingstone, New York 1981, pp. 72-76.	1981
J-351	Barbul, C., et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 2004; 109:275-78.	2004
J-352	Bartholini G, Lloyd, KG., Morselli, PL. editor (1986): GABA and Mood Disorders: Experimental and Clinical Research, Vol 4. New York: Raven Press.	1986

J-353	Baumeister and Frye. Self-injurious Behavior in Rats Produced by Intracranial Microinjection of GABA Agonists. Pharmacol Biochemical Behavior 1994; 21(1): 89-95.	1994
J-354	Bayer K, Seifollah A, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca ²⁺ channels. Neuropharmacol 2004; 46:743-749.	2004
J-355	Bell,GS, Mula, M and Sander, JW. Suicidality in People Taking Antiepileptic Drugs What is the Evidence? CNS Drugs 2009; 23(4):281-291.	2009
J-356	Belliotti T, Ekhatov IV, Capiris T, Kinsora J, Vartanian MG, Field M, Meltzer LT, Heffner T, Schwarz JB, Taylor CP, Thorpe A, Wise L, Su T-Z, Weber ML, Wustrow DJ (2005) Structure-activity relationships of pregabalin and analogs that target the $\alpha 2\text{-}\delta$ prote.	2005
J-357	Benavides J, Camelin JC, Mitrani N, Flamand F, Uzan A, Legrand JJ, et al (1985): 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--II. Biochemical properties. Neuropharmacology 24:1085-1092.	2001
J-358	Benes FM, Berretta S (2001): GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25:1-27.	2001
J-359	Ben-Menachem E, Hamberger A, Mumford J. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system--a case study. Epilepsy Research 1993; 16(3):241-243.	1993
J-360	Ben-Menachem E, Persson LI, Hedner T. Selected CSF biochemistry and Gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of Gabapentin. Epilepsy Research 1992; 11(1):45-49.	1992
J-361	Ben-Menachem E, Persson LI, Schechter PJ, Haegle KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. British Journal of Clinical Pharmac.	1989
J-362	Ben-Menachem E, Soderfelt B, Hamberger A, Hedner T, Persson LI. Seizure frequency and CSF parameters in a double-blind placebo controlled trial of Gabapentin in patients with intractable complex partial seizures. Epilepsy Research 1995; 21(3):231-236.	1995
J-363	Ben-Menachem E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsia 1989; 30 Suppl 3:S12-14.	1989
J-364	Bennett MI, Simpson KH. Gabapentin in the Treatment of Neuropathic Pain. Palliative Medicine. 2004; 18:5-11.	2004

J-365	Benoit E, Escande D (1991): Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflugers Arch 419:603-609.	1991
J-366	Benturquia N, Parrot S, Sauvinet V, Renaud B, Denoroy L. Simultaneous determination of vigabatrin and amino acid neurotransmitters in brain microdialysates by capillary electrophoresis with laser-induced fluorescence detection. Journal of Chromatography 2.	2004
J-367	Benveniste H. Brain microdialysis. Journal of Neurochemistry 1989; 52(6):1667-1679.	1989
J-368	Bergman, U., et al. Epidemiology of adverse drug reactions to phenformin and metformin. Brit Med J 1978; 2:464-66.	1978
J-369	Berlin JA and Kim CJ. Chapter 44. The use of meta-analysis in pharmacoepidemiology. In: Pharmacoepidemiology. 4th Edition. Strom Bed. Wiley & Sons. England. 2005. (electronic version).	2005
J-370	Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000): Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47:351-354.	2000
J-371	Bernasconi, R., "The GABA hypothesis of affective illness: Influence of Clinically Effective Antimanic Drugs on GABA turnover," in: Basic Mechanisms in the Action of Lithium: Proceedings of a Symposium held at Schloss Ringberg, Barvaria, FRG, Oct. 4-6, 19.	1982
J-372	Berndt, Ernst R., "Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price," The Journal of Economic Perspectives, Fall 2002.	2002
J-373	Berndt, Ernst R., "The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment?" Health Affairs, Volume 20(2), 2001.	2001
J-374	Berndt, Ernst R., Bhattacharja, Mishol, et al An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts, J Ment Health Policy Econ 5, 3-19 (2002).	1995
J-375	Berndt, Pindyck and Azoulay, "Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs," The Journal of Industrial Economics, June 2003.	2003
J-376	Berrettini, et al. Reduced Plasma and CSF Aminobutyric Acid in Affective Illness: Effect of Lithium Carbonate. Biol Psychiat 1983; 18(2):185-194.	1983
J-377	Bert Spilker, Concept of Cause and Effect, in Guide to Clinical Trials 528 (1991).	1991
J-378	Bertrand S, Morin F, Lacaille JC. Different actions of Gabapentin and baclofen in hippocampus from weaver mice. Hippocampus 2003a; 13(4):525-528.	2003

J-379	Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, Lacaille JC, Chronwall BM, Morris SJ. The anticonvulsant, antihyperalgesic agent Gabapentin is an agonist at brain gamma-aminobutyric acid type B r.	2001
J-380	Bertrand S, Nouel D, Morin F, Nagy F, Lacaille JC. Gabapentin actions on Kir3 currents and N-type Ca ²⁺ channels via GABAB receptors in hippocampal pyramidal cells. Synapse 2003; 50(2):95-109.	2003
J-381	Besag F. Psychotherapy in people with epilepsy and intellectual disability. J Neurol Neurosurg Psychiatry 2003; 74:1464.	2003
J-382	Besag FM. Behavioral effects of the new anticonvulsants. Drug Saf 2001; 24(7):513-536.	2001
J-383	Besag FM. Behavioral effects of the newer antiepileptic drugs: an update. Expert Opinion on Drug Safety 2004; 3(1):1-8.	2004
J-384	Betty A. Diamond et al., Silicone Breast Implants in Relation to Connective Tissue Diseases and Immunologic Dysfunction. A Report by a National Science Panel to the Honorable Sam C. Pointer Jr., Coordinating Judge for the Federal Breast Implant Multi-Dist.	1998
J-385	Bhagwagar Z, Wylezinska M, Jezard P, Evans J, Ashworth F, Sule A, et al (2007): Reduction in Occipital Cortex gamma-Aminobutyric Acid Concentrations in Medication-free Recovered Unipolar Depressed and Bipolar Subjects. Biol Psychiatry.	2007
J-386	Bhagwagar Z, Wylezinska M, Taylor M, Jezard P, Watthews PM, Cowen PJ (2004): Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161.	2004
J-387	Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006; 15(6):637-647.	2006
J-388	Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, Walker LC. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-.	2006
J-389	Bird SJ, Brown MJ: Diabetic Neuropathes. il Katirji B, Kaminski H, Preston D., Ruff R, Shapiro B (eds.), Neuromuscular Disorders in Clinical Practice, Butterworth-Heinemann, 2002, pp. 598-621.	2002
J-390	Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ, Petty F (2001): Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar	2001

	depressive disorder. Psychiatry Research 101:131-136.	
J-391	Böhning D, Schlattmann P, Lindsay BG. Re: "A statistical method for evaluating suicide clusters and implementing cluster surveillance". Am J Epidemiol. 1992 Jun; 135(11):1310-4.	1992
J-392	Bone M, Buggy D, Critchley P, Rowbotham D. Gabapentin Monotherapy in Post amputation Phantom Limb and Stump Pain: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study. Regional Anesthesia and Pain Medicine. September-October 2002;27(5):481-486.	2002
J-393	Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A (1988): On the role of endogenous GABA in the forced swimming test in rats. Pharmacology biochemistry & behavior 29:275-279.	1988
J-394	Bosnjak S, Jelic S, Susnajar S, et al. Gabapentin for relief of neuropathic pain related to anticancer treatment: A Preliminary Study. J. Chemother 2002; 14(20):214-9. PPI DN: 182949.	2002
J-395	Bostwck JM, Panatz VS. Affective disorders and suicide risk: a re-examination. Am J " Psychiatry. 200Q Dec;157(12):1925-32.	2000
J-396	Boswell M, Shah R, Everett C, et al. Interventional Techniques in the Management of Chronic Spinal Pain: Evidence-Based Practice Guidelines. Pain Physician. 2005;8:1-47.	2005
J-397	Botts SR, Raskind JL: Gabapentin and lamotrigine in bipolar disorder. Am J Health Syst Pharm 56(19):1939-44, Oct 1999.	1999
J-398	Bourgeois, M. Serotonin, Impulsivity and Suicide. Human Psychopharmacology 1991; 6: S31-36.	1991
J-399	Bourne JA. Intracerebral microdialysis: 30 years as a tool for the neuroscientist. Clinical and Experimental Pharmacology & Physiology 2003; 30(1-2):16-24.	2003
J-400	Bowden CL. The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse. Current Psychiatric Reports 2000; 2:490-494.	2000
J-401	Bowden C, Fawcett J. To the Editor: Pharmacotherapy and risk of suicidal behaviors among patients with bipolar disorder. JAMA 2004; 291(8):939.	2004
J-402	Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Chou JCY, Keck PE, Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57:481-489.	2000

J-403	Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 1993; 33:109-147.	1993
J-404	Bowler JM, Green AR, Minchin MCW, Nutt DJ (1983): Regional GABA concentrations and 3H-diazepam binding in rat brain following repeated electroconvulsive shock. J Neurol Transm 56:3-12.	1983
J-405	Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistic Med 2007; 26:53-77.	2005
J-406	Bradford-Hill, The environment and disease: Association or causation Royal Soc'y Med 295,295-96(1965).	1965
J-407	Bradley S. Galer. Painful Polyneuropathy, in Neurology Clinics 1998. Discusses use of Gabapentin for painful neuropathy (pg. 802).	1998
J-408	Brambilla P, Perez J, Barale F, Schettini G, Soares JC. GABAergic dysfunction in mood disorders. Molecular Psychiatry 2003;8:721-737.	2003
J-409	Brenner, G. J. and C. I. Woolf(2008). Mechanisms of Chronic Pain. Anesthesiology. D. E. Longnecker, D. L. Brown, M. F. Newman and W. Z. Zapol. New York, McGraw Hill: 2000-2019.	2008
J-410	Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry. 2007 Jul;164(7):989-91.	2007
J-411	Breslau N. Migraine suicidal ideation and suicide attempts. Neurology 1992;42:392-95.	1992
J-412	Bridges et al. Suicide Trends Among Youths Aged 10 to 19 Years in the United States, 1996 - 2005. JAM 2008;300:1025-6.	2008
J-413	Brock D, "A Model State Act to Authorize and Regulate Physician-Assisted Suicide".	2005
J-414	Brock D, "Euthanasia".	1992
J-415	Brown CH, Wyman PA, Brinales JM, Gibbons RD. The role of randomized trials in testing interventions for the prevention of youth suicide. Int Rev Psychiatry 2007 Dec;19(6):617-31.	2007
J-416	Brown J, Randall A. Gabapentin fails to alter P/Q-type Ca ²⁺ -channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 2005; 55:262-269.	2005
J-417	Brown JP, et al. Isolation of the [3H]Gabapentin-binding protein/ α 2 δ CA ²⁺ Channel subunit from porcine brain: development of a radioligand binding assay for α 2 δ subunits using [3H]leucine. Anal. Biochem. 1998; 255:236-243.	1998

J-418	Bruni, J, and Neon Study Group, Outcome and Evaluation of Gabapentin as Add-on Therapy for Partial Seizures. Can. J Neurol Sci 1998; 25: 134-140.	1998
J-419	Burke, LB., et al. Chapter 9. In: Pharmacoeepidemiology an Introduction, 3rd Edition, AG. Harzema, et al., ed. Cincinnati: Whitney Books Company, 1998.	1998
J-420	Busch et al., 1993; Clinical Features of in-patient suicide. Psychiatr. Ann. 23(5): 256-262.	1993
J-421	Busch KA, Fawcett J, Jacobs DG. Clinical Correlates of Inpatient Suicide. J Clin Psychiatry 2003; 64:14-19.	2003
J-422	Cabras PL, Hardoy MJ, Hardoy MC, et al. Clinical experience with Neurontin in patients with bipolar or schizoaffective disorder: results of an open-label study. J Clin Psychiatr 1999; 60:245-248.	1999
J-423	Campbell BM, Morrison J-L, Taylor CP (2006) Pregabalin Acts at Calcium Channel Alpha2-Delta ($\alpha 2$ - δ) Type 1 Proteins to Prevent Acute Stress-Induced Increases in Cerebellar cGMP. European Congress on Neuropsychopharmacology.	2006
J-424	Canti C, Davies A, Dolphin AC. Calcium channel alpha2-delta subunits: Structure, functions and target site for drugs. Curr Neuropharmacol 2003; 1(3):209-217.	2003
J-425	Canti C, Nieto-Rostro M, Foucault I, Heblich F, Wratten J, Richards MW, Hendrich J, Douglas L, Page KM, Davies A, Dolphin A. The metal-ion-dependent adhesion site in the Von Willebrand factor-A domain of subunits is key to trafficking voltage-dependent Ca.	2005
J-426	Caracceni A, Zecca E, Bonezzi C, Bennett MI. Gabapentin significantly improves analgesia in people receiving opioids for neuropathic cancer pain. Cancer Treat Rev 2005; 31(I):58-62.	2005
J-427	Caraceni A, Zecca E, Martini C, DeConno F. Differences in Gabapentin efficacy for cancer pain more apparent than real? Journal of Pain and Symptom Management 2001; 21(Feb):93-4.	2001
J-428	Caraceni A, Zecca E, Martini C, DeConno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J. Pain Symptom Manage 1999; 17(Jun):441-5 .	1999
J-429	Carlson PJ, Singh JB, Zarate CA, Jr., Drevets WC, Manji HK (2006): Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx 3:22-41.	2006
J-430	Carta et al., The Clinical Use of Gabapentin In Bipolar Spectrum Disorders. Journal of Affective Disorders, 75:83-91 (2003).	2003

J-431	Castle, K., Duberstein, PR., Meldrum, S., Conner, KR., Conwell, Y. Risk Factors for Suicide in Blacks and Whites: An Analysis of data from the 1993 National Mortality Followback Survey. Am J Psychiatry 2004; 161(3): 452-458.	2004
J-432	Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacological Reviews 2005; 54:411-425.	2005
J-433	Cavanaugh S, Clark DC, Gibbons RD. Diagnosing depression in the hospitalized medically ill. Psychosomatics. 1983 Sep;24(9):809-15.	1983
J-434	Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WSQARS) (online) (2004 Data Analysis) Available from URL: www.cdc.gov/ncipc/wisgars .	2004
J-435	Centers for Disease Control and Prevention. National Vital Statistics Reports (NSS). Deaths: Preliminary Data for 2002: Vol. 52, No. 13, Washington: Public Health Service, February 11, 2004.	2004
J-436	Chandler A, Williams IE. Gabapentin, an Adjuvant Treatment for Neuropathic Pain in a Cancer Hospital (Letters). Journal of Pain and Symptom Management. Aug 2000; 20(2):82-86.	2000
J-437	Chang L, Cloak CC, Ernst T. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J. Clin. Psychiatry 2003 ;64 Supp. 3:7-14.	2003
J-438	Charney DS, Manji HK. Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004.	2004
J-439	Chen, H., et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid Population. Pharmacoepidemiology & Drug Safety 2005; 14:629-38.	2005
J-440	Cheng JK, Chen CC, Yang JR, Chiou LC. The antiallodynic action target of intrathecal gabapentin: Ca ²⁺ channels, KATP channels or N-methyl-D-aspartic acid receptors? Anesthes. Analges. 2006;102:182-187.	2006
J-441	Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of Gabapentin. Journal of Pharmacological Sciences 2006; 100(5):471-486.	2006
J-442	Cheng JK, Lee SZ, Yang JR, Wang CH, Liao YY, Chen CC, Chiou LC. Does Gabapentin act as an agonist at native GABAB receptors? Journal of Biomedical Science 2004; 11(3):346-355.	2004
J-443	Cheng VY, Bonin RP, Chiu MW, Newell JG, MacDonald JF, Orser BA. Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons.	2006

	Anesthesiology 2006; 105(2):325-333.	
J-444	Cheramy A, Barbeito L, Godeheu G, Glowinski J (1992): Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209-212.	1992
J-445	Chiaromonti R, Lori S, Baggioire CM, et al. Nociceptive Reflex of the Short Femoral Biceps in Patients with Painful Diabetic Neuropathy Treated with Gabapentin (GBP). Neurology. 52:A169- 170, 1999.	1999
J-446	Ching, Andrew, and Masakazu Ishihara, "The Effects of Detailing on Prescribing Decisions under Quality Uncertainty," Draft Paper, August 2006.	2006
J-447	Cho SW, Cho EH, Choi SY. Activation of two types of brain glutamate dehydrogenase isoproteins by Gabapentin. FEBS Lett 1998; 426(2):196-200.	1998
J-448	Chou, R., A. Qaseem, et al. (2007). "Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society." Ann Intern Med 147(7): 478-91.	2007
J-449	Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al (2005): Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102:15653-15658. Epub 12005 Oct 15617.	2005
J-450	Chouinard G, Beauclair L, Belanger MC. Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 1998; 43(3):305.	1998
J-451	Christensen et al., Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol. 2007 6:693-698.	2007
J-452	Chu, L. F., M. S. Angst, et al. (2008). "Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations." Clin J Pain 24(6): 479-96.	2008
J-453	Clark DC, Gibbons RD, Fawcett J, Aagesen CA, Sellers D. Unbiased criteria for severity of depression in alcoholic inpatients. J Nerv Ment Dis. 1985 Aug;173(8):482-7.	1985
J-454	Clark DC, Gibbons RD, Fawcett J, Scheftner WA. What is the mechanism by which suicide attempts predispose to later suicide attempts? A mathematical model. J Abnorm Psychol. 1989 Feb;98(1):42-9.	1989
J-455	Clark DC, Gibbons RD, Haviland MG, Hendryx MS. Assessing the severity of depressive states in recently detoxified alcoholics. J Stud Alcohol. 1993 Jan;54(1):107-14.	1993
J-456	Clark DC, Gibbons RD. Does one nonlethal suicide attempt increase the risk for a subsequent nonlethal attempt? Med	1987

	Care 1987 Dec;25(12 Suppl):S87-9.	
J-457	Clark DC, vonAmmon Cavanaugh S, Gibbons RD. The core symptoms of depression in medical and psychiatric patients. J Nerv Ment Dis. 1983 Dec;171(12):705-13.	1983
J-458	Cockerell OC, Moriarty J, Trimble M, Sander JW, Shorvon DS. Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Res 1996; 25(2):119-131.	1996
J-459	Coderre TJ, Kumar N, Lefebvre CD, Yu JSC. Evidence that Gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005; 94:1131-1139.	2005
J-460	Collins JC, McFarland BH (2007): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord.	2007
J-461	Compton, P., V. C. Charvastra, et al. (2001). "Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent." Drug Alcohol Depend 63(2): 139-46.	2001
J-462	Congressional Budget Office. Research and Development in the Pharmaceutical Industry, October 2006 (www.cbo.gov/ftpdocs/76xx/doc761S/10-02-DrugR-D.pdf.	2006
J-463	Cooper JR, Bloome FE & Roth RH, The Biochemical Basis of Neuropharmacology 8th ed. 2003.	2003
J-464	Coric V, Milanovic S, Wasyluk S, Patel P, Malison R, Krystal JH (2003): Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 167:219-220.	2003
J-465	Coscelli, Andrea, and Matthew Shum, "An Empirical Model of Learning and Patient Spillovers in New Drug Entry," Journal of Econometrics, Volume 122(2), 2004.	2004
J-466	Cotter D, Landau S, Beasley C, Stevenson R, Chana G, MacMillan L, Overall I (2002): The density and spatial distribution of GABAergic neurons, labeled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar d.	2002
J-467	Crafford, Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-1273.	2005
J-468	Cramer, J.A., De Rue, K., Devinsky, O., Edrich, P. and Trimble, M.R. (2003). "A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials." Epilepsy Behav 4(2): 124-32.	2003

J-469	Cuignet, O., Pirson J., et al. (2007). "Effects of Gabapentin on morphine consumption and pain in severely burned patients." Bums 33(1): 81-6.	2007
J-470	Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RSG. Dual effects of Gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004; 20(6):1566-1576.	2004
J-471	Currie, S., et al., Clinical Course and Prognosis of Temporal Lobe Epilepsy: A Survey of 666 Patients. Brain 1971; 94:173-90.	1971
J-472	Dalby N. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000; 39(12):2399-2407.	2000
J-473	Dalocchio C, Buffa C, Ligure N, et al. Gabapentin Versus Amtrpyline in Painful Diabetic Neuropathy. Neurology. 50:A102-3, 1998.	1998
J-474	Dalocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs. Amtrpylie in Painful Diabetic Neuropathy. Journal of Pain and Symptom Management. 20:280-285, 2000.	2000
J-475	Dang K, Bowery N, Sugiyura T, Urban L. Sustained depolarization of the ventral root following washout of GABAB receptor agonists in a novel juvenile mouse hemisected spinal cord preparation: Is this due to desensitization? American Pain Society Abstracts.	2003
J-476	Darel A. Regier & Jack D. Burke, Jr., 5.1 Epidemiology, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Volume I, 500 (Benjamin J. Sadock & Virginia A. Sadock eds., 7th ed. 2000).	2000
J-477	Davies A, Douglas L, Hendrich J, Wratten J, Tran Van Minh A, Foucault I, Koch D, Pratt WS, Saibil HR, Dolphin AC. The calcium channel alpha2delta-2 subunit partitions with CaV2.1 into lipid rafts in cerebellum: implications for localization and function..	2006
J-478	Davies, A., J. Hendrich, et al. (2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels." Trends Pharmacol Sci 28(5): 220-8.	2007
J-479	Davis JM, Janicak PG, Wang Z, Gibbons RD, Sharma RP. The efficacy of psychotropic drugs: implications for power analysis. Psychopharmacol Bull. 1992;28(2):151-5.	1992
J-480	Davis JM, Koslow SH, Gibbons RD, Maas JW, Bowden CL, Casper R, Hanin I, Javaid JI, Chang SS, Stokes PE. Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls. Arch Gen Psychiatry. 1988 Aug;45(8):705-17.	1988
J-481	Debono MW, Le Guern J, Canton T, Doble A, Pradier L (1993): Inhibition by riluzole of electrophysiological	1993

	responses mediated by rat kainate and NMDA receptors expressed in <i>Xenopus</i> oocytes. <i>Eur J Pharmacol</i> 235:283-289.	
J-482	Delgado PL. Depression: the case for a monoamine deficiency. <i>J Clin Psychiatry</i> . 2000; 61 Suppl 6:7-11.	2000
J-483	de-Paris F, Sant'Anna MK, Vianna MR, Barichello T, Busnello JV, Kapczinski F, Quevedo J, Izquierdo I. Effects of Gabapentin on anxiety induced by simulated public speaking. <i>Journal of Psychopharmacology</i> (Oxford, England) 2003; 17(2):184-188.	2003
J-484	Department of Health and Human Services, The Surgeon General's Call to Action to Prevent Suicide (1999).	1999
J-485	Devulder J, Lambert J, Naeyaert JM. Gabapentin for pain control in cancer patients' wound dressing care. <i>J. Pain Symptom Manage</i> 2001; 22(I)(Jul):622-6.	2001
J-486	Diamond KR, Pande AC, Lamoreaux L, Pierce MW (1996): Effect of Gabapentin (Neurontin®) on Mood and Well-Being in Patients with Epilepsy. <i>Prog Neuro-Psychopharmacol & Biol Psychiat</i> 20: 407-17.	1996
J-487	Doble A, Hubert JP, Blanchard JC (1992): Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells. <i>Neurosci Lett</i> 140:251-254.	1992
J-488	Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of Gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. <i>Synapse</i> 2002; 45(3):171-190.	2002
J-489	Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by Gabapentin and Pregabalin. <i>J Pharmacol Exp Ther</i> 2000; 296(3):1086-1098.	2000
J-490	Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by Gabapentin. <i>Neurosci Lett</i> 2000; 280(2):107-110.	2000
J-491	Dooley DJ, Suman Chauhan N, Madden Z. Inhibition of K+-evoked [3H]noradrenaline release from rat neocortical slices by the anticonvulsant Gabapentin. <i>Soc Neurosci Abstr</i> 1996; 22:1992-1992.	1996
J-492	Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca ²⁺ channel $\alpha 2\text{-}\delta$ ligands: Novel modulators of neurotransmission. <i>Trends in Pharmacological Sciences</i> 2007;28(2):75-82.	2007
J-493	Dorus W, Kennedy J, Gibbons RD, Ravi SD. Symptoms and diagnosis of depression in alcoholics. <i>Alcohol Clin Exp Res</i> . 1987 Apr;11(2):150-4.	1987

J-494	Drugan RC, Maier SF, Skolnick P, Paul SM, Crawley JN (1985): An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur J Pharmacol 113:453-457.	1985
J-495	Duner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. Bipolar Disorders 2005; 7:307-325.	2000
J-496	Dunlop J, Beal McIlvain H, She Y, Howland DS (2003): Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 23:1688-1696.	2003
J-497	Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M (2000): The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 57:906-912.	2000
J-498	Dworkin RH, Backonja M, Rowbotham M, et al. Advances in Neuropathic Pain. Arch. Neural. 2003; 60: 1524-1534.	2003
J-499	Dworkin, R. H., A. B. O'Connor, et al. (2007). "Pharmacologic management of neuropathic pain: evidence-based recommendations." Pain 132(3): 237-51.	2007
J-500	Eckhardt, K., S. Ammon, et al. (2000). "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91(1): 185-91.	2000
J-501	Edwards, RR., Smith, MT., Kudel, I., Haytorntwaite, J. Pain- related catastrophizing as a risk factor for suicidal ideation in chronic pain. Pain 2006; 126:272-279.	2006
J-502	Eichler, H-G, Abadie, E., Raine, J. And Salmonson, T. Safe Drugs and the Cost of Good Intentions. New Eng. J. Med. 2009 360:1378 – 1380.	2009
J-503	Eisenberg, E., E. D. McNicol, et al. (2005). "Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials." JAMA 293(24): 3043-52.	2005
J-504	Elkin I, Gibbons RD, Shea MT, Sotsky SM, Watkins JT, Pilkonis PA, Hedeker D. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol. 199.	1995
J-505	Epstein B, Childers MK. The use of Gabapentin for neuropathic and musculoskeletal pain: a case series. J Neurol Rehabil 1998; 12(2):81-5.	1998
J-506	Erfurth A, Kammerer C, Grunze H, et al. An open label study of Neurontin in the treatment of acute mania. J Psychiatry Res 1998; 32:261-264.	2005

J-507	Errante LD, Petroff OAC. Acute effects of Gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. <i>Seizure</i> 2003; 12:300-306.	2003
J-508	Errante LD, Williamson A, Spencer DD, Petroff OA. Gabapentin and vigabatrin increase GABA in the human neocortical slice. <i>Epilepsy Research</i> 2002; 49(3):203-210.	2002
J-509	Essentials of Epidemiology in Public Health. Ann Aschengrau, George R. Seage, ScD, Editors. Jones & Barlett 2nd ed. 2007.	2007
J-510	Evans, S., Waller, P., Davis, S. Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reaction reports. <i>Pharmacoepidemiol Drug Saf</i> 2001; 10:483-486.	2001
J-511	Faich GA., et al. National adverse drug reaction surveillance. 1986. <i>Arch Intern Med</i> 1988; 148:785-87.	1988
J-512	Fathalla MF. A Practical Guide for Health Researchers (2004). Nasr City, Cairo:WHO Regional Publications.	2004
J-513	Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbons RD. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. <i>Arch Gen Psychiatry</i> . 1987 Mar;44(3):248-56.	1987
J-514	Fawcett J, Clark DC, Gibbons RD, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, Stutzman D. Evaluation of lithium therapy for alcoholism. <i>J Clin Psychiatry</i> . 1984 Dec;45(12):494-9.	1984
J-515	Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Assessing anhedonia in psychiatric patients. <i>Arch Gen Psychiatry</i> . 1983 Jan;40(1):79-84.	1983
J-516	Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, Gibbons R. Time-related predictors of suicide in major affective disorder. <i>Am J Psychiatry</i> . 1990 Sep; 147(9): 1189-94.	1990
J-517	Fawcett J. Treating impulsivity and anxiety in the suicidal patient. <i>Ann NY Acad Sci</i> . 2001. Apr; 932:94-105.	2001
J-518	FDA Reviews Data on Anticonvulsants for Suicide Risk (Carroll, L. <i>Neurology Today</i> , June 2005).	6/1/2005
J-519	FDA. FDA Drug Safety Newsletter Fact Sheet. FDA Drug Safety Newsletter.	6/19/2008
J-520	Fehrenbacher JC, et al. Pregabalin and Gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. <i>Pain</i> . 2003; 105:133-144.	2003
J-521	Feld M, Horstmann H, Koehlhofer U, Mahlmann H, Most M, Schneider F, Verma V, Reimann W. Effect of Gabapentin, Gö 4942 and valproate on GABA content in mouse brain	1985

	nerve endings. Pfizer Research Report 1985; RR-No. 4192-0189.	
J-522	Feng MR, Turluck D, Burleigh J, Lister R, Fan C, Middlebrook A, Taylor CP, Su TZ (2001). Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur Journal of Drug Metabolism and Pharmacokinetics 26:123-128.	2001
J-523	Feng Y, Cui M, Willis WD. Gabapentin markedly reduces acetic acid-induced visceral nociception. Anesthesiology 1998; 98(3):729-733.	1998
J-524	Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioral reactions to vigabatrin: a review. Acta Neurol. Scan. 1996; 93(a):1-8.	1996
J-525	Ferrier IN: Lamotrigine and gabapentin. Alternatives in the treatment of bipolar disorder. Neuropsychobiology 38(3):192-7, 1998.	1998
J-526	Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Dolphin AC, Hendrich J, Webb T, Williams D. Identification of the alpha 2-delta-1 subunit of voltage dependent calcium channels as a novel molec.	2006
J-527	Field MJ, Holloman EF, McCleary S, Hughes J, Singh L. Evaluation of Gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther 1997; 282(3):1242-1246.	1997
J-528	Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 1999; 80(1-2):391-398.	1999
J-529	Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. British Journal of Pharmacology 1997; 121(8):1513-1522.	1997
J-530	Figiel G, et al., Electroconvulsive Therapy, p. 523 in: The American Psychiatric Press Textbook of Psychopharmacology (Schatzberg A, Nemeroff C, eds., 2d ed. 1998).	1998
J-531	Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. Inhibition of neuronal Ca-2+ influx by Gabapentin and pregabalin in the human neocortex. Neuropharmacol 2002; 42:229-236.	2002
J-532	Fink K, Meder W, Dooley DJ, Gothert M. Inhibition of neuronal Ca(2+) influx by Gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 2000; 130(4):900-906.	2000

J-533	Fink K, Schmitz V, Boing C, Gothert M. Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via alpha 2-heteroreceptors. Naunyn-Schmiedeberg's Archives of Pharmacology 1995; 352(4):394.	1995
J-534	Finlay & Abercrombie. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neurosci. 1995; 64:619-628.	1995
J-535	Finnerup, N. B., M. Otto, et al. (2005). "Algorithm for neuropathic pain treatment: an evidence based proposal." Pain 118(3): 289-305.	2005
J-536	Fiordell E et al. Epilepsy and psychiatric disturbance: a cross sectional study. Br J Psychiatry 1993;163:446-50.	1993
J-537	Fishbain DA et al. Completed suicides in chronic disease. Clin J Pain 1991;7:29-36.	1993
J-538	Fishbain DA, Cuter R, Rosomoff HL, Rosomoff RS. Chronic Pain-Associated Depression: Antecedent or Consequence of Chronic Pain? A Review. Clinical Journal of Pain 1997; 13(2):116-137.	1997
J-539	Fishbain DA. Current research on chronic pain and suicide. American Journal of Public Health. 1996;86:1320-1321.	1996
J-540	Fishbain, D.A. Association of chronic pain and suicide. Seminars in Clinical Neuropsychiatry 4:221-27 (1999).	1999
J-541	Fisher, et al., "Suicidal intent in patients with chronic pain," Pain 89 (2001) 199-206.	2001
J-542	Flattery KV, Spero L. Chapter 18: Drugs acting on adrenergic neurons (adrenergic neuronal blocking drugs). In: Principles of Medical Pharmacology, Fourth Edition. Kalant H, Roschlau WHE, Selle EM (Eds.). Department of Pharmacology, Faculty of Medicine, University of Toronto, Canada. Toronto, Canada, 1975.	5/28/1905
J-543	Foley KM. Controlling Cancer Pain. Hospital Practice. April 15, 2000: 101-112.	2000
J-544	Forde, G. (2007). "Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles." J Fam Pract 56(2 Suppl Pain): 3-12.	2007
J-545	Forman, EM., Berk, MS., Henrques, GR., Brown, GK, Beck, AT. History of Multiple Suicide Attempts as a Behavioral Marker of Severe Psychopathology. Am J Psychiatry 2004; 161(3): 437-443.	2004
J-546	Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ. Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. British Journal of Pharmacology	1999

	1999; 126(7):1634-1638.	
J-547	Frederick K. Goodwin, M.D., "Impact of Formularies on Clinical Innovation", 64 J. Clin Psychiatry 11 (2003)..	2003
J-548	Freiman, Modulation of K ⁺ -evoked (3H)-noradrenaline release from rat and human brain slices by Gabapentin: involvement of KATP channels. Naunyn-schmiedeber's Arch Pharmacol 2001; 363: 537-42.	2001
J-549	Freynhagen, Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind multicenter, placebo-controlled trial of flexible and fixed-dose regimens. Pain 2005; 115: 254-263.	2005
J-550	Friedman, Seth, et al. Lithium and Valproic Acid Treatment Effects on Brain Chemistry in Bipolar Disorder. Biol Psychiat 2004; 56(5): 340-348.	2004
J-551	Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Locatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607-14, Dec 2000.	2000
J-552	Furberg, Class Effects and Evidence-Based Medicine, Clin. Cardiol. 2000;23;7 Suppl 4:IV15-19, at IV-15.	2000
J-553	Furberg et al., Class Effects: Are Drugs within a Class Interchangeable?, Lancet 1999;354:1202-04, at 1202.	1999
J-554	Furberg & Pitt, Are All Angiotensin-Converting Enzyme Inhibitors Interchangeable?, J. Am. Coll. Cardiol. 2001;37:1456-60, at 1456.	2001
J-555	Furberg & Psaty, Should Evidence-Based Proof of Drug Efficacy Be Extrapolated to a "Class of Agents"?, Circulation 2003;108:2608-10, at 2610.	2003
J-556	Galer BS. Painful Polyneuropathy. Neurologic Clinics. 16:791-811, 1998.	1998
J-557	Galli T, Haucke V. Cycling of synaptic vesicles: how far? how fast! Sci STKE. 2004; 2004(264):re19.	2004
J-558	Garnett, William R, "New Opportunities for the Treatment of Epilepsy," Am. J. Health Systems Pharm., Vol. 52, Jan. 1, 1995.	1995
J-559	Gatti A, Jann S, Sandro B, Manuela B. Gabapentin in the Treatment of Distal Symmetric Axonopathy in HIV Infected Patients. Neurology. 50:A216, 1998.	1998
J-560	Gee NS, Brown JP, Dissanayake VUK, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, Gabapentin (Neurontin), binds to the $\alpha 2\delta$ subunit of a calcium channel. J. Biol. Chem. 1996; 271(10):5768-5776.	1996

J-561	Gerner R, Fairbanks, L., Anderson, M., Young, JG., Scheinin, M., Linnoila, M., Hare, TA., Shaywitz, BA., Cohen, DJ. (1984): CSF neurochemistry in depressed, manic and schizophrenic patients compared with normal controls. American Jrn of Psychiatry 141:153.	1984
J-562	Gerner R, Hare, TA. (1981): CSF GABA levels in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. American Jrn Psychiatry 138:1098-1101.	1981
J-563	Ghaemi SN, Goodwin FK: Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord 65(2):167-71, 2001.	2001
J-564	Ghaemi SN, HSU DJ, Solda F, Goodwi FK. Antidepressants in Bipolar Disorder: The Case for Caution. Bipolar Disorder 2003; 5(6):421-33.	2003
J-565	Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK: Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 59:426-9, 1998.	1998
J-566	Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007 Sep;164(9):1356-63.	2007
J-567	Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. Am J Psychiatry 2007 Jul;164(7):1044-9.	2007
J-568	Gibbons RD, Clark DC, Davis JM. A statistical model for the classification of imipramine response in depressed inpatients. Psychopharmacology (Berl).	
J-1982;78(2):185-9.	1982	
J-569	Gibbons RD, Clark DC, Fawcett J. A statistical method for evaluating suicide clusters and implementing cluster surveillance. Am J Epidemiol. 1990 Jul;132(1 Suppl):S183-91.	1990
J-570	Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res. 1993 Jul-Sep;27(3):259-73.	1993
J-571	Gibbons RD, Clark DC, VonAmmon Cavanaugh S, Davis JM. Application of modern psychometric theory in psychiatric research. J Psychiatr Res. 1985;19(1):43-55.	1985
J-572	Gibbons RD, Davis JM, Hedeker DR. A comment on the selection of 'healthy controls' for psychiatric experiments. Arch Gen Psychiatry. 1990 Aug;47(8):785-6.	1990

J-573	Gibbons RD, Davis JM. The price of beer and the salaries of priests: analysis and display of longitudinal psychiatric data. Arch Gen Psychiatry. 1984 Dec;41(12):1183-4.	1984
J-574	Gibbons RD, Dorus E, Ostrow DG, Pandey GN, Davis JM, Levy DL. Mixture distributions in psychiatric research. Biol Psychiatry. 1984 Jul;19(7):935-61.	1984
J-575	Gibbons RD, Hedeker D, Davis JM. Regression toward the mean: more on the price of beer and the salaries of priests. Psychoneuroendocrinology. 1987;12(3):185-92.	1987
J-576	Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collabor.	1993
J-577	Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005 Feb;62(2):165-72.	2005
J-578	Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 2006 Nov;163(11):1898-904.	2006
J-579	Gibbons RD, Lavigne JV. Emergence of childhood psychiatric disorders: a multivariate probit analysis. Stat Med. 1998 Nov 15;17(21):2487-99.	1998
J-580	Gibbons RD, Rush AJ, Immekus JC. On the psychometric validity of the domains of the PDSQ: an illustration of the bi-factor item response theory model. J Psychiatr Res. 2009 Jan;43(4):401-10. Epub 2008 Jun 12.	2009
J-581	Gibbons RD, Segawa E, Karabatsos G, Amatya AK, Bhaumik DK, Brown CH, Kapur K, Marcus SM, Hur K, Mann JJ. Mixed-effects Poisson regression analysis of adverse event reports: The relationship between antidepressants and suicide. Stat Med. 2008 May 20; 27.	2008
J-582	Gibbons Replies to Wohlfarth, Jureidini and Olfson. Am J Psychiatry. 2007 Dec;164(12):1908-10.	2007
J-583	Gibbons, RD & Davis, JM. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. Acta psychiatr scand 1986; 74(1): 8-12.	1986
J-584	Gibbons, RD, Amatya, A.K., Brown, C.H., Hur, K., Marcus, S.M., Bhaumik, D.K., Mann, J.J. Post-approval drug safety surveillance. Annual Review of Public Health, in press.	2009
J-585	Gibbons, R.D., Hur, K., Brown, C.H., Mann, J.J. The Relationship Between Antiepileptics and Suicide Attempts in Patients with Bipolar Disorder, Arch Gen Psychiatry. 2009;66(12):1354-1360.	2009

J-586	Gilliam, et al., "Depression in Epilepsy: Ignoring Clinical Expression of Neuronal Network Dysfunction?" <i>Epilepsia</i> , 45 (Suppl. 2): 28-33, 2004.	2004
J-587	Gilron L, Orr E, Dongsheng T, O'Neil, Zamora J, Bell A. A Placebo- Controlled Randomized Clinical Trial of Perioperative Administration of Gabapentin, Rofecoxib and Their Combination for Spontaneous and Movement-Evoked Pain After Abdominal Hysterectomy.	2005
J-588	Gilron, L. (2007). "Gabapentin and pregabalin for chronic neuropathic and early post surgical pain: current evidence and future directions." <i>Curr Opin Anaesthesiol</i> 20(5): 456-72.	2007
J-589	Gilron, L., J. M. Bailey, et al. (2005). "Morphine, Gabapentin, or their combination for neuropathic pain." <i>N Engl J Med</i> 352(13): 1324-34.	2005
J-590	Girard M, Conclusiveness of rechallenge in the interpretation of adverse reactions. <i>Br J Clin Pharmacol.</i> , 1987; 23:73-79.	1987
J-591	Girard, M. Oral Provocation Limitations. <i>Sem Dermatol</i> 1989; 8(3):192-195.	1987
J-592	Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, et al (2001): Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. <i>Archives of General Psychiatry</i> 58:556-561.	2001
J-593	Goddard AW, Mason GF, Rothman DL, Behar KL, Petroff OA, Krystal JH (2004): Family psychopathology and magnitude of reductions in occipital cortex GABA levels in panic disorder. <i>Neuropsychopharmacology</i> 29:639-640.	2004
J-594	Gold B, Bowers, MB., Roth RH., Sweeney, DW. (1980): GABA levels in CSF of patients with psychiatric disorders. <i>American J Psychiatry</i> 137:362-364.	1980
J-595	Goldlust A, Su TZ, Welty DF, Taylor CP, Oxender DL (1995): Effects of anticonvulsant drug Gabapentin on the enzymes in metabolic pathways of glutamate and GABA. <i>Epilepsy Res</i> 22:1-11.	1995
J-596	Goldsmith SK. Pellmar TC, Klein AM, Bunney WE (E). <i>Reducing Suicide: A National Imperative</i> (2002). Washington, DC: National Academies Press.	2002
J-597	Gong HC, Hang J, Kobler W, Li L, Su TZ. Tissue-specific expression and Gabapentin-binding properties of calcium channel $\alpha 2\delta$ subunit subtypes. <i>J Membrane Biol.</i> 2001; 184:35-43.	2001
J-598	Gonul, Fusun, F. et al., "Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," <i>Journal of Marketing</i> , Volume 65, 79-90, July 2001.	2001

J-599	Goodman, M. and Nordin, J. Vaccine Adverse Event Reporting Source: A Possible Source of Bias in Longitudinal Studies. Pediatrics 2006; 117:387-90.	2006
J-600	Goodwin FK, et al., Manic-depressive illness. New York: Oxford University Press, 1990.	1990
J-601	Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression (2007). New York, New York: Oxford University Press, Inc; 247-269.	2007
J-602	Goodwin, F.K., 1999. Anticonvulsant therapy and suicide risk in affective disorders. J. Clin. Psychiatry 60 (Suppl. 2), 89-93.	1999
J-603	Goodwin, F.K., Fireman, B., Simon, G.E., Hunkeler, E.M., Lee, J. Revicki, D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290:1467-1473.	2003
J-604	Gorson KC, Schott C, Herman R, Ropper A. Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo Controlled, Double Blind, Crossover J Neurol. Neurosurg. Psychiatry. February 1999; 66(2);251-252.	1999
J-605	Gorson KC, Schott C, Rand WM, et al. Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo-Controlled, Double-Blind, Crossover Trial. Neurology. 1998; 50:A103, 1998.	1998
J-606	Gottesfeld, Z. Effect of Lithium and Other Alkali Metals on Brain Chemistry and Behavior: I Glutamic Acid and GABA in Brain Regions. Psychopharmacologia Berl. 1976; 45(3): 239-242.	1976
J-607	Grabowska-Grzyb, et al., "Risk factors for depression in patients with epilepsy," Epilepsy & Behavior 8 (2006) 411-417.	2006
J-608	Greenland S. Relation of probability of causation to relative risk and doubling dose: a methodologic error that has become a social problem. Am J Public Health. 1999 Aug;89(8):1166-9.	1999
J-609	Greenland, S. Can Meta-analysis Be Salvaged? Am. J. Epidemiol. 1994;140: 783-787.	1994
J-610	Groh, CL Poverty, Mental Health, and Women: Implications for Psychiatric Nurses in Primary Care Settings. Journal of the American Psychiatric Nurses Association 2007; 13(5):267-274.	2007
J-611	Gronseth, G., G. Cruccu, et al. (2008). "Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Fed.	2008

J-612	Grunze H, Greene RW, Moeller H-J, Meyer T, Walden J. Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Res. 1998;791:330-334.	1998
J-613	Gryder DS, Rogawski MA. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J. Neurosci. 2003;23:7069-7074.	2003
J-614	Gu Y, Huang LYM. Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain. 2001; 93:85-92.	2001
J-615	Gu Y, Huang LYM. Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons. Neurosci Lett. 2002; 324:177-180.	2002
J-616	Hahn RA. The Nocebo Phenomenon: Concept, Evidence, and Implications for Public Health. Preventive Medicine 26, 607–611 (1997).	1997
J-617	Hainline B. Chronic Pain: Physiological, Diagnostic, and Management Considerations. Psychiatr. Clin. N. Am. 2005; 28;713-735.	2005
J-618	Hall RC, Platt DE, Hall RC. Suicide risk assessment: a review of risk factors for suicide in 100 patients who made severe suicide attempts. Evaluation of suicide risk in a time of managed care. Psychosomatics. 1999 Jan-Feb; 40(1):18-27.	1999
J-619	Halonen T, Pitkanen A, Saano V, Riekkinen PJ. Effects of vigabatrin (gamma-vinyl gaba) on neurotransmission-related amino acids and on gaba and benzodiazepine receptor binding in rats. Epilepsia 1991; 32(2):242-249.	1991
J-620	Ham, BJ et al., Decreased GABA Levels in Anterior Cingulate and Basal Ganglia in Medicated Subjects with Panic Disorder: A Proton Magnetic Resonance Spectroscopy (H-MRS) Study. Progress Neuropsychopharmacol Biologic Psychiatry 2007; 31: 403-411.	2007
J-621	Hamad, T. Relationship between psychotropic drugs and pediatric suicidality. U.S. Food and Drug Administration, August 16, 2004.	2004
J-622	Hanley MA, Ehde D, Campbell KM, Osborn B, Smith D. Self-Reported Treatments Used for Lower-Limb Phantom Pain: Descriptive Findings. Arch. Phys. Med. Rehabilitation February 2006;87:270-277.	2006
J-623	Hanna, M., O'Brien C, et al. (2008). "Prolonged-release oxycodone enhances the effects of existing Gabapentin therapy in painful diabetic neuropathy patients." Eur J Pain 12(6): 804-13.	2008
J-624	Harden C et al. Mood disorders in patients with epilepsy. CNS Drugs 2002;15:291-302.	2002

J-625	Harris EC, Baraclough B. Suicide as an Outcome for Mental Disorders. A Meta Analysis. Br. J. Psychiatry 1997; 170:205-228.	1997
J-626	Harrison's Online. Par 14: Neurologic Disorders: Section 5; Chapter 385: Anxiety Disorders. McGraw-Hill Companies, 26 Sept 2002. Available at URL: http://www.harsons.accessmedicine.com/serverjava/Arknoide/madeharsons/chapters/ch385/ch385_01.htm?searchter .	2002
J-627	Hashimoto K, Sawa A, Iyo M (2007): Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316.	2007
J-628	Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007): Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64:193-20.	2007
J-629	Hauben & Aronson. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Safety 32:99 - 110 (2009).	2009
J-630	Hauben & Bate. Decision support methods for the detection of adverse events in post-marketing data. Drug Discovery Today 14:343 - 357 (2009).	2009
J-631	Hauben, et al. Evaluation of Suspect Adverse Drug Reactions. JAMA, March 16, 2005 - Vol. 293, No. 11, pg. 1324.	2005
J-632	Hauben, M., Horn, S., Reich, L. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Drug Safety 2007; 30(2):143-155.	2007
J-633	Hauben, M., Patadia, V., Gerrits, C., Walsh, L., Reich, L. Data mining in pharmacovigilance: the need for a balanced perspective. Drug Safety 2005; 28(10):835-842.	2005
J-634	Hauben, M., Reich, L., Chung, S. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms. European Journal of Clinical Pharmacology 2004; 60(10):747-50.	2004
J-635	Hauben, M., Reich, L., Gerrits, CM. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study. Pharmacoepidemiol Drug Safety 2006; 15(11):775-783.	2006
J-636	Hauben, M., Reich, L., Van Puijenbroek, EP., Gerrits, CM., Patadia, VK. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol 2006; 62(11):967-970.	2006
J-637	Hauben, M., Zhou, X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf 2003; 26(3):159-186.	2003

J-638	Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66(6):693-704.	2005
J-639	Hayashida KI, Degoes S, Curry R, Eisenach JC. Gabapentin activates spinal noradrenergic activity in rats and humans and reduces hypersensitivity after surgery. Anesthesiol. 2007;106(3):557-562.	2007
J-640	Hebert T, Drapeau P, Pradier L, Dunn RJ (1994): Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45:1055-1060.	1994
J-641	Heblich, F., A. Tran Van Minh, et al. (2008). "Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin." Channels (Austin) 2(1): 4-9.	2008
J-642	Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J et al. Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc. Natl. Acad. Sci. USA 2008;105:3628-3633.	2008
J-644	Hendricson AW, Sibbald JR, Morrisett RA. Ethanol alters the frequency, amplitude, and decay kinetics of Sr ²⁺ - supported, asynchronous NMDAR mEPSCs in rat hippocampal slices. J Neurophysiol 2004; 91:2568-2577.	2004
J-645	Herman JP, Mueller NK, Figueiredo H (2004): Role of GABA and glutamate circuitry in hypothalamo-pituitary-adrenocortical stress integration. Ann N Y Acad Sci 1018:35-45.	2004
J-646	Hill A.B., The Environment and Disease: Association or Causation? (1965) Proceedings of the Royal Society of Medicine: 58: 295-300, reprinted in Bulletin of the WHO, Oct. 2005; 83(10):796-798.	2005
J-647	Hill DR, Suman CN, Woodruff GN. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993; 244(3):303-309.	1993
J-648	Hitchcock LS et al. The experience of chronic nonmalignant pain. J Pain Symptom Manage. 1994;9:312-18.	1994
J-649	Honig A, Bartlett JR, Bouras N, Bridges PK. Amino acid levels in depression: a preliminary investigation. Journal of Psychiatric Research 1988;22(3):159-164.	1988
J-650	Honmou O, Kocsis JD, Richerson GB. Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro. Epilepsy Res 1995a; 20(3):193-202.	1995
J-651	Honmou O, Oyelese AA, Kocsis JD. The anticonvulsant Gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 1995b; 692(1-2):273-277.	1995

J-652	House, JS., Strecher, V., et al. Occupational Stress and Health Among Men and Women in Tecumseh Community Health Study. J Health Soc Behav 27: 62, 1986.	1986
J-653	Hua, et al., An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoeconomics and Drug Safety 2005; 14: 629-638.	2005
J-654	Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T (1997): Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 282:1280-1290.	1997
J-655	Hurley RW, Chatterjea D, Feng MR, Taylor CP, Hammond DL. (2002) Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiol 97:1263-1273.	2002
J-656	Hurley, R. W., S. P. Cohen, et al. (2006). "The analgesic effects of perioperative Gabapentin on postoperative pain: a meta-analysis." Reg Anesth Pain Med 31(3): 237-47.	2006
J-657	Hutson SM, Berkich D, Drown P, Xu B, Aschner M, LaNoue KF. Role of branched-chain aminotransferase isoenzymes and Gabapentin in neurotransmitter metabolism. J Neurochem 1998; 71(2):863-874.	1998
J-658	Hutson SM, Lieth E, LaNoue KF. Function of leucine in excitatory neurotransmitter metabolism in the central nervous system. Journal of Nutrition 2001; 131(3):846S-850S.	2001
J-659	Hwang JH, Yaksh TL. Effect of subarachnoid Gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg Anesthesia 1997; 22(3):249-256.	1997
J-660	Institute of Medicine report on Causal Assessment.	
J-661	Iqbal S, Baziany A, Gordon S, Wright S, Hussain M, Miyashita H, Shuaib A, Hasan Rajput A. Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res 2002; 946(2):162-.	2002
J-662	Isenberg K, Zorumski C. Chapter 31, Electroconvulsive Therapy, in: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol. II, pp. 2503-2507 (Sadock B, Sadock V, eds., 7th ed. 2000.	2000
J-663	Jackson & Turkington, "Depression and Anxiety in Epilepsy," J Neurol. Neurosurg. Psychiatry 2005; 76 (Suppl. I): i45-i47.	2005
J-664	Jacobs DG (Ed.) The Harvard Medical School Guide to Suicide Assessment and Intervention (1999). Jossey-Bass: New York, New York.	1999

J-665	Jacobs DG, Deutch NL, Brewer M. Suicide, Depression and Isotretinoin: Is There a Causal Link? J Am Acad Dermatol 2001; 45:S168-75.	2001
J-666	Jacobs DG. A 52-Year-Old Suicidal Man. JAMA 2000; 283(20):2693-2699.	2000
J-667	Jacobs, D, Brewer, M. APA Practice Guideline Summary: Recommendations for Assessing and Treating Patients with Suicidal Behaviors. Psychiatric Ann 2004; 34 (5): 373-380.	2004
J-668	Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61 Suppl. 9:47-51.	2000
J-669	Janakiramaiah N, Gangadhar BN, Naga VMPIJ. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: A randomized comparison with electroconvulsive therapy (ECT) and imipramine. Journal of Affective Disorders 2000;47:255-259.	2000
J-670	Jancsar SM, Leonard BE (1984): Changes in neurotransmitter metabolism following olfactory bulbectomy in the rat. Prog Neuropsychopharmacol Biol Psychiatry 8:263-269.	1984
J-671	Janicak PG, Davis JM, Gibbons RD, Ericksen S, Chang S, Gallagher P. Efficacy of ECT: a meta-analysis. Am J Psychiatry 1985 Mar;142(3):297-302.	1985
J-672	Jehle T, Bauer J, Blauth E, Hummel A, Darstein M, Freiman TM, Feuerstein TJ (2000):Effects of riluzole on electrically evoked neurotransmitter release. Br J Pharmacol 130:1227-1234.	2000
J-673	Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, Abrahamsen B, Mattsson JP, Lehmann A, Bettler B, Braeuner-Osborne H. The anticonvulsant Gabapentin (Neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol 20.	2002
J-674	Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and ltp: Do pain and memory share similar mechanisms? Trends Neurosci 2003; 26(12):696-705.	2003
J-675	Jones JE et al. Rates and risks for suicide, suicidal ideation, and suicide attempts in chronic epilepsy. Epilepsy and Behavior 2003;S31-38.	2003
J-676	Joshi I, Taylor CP (2005) Pregabalin action at a model synapse: binding to presynaptic ($\alpha 2$ - δ) subunit reduces neurotransmission in mice. Soc. Neurosci. Abstr.	2005
J-677	Joshi I, Taylor CP (2006) Pregabalin action at a model synapse: binding to presynaptic Ca ²⁺ channel $\alpha 2$ -delta ($\alpha 2$ - δ) subunit reduces neurotransmission in mice. For Eur J Pharmacol. 553:82-88.	2006
J-678	Jureidini J. The black box warning: decreased prescriptions and increased youth suicide? Am J Psychiatry. 2007	

	Dec;164(12):1907; author reply 1908-10	
J-.	2007	
J-679	Juunnk, DN, Herman, N, Szalai, JP, Kopp, A, Redelmeier, DA. Medical illness and the Risk of Suicide in the Elderly. Arch Int Med June 2004; 64: 1179-1184.	2004
J-680	Kalinin V. Suicidality and antiepileptic drugs: Is there a link? Drug Safety 2007; 30(2):123-142.	2007
J-681	Kandel ER, Schwartz JH, Jessell TM (eds.). Principles of Neural Science, 4th Edition. New York: McGraw-Hill, 1414 1991.	1991
J-682	Kandel ER, Seigelbaum SA. Transmitter release. Chapter 14 in: Principles of Neural Science, 4th edition, Kandel ER, Schwartz JH, Jessell TM (eds.), McGraw-Hill, New York, 2001.	2001
J-683	Kanemoto K, Kawas J, Mori E. Violence and Epilepsy: A Close Relation Between Violence and Postictal Psychosis. Epilepsia 1999; 40(1):107-109.	1999
J-684	Kaner AM, Stagno S, Kotal P, Morris HH. Postictal Psychiatric Events During Prolonged Video-Electroencephalographic Monitoring Studies. Arch Neurol 1996 Mar; 53(3):258-63.	1996
J-685	Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vols. I and II (B. Sadock & V. Sadock eds., 7th ed. 2000).	2000
J-686	Kaplan et al., Physical illness, functional limitations, and suicide risk: a population-based study. Am J Orthopsychiatry 2007; 77:56-60.	2007
J-687	Kasa K, Otsuki, S., Yamamoto, M., Sato, M., Kuroda, H., Ogawa, N. (1982): Cerebrospinal fluid gamma-aminobutyric acid and homovanillic acid in depressive disorders. Biological Psychiatry 17:877-883.	1982
J-688	Kasper S, Olie JP (2002): A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur Psychiatry 17 Suppl 3:331-340.	2002
J-689	Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K (2002): Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB Journal 16:1328-13.	2002
J-690	Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(suppl. 2):53-67.	1999
J-691	Kellner C, Fink M, Knapp R, Petrides G, Husain M, Rummans T, Mueller M, Bernstein H, Rasmussen K,	2005

	O'Connor K, Smith G, Rush AJ, Biggs M, McClintock S, Bailine S, Malur C. Relief of Expressed Suicidal Intent by ECT: A Consortium for Research in ECT Study.	
J-692	Kelly KM (1998): Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology 38:139-144.	1998
J-693	Kendler KS (2005): Toward a philosophical structure for psychiatry. Am J Psychiatry 162:433-440.	2005
J-694	Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005): Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.	2005
J-695	Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the united states at the beginning of the twenty-first century. Annual Review of Clinical Psychology 2007;3:137-158.	2007
J-696	Kessler, RC, Berglund, ZP., Borges, G., Nock, M., Wang, PS. Trends in Suicide Ideation: Plans, Gestues and Attempts in the U.S. 1990-1992 to 2001-2003. JAMA 2005; 293:2487-2495.	2005
J-697	Kessler, RC., Borges, G., Walters, EE. Prevalence of and Risk Factors for Lifetime Suicide Attempts in the National Comorbidity Survey. Arch Gen Psych 1999; 56: 617-626.	1999
J-698	Khan A et al. Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database. J of Affective Disorders 2002;68:183-90.	2002
J-699	Khan A, Warner HA, Brown W A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000 Apr;57(4):311-7.	2000
J-700	Khan RB, Hunt DL, Thompson SJ. Gabapentin in control seizures in children undergoing cancer treatment. J Child Neurol 2004; 19(2)(Feb):97-101.	2004
J-701	Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;.	1996
J-702	King, Charles (2002). "Marketing, Product Differentiation, and Competition in the Market for Antiulcer Drugs," HBS Working Paper 01-014.	2002
J-703	Klein D, Strom BL, Wang P, Cunningham F, Herings RMC, O'Brien CP. (2007): The Future of Postmarketing Surveillance of Psychotropic Medications. CNS Spectr 12: 9(Suppl 16)1-20.	2007

J-704	Knowles SR, Uetrecht JP, Shear NH. Confirming false adverse reactions to drugs by performing individualized, randomized trials. Can J Clin Pharmacol 2002; 9(3): 149-53.	2002
J-705	Kocsis JD, Honmou O. Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve. Neurosci Lett 1994; 169(1-2):181-184.	1994
J-706	Kocsis JD, Mattson RH. GABA levels in the brain: a target for new antiepileptic drugs. Neuroscientist 1996; 2:326-334.	1996
J-707	Korf J, Venema K (1983): Desmethylinipramine enhances the release of endogenous GABA and other neurotransmitter amino acids from the rat thalamus. J Neurochem 40:946-950.	1983
J-708	Kraemer, H.C., Gibbons, R.D. Where do we go wrong in assessing risk factors, diagnostic and prognostic tests? The problems of two-by-two association.	2009
J-709	Kramer MS, Algorithm for the operational assessment of adverse drug reactions. JAMA, Vol. 242 No. 7, 623-632 (1979).	1979
J-710	Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al (2002): Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 7:S71-80.	2002
J-711	Kubota, K., Koide, D., Hirai, T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiology & Drug Safety 2004; 13(6):387-94.	2004
J-712	Kugaya A, Sanacora G (2005): Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10:808-819.	2005
J-713	Kung, H., et al. Deaths: Preliminary Data for 2005.	2005
J-714	Kuzniecky R, Ho S, Pan J, Martin R, Gilliam F, Faught E, Hetherington H (2002): Modulation of cerebral GABA by topiramate, lamotrigine, and Gabapentin in healthy adults. Neurology 58:368-372.	2002
J-715	Kuzniecky RI, Hetherington HP, Ho S, Pan JW, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. Neurol 1998; 51:627-629.	1998
J-716	La Spina I, Porrazzi D, Maggiolo F, et al. Gabapentin (GBP) in Painful AIDS-Related Neuropathy. Neurology. 1999; 52:A190.	1999
J-717	Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, Charles KJ, Wood M, Davies CH, Pangalos MN. Gabapentin is not a GABAB receptor agonist. Neuropharmacology 2001; 41(8):965-975.	2001
J-718	Leach JP, Sills GJ, Butler E, Forrest G, Thompson GG, Brodie MJ. Neurochemical actions of Gabapentin in mouse	1997

	brain. Epilepsy Research 1997; 27(3):175-180.	
J-719	Leckman JF, King RA. A developmental perspective on the controversy surrounding the use of SSRIs to treat pediatric depression. Am J Psychiatry. 2007 Sep;164(9):1304-6.	2007
J-720	Levendoglu F, Ogun, CO, Ozerbil O, Ogun TC, Ugulu H. Gabapentin is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury. Spine. 2004; 29(7):743-751.	2004
J-721	Levine, JG., Tonning, JM., Szarfman, A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned (comment) (erratum appears in Br J Clin Pharmacol 2006; 61 (1):.	2006
J-722	Levinson DE, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999; 53(7):1503-1511.	1999
J-723	Levitt AJ, Psychogenic panic after zidovudine therapy: the therapeutic benefit of an N of 1 trial. Can Med Assoc J 1990; 142 (4) 341-342.	1990
J-724	Levy DL, Dorus E, Shaughnessy R, Yasillo NJ, Pandey GN, Janicak PG, Gibbons RD, Gaviria M, Davis JM. Pharmacologic evidence for specificity of pursuit dysfunction to schizophrenia. Lithium carbonate associated with abnormal pursuit. Arch Gen Psychiatry. 1.	1985
J-725	Levy DL, Yasillo NJ, Dorus E, Shaughnessy R, Gibbons RD, Peterson J, Janicak PG, Gaviria M, Davis JM. Relatives of unipolar and bipolar patients have normal pursuit. Psychiatry Res. 1983 Dec;10(4):285-93.	1983
J-726	Lewis DA, Volk DW, Hashimoto T (2004): Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl) 174:143-150.	2004
J-727	Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson AH, Feng G, Luo ZD. Calcium channel alpha2delta1 subunit mediates spinal hyper excitability in pain modulation. Pain 2006; 125(1-2):20-34.	2006
J-728	Li Z et al. Poster presented at Society for Neuroscience 32nd Annual Meeting. Abstract 798.1, 2002. Gabapentin Inhibits ERK MAP Kinase Phosphorylation in NK1 Expressing Cells.	2002
J-729	Liccardia, et al. Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions. J Invest Allergol Clin Immunol 2004; Vol. 14(2): 104-107.	2004

J-730	Linthorst AC, Reul JM. Stress and the brain: Solving the puzzle using microdialysis. Pharmacol Biochem Behav 2007.	2007
J-731	Lloyd and colleagues. Biochemical Evidence of Dysfunction of Brain Neurotransmitters in the Lesch-Nyhan Syndrome. NEJM 1994; 305(19): 1106-11.	1994
J-732	Lloyd KG, Morselli PL, Bartholini G (1987a): GABA and affective disorders. Med Biol 65:159-165.	1987
J-733	Lloyd KG, Morselli PL, Depoortere J, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 1983; 18(6):957-966.	6/5/1905
J-734	Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G (1987b): Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 241:245-250.	1987
J-735	Loffler M, Bubl B, Huethe F, Hubbe U, McIntosh JM, Jackisch R, Feuerstein TJ. Dopamine release in human neocortical slices: Characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. Brain Research Bulletin 2006;.	2006
J-736	Loscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neuroscience Letters 1991;128(2):150-154.	1991
J-737	Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res. 2006; 69:183-272.	2006
J-738	Lotarski SM, Kinsora J. Behavioral characterization of pregabalin in congenic $\alpha 2$ -d-1(R217A) mouse mutants in models of anxiety and side effects. Soc Neurosci Abstr 2006 (program number 829.3).	2006
J-739	Lubell, et al. Suicide Trends Among Youths and Young Adults Aged 10--24 Years ---United States, 1990-2004. MMWR. September 7,2007/56(35);905-908.	2007
J-740	Lumley, CD., et al. The under-reporting of adverse drug reactions seen in general practice. Pharmaceut Med 1986; 1:205-12.	1986
J-741	Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR. Injury type-specific calcium channel α -2-delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of Gabapentin. J Pharmacol Exp Ther.	2003

J-742	Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion alpha-2-delta calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001; 21(6):1868-1875.	2001
J-743	Lydiard RB. Panic disorder and social phobia: possible implications of comorbid depression for drug therapy. Anxiety. 1996;2(2):61-70.	1996
J-744	Magee WJ et al. Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 1996;53:159-68.	1996
J-745	Magni G et al. Suicidality in chronic abdominal pain: an analysis of the Hispanic Health and Nutritional Examination Survey (NS). Pain 1998;76:137-144.	1998
J-746	Magni G, Garreau M, Orofiamma B, Palminteri R (1989): Fengabine, a new GABA-mimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology 20:126-131.	1989
J-747	Maier SF, Busch CR, Maswood S, Grahm RE, Watkins LR (1995): The dorsal raphe nucleus is a site of action mediating the behavioral effects of the benzodiazepine receptor inverse agonist DMCM. Behav Neurosci 109:759-766.	2003
J-748	Mairs, RW. Social and Familial Risk Factors in Suicidal Behavior. Suicide 1997; 20(3): 519-551.	1997
J-749	Manchanda R et al. Psychiatric disorders in candidates for epilepsy surgery. J Neurol Neurosurg Psychiatry 1996;61 :82-9.	1996
J-750	Manchikanti L, Singh V. Managing phantom pain. Pain Phys 2004; 7(3):365-75.	2004
J-751	Manchikanti L, Singh, V, Kloth D. Slipman W. Et al. Interventional Techniques in Management of Chronic Pain: Part 2.0. Pain Physician. 2001; 4(1):24-98.	2001
J-752	Maneuf YP, Blake R, Andrews NA, McKnight AT. Reduction by Gabapentin of K+-evoked release of [3H]-glutamate from the caudal trigeminal nucleus of the streptozotocin-treated rat. British Journal of Pharmacology 2004; 141(4):574-579.	2004
J-753	Maneuf YP, Gonzalez MI, Sutton KG, Chung FZ, Pinnock RD, Lee K. Cellular and molecular action of the putative GABA-mimetic, Gabapentin. Cell Molec Life Sci 2003; 60(4):742-750.	2003
J-754	Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001; 93(2):191-196.	2001

J-755	Maneuf YP, McKnight AT. Block by Gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001; 134(2):237-240.	2001
J-756	Maneuf, Y. P., Z. D. Luo, et al. (2006). "alpha2delta and the mechanism of action of Gabapentin in the treatment of pain." Semin Cell Dev Biol. 17(5): 565-70.	2006
J-757	Mann, J. J. Searching for Triggers of Suicidal Behavior. Am J Psychiatry 2004; 161(3): 395-397.	2004
J-758	Mann, J.J. and Gibbons R.D. SSRIs and the risk of suicide attempt and completion: a systematic review of observational studies. Canadian Medical Association Journal, in press.	2009
J-759	Manor D, Rothman DL, Mason GF, Hyder F, Petroff OA, Behar KL. The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA). Neurochemical Research 1996; 21(9):1031.	1996
J-760	Marangell L et al., Psychopharmacology and Electroconvulsive Therapy, p. 1025 in: The American Psychiatric Press Textbook of Psychiatry (Hales R, et al., eds.) 3rd ed. 1999.	1999
J-761	Marcangelo, M. Psychiatric Aspects of Epilepsy. Psychiatr Clin N Am 30 (2007) 781-802.	2007
J-762	Maris, R. Suicide. Lancet 2002; 360:319-26.	2002
J-763	Maris, RW. Social and Familial Risk Factors in Suicidal Behavior. Suicide 1997; 20(3): 519-551.	1997
J-764	Maris, RW. Suicide Prevention in Adults (age 30-65). Suicide and Life Threatening Behavior 1995; 25(1): 171-179.	1995
J-765	Marsteller DA, Barbarich-Marsteller NC, Patel VD, Dewey SL (2007): Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and gamma-amino butyric acid levels. Synapse 61:877-881.	2007
J-766	Martin D, Thompson MA, Nadler JV (1993): The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 250:473-476.	1993
J-767	Martin DJ, McClelland D, Herd MB, Sutton KG, Hall MD, Lee K, Pinnock RD, Scott RH. Gabapentin-mediated inhibition of voltage-activated Ca-2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression.	2002
J-768	Mason G, Watzl J, Gomez R, Krystal J, Rothman D, Sanacora G. Effects of light deprivation on brain GABA and glutamate in healthy and depressed individuals.	2006

	Neuropsychopharmacology 2006;31:S160.	
J-769	Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005): Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379-2381.	2005
J-770	Mattews, W. and Barabas, G. Suicide and epilepsy: A review of the literature. Psychosomatics 1981; 22:515-24.	1981
J-771	Matthews, SC., Dimsdale, JE. Priapism after a Suicide Attempt by the Ingestion of Olanzapine and Gabapentin. Psychosomatics 2001; 42(3): 280-281.	2001
J-772	Mattson RH, Petroff OA, Rothman D, Behar K. Vigabatrin: Effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol. Scand. Suppl. 1995;162:27-30.	1995
J-773	Mauri MC, et al.: Gabapentin and the prophylaxis of bipolar disorders in patients intolerant to lithium. Clin Drug Invest 21(3):169-74, 2001.	2001
J-774	Max MB, Culname M, Schafer SC, et al. Amtrptyline relieves diabetic neuropathic pain in patients with normal or depressed mood. Neurology. 1987; 37:589-590.	1987
J-775	Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 1991; 45:3-5.	1991
J-776	McCleane G. Pharmacological Strategies in Relieving Neuropathic Pain. Expert Opin. Pharmacother. 2004; 5(6):1299-1312.	2004
J-777	McClelland D, Evans RM, Barkworth L, Martin DJ, Scott RH. A study comparing the actions of Gabapentin and pregabalin on the electrophysiological properties of cultured DRUG neurones from neonatal rats. BMC Pharmacol 2004; 4:14-24.	2004
J-778	McElroy SL, Keck PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biological Psychiatry 48(6):539-57, Sep 15 2000.	2000
J-779	McElroy SL, Soutulo CA, Keck PE Jr., et al. A pilot trial of adjunctive Neurontin in the treatment of bipolar disorder. Ann Clin Psychiatry 1997; 9:99-103.	1997
J-780	McEwen BS, Olie JP (2005): Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol Psychiatry 10:525-537.	2005
J-781	McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus-Miller L, Bernstein P, Rose-Legatt A. Safety and tolerability of gabapentin as adjunctive therapy in a large, multicenter study. Epilepsia 1999;40(7):965-72.	1999

J-782	McKenna KF, McManus DJ, Baker GB, Coutts RT (1994): Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm 41S:115-122.	1994
J-783	McManus DJ, Baker GB, Martin IL, Greenshaw AJ, McKenna KF (1992): Effects of the antidepressant/antipanic drug phenelzine on GABA concentrations and GABA-Transaminase activity in rat brain. Biochem Pharmacol 43:2486-2489.	1992
J-784	McPhee SJ, Papadakis MA and Tierney LM. Neuropathic Pain. In Current Medical Diagnosis and Treatment, McGraw Hill Medical, New York. 2007, pp. 68-86.	2007
J-785	McQuay, H. J., K. H. Poon, et al. (2008). "Acute pain: combination treatments and how we measure their efficacy." Br J Anaesth 101(1): 69-76.	2008
J-786	Meder WP et al, Modulation of K ⁺ -induced synaptosomal calcium influx by Gabapentin. Brain Res. 2000; 875: 157-159.	2000
J-787	Medical Uses of Statistics, 2nd Edition.	
J-788	Meininger, MM. and Bar, WS. Prospective Study of the Influence of the Media on Reporting Medical Events. Drug Inf J 1990; 24:575-77.	1990
J-789	Meldrum, B. S. and M. A. Rogawski (2007). "Molecular targets for antiepileptic drug development." Neurotherapeutics 4(1): 18-61.	2007
J-790	Mellegars MA, Furlan AD, Mailis A. Gabapentin for Neuropathic Pain: Systematic Review of Controlled and Uncontrolled Literature. Clin. J. Pain. 2001; 17(4):284-295.	2001
J-791	Mellick GA, Mellick LB. Reflex Sympathetic Dystrophy Treated With Gabapentin. Arch. Phys. Med. Rehabil. 1997; 78:98-105.	1997
J-792	Mendez, MF., et al. Depression in Epilepsy: Significance and Phenomenology. Arch Neurol 1986; 43(8):766-70.	1986
J-793	Menigaux C, Adam F, Guignard B, Sessler D, Chauvin M. Preoperative Gabapentin Decreases Anxiety and Improves Early Functional Recovery From Knee Surgery. Anesth. Analg. 2005; 100:1394-1399.	2005
J-794	Mera J, Martinez-Castrillo JC, Mariscal A, Herrero A, Alvarez-Cemeno JC. Autonomous stump movements responsive to Gabapentin. J Neurol 2004; 25(3)(Mar):346-7.	2004
J-795	Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Cancer 2001; 9(3)(May):205-6.	2001

J-796	Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B (2003): Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychological Med.	2003
J-797	Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006; 70(2):467-476.	2006
J-798	Miller RG, Mitchell JD, Lyon M, Moore DH (2007): Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev:CD001447.	2007
J-799	Milstein JR, et al. Factors affecting physician reporting of adverse drug reactions. Drug Inf J 1986; 20:157-64.	1986
J-800	Mirchandani GR, Agulian S, Abi-Saab W, Tyrrell L, Mattson RH, Kocsis JD. Vigabatrin increases total GABA levels in rat optic nerve while Gabapentin and pregabalin do not. Soc Neurosci Abstr 1999; 25:1868-1868.	1999
J-801	Mizik, Natalie, and Jacobson, Robert, "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," Management Science, Volume 50, Dec. 2004.	2004
J-802	Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, et al (1985): 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission--I. Anticonvulsant properties. Neuropharmacology 24:767-773.	1985
J-803	Moghaddam B, Jackson M (2004): Effect of stress on prefrontal cortex function. Neurotox Res 6:73-78.	2004
J-804	Mongeau R, De Montigny C, Blier P. Effect of long-term administration of antidepressant drugs on the 5-HT ₃ receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus. European Journal of Pharmacology 1994; 271(1):12.	1994
J-805	Moore, N., et al. Biases Affecting the Proportional Reporting Ratio (PRR) in Spontaneous Reports Pharmacovigilance Databases: the Example of Sertindole. Pharmacoepidemiology and Drug Safety 2003; 12(4):271-81.	2003
J-806	Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized Double-Blind Study Comparing the Efficacy of Gabapentin with Amitriptyline on Diabetic Peripheral Neuropathy Pain. Arch. Int. Med. September 13, 1999;159:"1931-1937.	1999
J-807	Morilak DA, Barrera G, Echevarria DJ, Garcia AS, Hernandez A, Ma S, Petre CO. Role of brain norepinephrine in the behavioral response to stress. Progress in Neuro-	2005

	Psychopharmacology & Biological Psychiatry 2005;29(8):1214-1224.	
J-808	Morse R. Search script for the COSTART Thesaurus of Adverse Reaction Jan 1994. Available at: http://hedwig.mgh.harvard.edu/biostatistics&iode/17 .	1994
J-809	Morrell, MJ. Dosing to Efficacy with Neurontin: The STEPS Trial. <i>Epilepsia</i> 1999; 40 (supp 6): S23-26.	1999
J-810	Morrell MJ, Mclean MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus L, Bernstein P, Rose-Legatt A. Efficacy of gabapentin as adjunctive therapy in a large, multicenter study. <i>Seizure-European Journal of Epilepsy</i> 2000;9(Jun):241-8.	2000
J-811	Moscicki E. Epidemiology of suicide. In: Goldsmith S, ed. "Risk factors for Suicide" Washington, DC: National Academy Press, 2001:10-12.	2001
J-812	Mosholder AD, C. Pamer. "Postmarketing Surveillance of Suicidal Adverse Events with Pediatric Use of Antidepressants." <i>Journal of Child and Adolescent Psychopharmacology</i> 16(2006): 33-36.	2006
J-813	Moulin DE. Peripheral Neuropathic Pain Disorders. In Noseworthy JH (00.), <i>Neurologic Therapeutics: Principles and Practice</i> , Marn Dunitz, London. 2003, pp. 222-229.	2003
J-814	Moulin, D. E., A. J. Clark, et al. (2007). "Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society." <i>Pain Res Manag</i> 12(1): 13-21.	2007
J-815	Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. <i>Drug Safety</i> 2007; 30(7):555-567.	2007
J-816	Nakagawa A, Grunebaum MF, Ellis SP, Oquendo MA, Kashima H, Gibbons RD, Mann JJ. Association of suicide and antidepressant prescription rates in Japan, 1999-2003. <i>J Clin Psychiatry</i> 2007 Jun;68(6):908-16.	2007
J-817	Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T (1996): Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. <i>Brain Res</i> 709:21.	1996
J-818	Namaka M, Gramlich CR, Ruben D, Melanson M, Sutton I, Major J. A Treatment Algorithm for Neuropathic Pain. <i>Clin. Therapeutics</i> . 2004; 26(7):951 -979.	2004
J-819	Nasr SJ, Gibbons RD. Depressive symptoms associated with dexamethasone resistance. <i>Psychiatry Res</i> . 1983 Nov;10(3):183-9.	1983

J-820	Neal, A., Huntly, K., Doan, V., Zielonka, J. MedDRA and pharmacovigilance - the way forward. DIA annual meeting. June 27-July 1999. Slide # 7.	1999
J-821	Nemeroff, CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37(4):133-146.	2003
J-822	Neugebauer V, Carlton SM. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opinion on Therapeutic Targets 2002; 6(3):349-361.	2002
J-823	Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE. Gamma-aminobutyric acid type B receptors with specific heterodimer composition and post.	2001
J-824	Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A, et al (2003): Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23:155-168.	2003
J-825	Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth 2001; 87(1):107-16.	2001
J-826	Nilsson Let al. Risk factors for suicide in epilepsy: a case control study. Epilepsia 2002;43:644-51.	2002
J-827	Nodera H, ReDmann DN. A Diagnostic and Treatment Approach to Painful Neuropathy. In Bromberg MB, Smith AG (eds.), Handbook of Periphera Neuropathy, Taylor & Francis, Boca Raton. 2005.	2005
J-828	O'Brien RF. Medical Conditions with Psychiatric Manifestations. Adolesc Med 17 (2006) 49-77.	2006
J-829	O'Connell KA, Wilkin JK, Pitts M. Isotretinon (Accutane) and Serious Psychiatric Adverse Events. JAm Acad Dermatol 2002; 48(2): 306-308.	2002
J-830	Ohayon, "Specific Characteristics of the Pain/Depression Association in the General Population," J Clin Psychiatry 2004; 65 (suppl 12): 5-9.	2004
J-831	Ohayon, et al., "Using Chronic Pain to Predict Depressive Morbidity in the General Population," Arch Gen Psychiatry 2003; 60:39-47.	2003
J-832	Ohring R, Apter A, Ratzoni G, Weizman R, TyanoS, Plutchik R. State and trait anxiety in adolescent suicide attempters. JAm Acad child Adolesc Psychiatry. 1996 Feb;35(2):154-7.	1996
J-833	Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T. A comparison of Ca ²⁺ channel blocking mode between Gabapentin and verapamil: implication for protection against hypoxic injury in rat cerebrocortical slices. British Journal of Parmacology 2003a; 39(2):435-443.	2003

J-834	Oka M, Itoh Y, Wada M, Yamamoto A, Fujita T. Gabapentin blocks L-type and P/Q-type Ca ²⁺ channels involved in depolarization-stimulated nitric oxide synthase activity in primary cultures of neurons from mouse cerebral cortex. <i>Pharm Res</i> 2003; 20(6):897-899.	2003
J-835	Olfson M, Shaffer D. SSRI prescriptions and the rate of suicide. <i>Am J Psychiatry</i> . 2007 Dec;164(12):1907-8; author reply 1908-10.	2007
J-836	Olsen RW, Ticku MK, Van Ness PC, Greenlee D (1978): Effects of drugs on gamma-aminobutyric acid receptors, uptake, release and synthesis in vitro. <i>Brain Res</i> 139:277-279.	1978
J-837	Oquendo MA, Malone KM, Ells SP, Sackeim HA, Man JJ. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. <i>Am J Psychiatry</i> . 1999 Feb;156(2):190-4.	1999
J-838	Ostrow DG, Halaris A, DeMet E, Gibbons RD, Davis JM. Ion transport and adrenergic function in major affective disorder. <i>Biol Psychiatry</i> . 1982 Sep;17(9):971-80.	1982
J-839	Page ME, Abercrombie ED. An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. <i>Neuropsychopharmacology</i> 1997; 6(6):419-425.	1997
J-840	Pande AC, Crockett JG, Janney CA, Worth JL, Tsamoucha O. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. <i>Bipolar Disord</i> 2000; 220:(3 Pt 2): 249-255.	2000
J-841	Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with Gabapentin: A placebo-controlled study. <i>J Clin Psychopharmacol</i> 1999; 19(4):341-348.	1999
J-842	Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of Gabapentin treatment of panic disorder. <i>J Clin Psychopharmacol</i> . 2000 Aug;20(4):467-71.	2000
J-843	Pandey CK, Sahay S, Gupta D, et al. Preemptive Gabapentin Decreases Postoperative Pain After Lumbar Discectomy. <i>Regional Anesthesia and Pain</i> . <i>Can J. Anesth</i> . 2004; 51(10):986-989.	2004
J-844	Pandey CK. Does Preemptive use of Gabapentin Have No Effect on Postoperative Pain and Morphine Consumption Following Lumbar Laminectomy and Discectomy (Correspondence). <i>Neurosurg. Anesthesiol</i> . July 2005; 17(3): 172-173.	2005
J-845	Pape HC (2005): GABAergic neurons: gate masters of the amygdala, mastered by dopamine. <i>Neuron</i> 48:877-879.	2005

J-846	Parent MB, Master S, Kashlub S, Baker GB (2002): Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenyl ethylamine hydrazine on extracellular gamma-aminobutyric acid levels in the striatum. <i>Biochem Pharmacol</i> 63:57-64.	2002
J-847	Parker DA, Ong J, Marino D, Kerr DI. Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. <i>Eur J Pharmacol</i> 2004; 495(2-3):137-143.	2004
J-848	Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. <i>Neuropharmacology</i> 1999; 38(6):735-767.	1999
J-849	Paslawski TM, Sloley BD, Baker GB. Effects of the mao inhibitor phenelzine on glutamine and gaba concentrations in rat brain. <i>Progress in Brain Research</i> 1995; 106:181-186.	1995
J-850	Patel GJ, Schatz RP, Constantinides SM, Lal H (1975): Effect of desipramine and pargyline on brain gamma-aminobutyric acid. <i>Biochem Pharmacol</i> 24:56-60.	1975
J-851	Patel S, Naeem S, Kesingland A, Froestl W, Capogna M, Urban L, Fox A. The effects of GABA(b) agonists and Gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. <i>Pain</i> 2001; 90(3):217-226.	2001
J-852	Pentien J. Back pain and risk of suicide among Finnish farmers. <i>Am J Public Health</i> 1995 ;85: 1452-53.	1995
J-853	Perry TL, Hansen S (1973): Sustained drug-induced elevation of brain GABA in rat. <i>J Neurochem</i> 21:1667-1175.	1973
J-854	Perry, CFS amino acids and plasma CSF amino acid ratios in adults. <i>J Neurochem</i> 1975; 24: 587-89.	1975
J-855	Perugi G, et al.: Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. <i>Pharmacopsychiatry</i> 32:136-41, 1999.	1999
J-856	Perugi G, Toni C, Frare F, Ruffulo G, Moretti L, Torti C, Akiskal HS (2002):Effectiveness of adjunctive Gabapentin in Resistant Bipolar Disorder: Is It Due to Anxious-Alcohol Abuse Comorbidity? <i>J Clin Psychopharmacol</i> 22(6): 584-91.	2002
J-857	Petroff OA, Behar KL, Mattson RH, Rothman DL. Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. <i>J Neurochem</i> 1996; 67(6):2399-2404.	1996
J-858	Petroff OA, Hyder F, Collins T, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. <i>Epilepsia</i> 1999; 40(7):958-964.	1999

J-859	Petroff OA, Hyder F, Mattson RH, Rothman D. Topiramate increases brain GABA, homocarnosine and pyrrolidinone in patients with epilepsy. <i>Neurology</i> 1999; 52:473-478.	1999
J-860	Petroff OA, Hyder F, Rothman DL, Collins TL, Mattson RH. Gabapentin increases human brain GABA within one hour. <i>Epilepsia</i> 1998; 39(Suppl. 6):71.	1998
J-861	Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of Gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. <i>Epilepsia</i> 2000; 41(6):675-680.	2000
J-862	Petroff OA, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. <i>Neurology</i> 1996; 47(6):1567-1571.	1996
J-863	Petroff OA, Rothman DL, Behar KL, Hyder F, Mattson RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures. <i>Seizure</i> 1999; 8(2):120-127.	1999
J-864	Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of Gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. <i>Ann Neurol</i> 1996; 39(1):95-99.	1996
J-865	Petroff OA, Rothman DL. Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. <i>Mol Neurobiol</i> 1998; 16(1):97-121.	1998
J-866	Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations on effect of vigabatrin on in vivo 1H spectroscopic measurements of gamma-aminobutyric acid, glutamate and glutamine in human brain. <i>Epilepsia</i> 1995; 36(5):457-464.	1995
J-867	Petty F (1994): Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? <i>Clin Chem</i> 40:296-302.	1994
J-868	Petty F, Kramer GL, Hendrickse W (1993): GABA and depression. In: Mann JJ, Kupler DJ editors. <i>Biology of depressive disorders, Part A: A systems perspective</i> . New York: Plenum Press, pp 79-108.	1993
J-869	Petty F, Sherman AD (1981): GABAergic modulation of learned helplessness. <i>Pharmacol Biochem Behav</i> 15:567-570.	1981
J-870	Petty, F, et. al, Plasma GABA Predicts Acute Response to Divalproex in Mania. <i>Biol Psychiatry</i> 1996; 39(4): 278-284.	1996
J-871	Petty, F, Schlessner, MA Plasma GABA in Affective Illness: Preliminary Investigation <i>J Aff Dis</i> 1981; (3): 339-43.	1981
J-872	Petty, F, Sherman, AD. Plasma GABA Levels in Psychiatric Illness. <i>J Aff Dis</i> 1984; (6): 131-38.	1984
J-873	Piazza-Hepp, TO. and Kennedy, DL. Reporting of Adverse Events to MedWatch. <i>Am J Health-Syst Pharm</i> 1995;	1995

	52:1436-39.	
J-874	Pilc A, Lloyd KG (1984): Chronic antidepressants and GABAB receptors: A GABA hypothesis of antidepressant drug action. <i>Life Sci</i> 35:2149-2154.	1984
J-875	Pittaluga A, Raiteri L, Longordo F, Luccini E, Barbiero VS, Racagni G, et al (2007): Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. <i>Neuropharmacology</i> 53:27-36.	2007
J-876	Polydefkis M. Painful Neuropathy. In Johnson RT, Griffin JW, McArthur JC (eds.), <i>Current Therapy in Neurologic Disease</i> , 6th Edition, Mosby, St Louis. 2002, pp. 373-375.	2002
J-877	Poncelet M, Martin P, Danti S, Simon P, Soubrie P (1987): Noradrenergic rather than GABAergic Processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals. <i>Pharmacol Biochem & Behavior</i> 28:321-326.	1987
J-878	Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of H-channels reduces the excitability of pyramidal neuron dendrites. <i>Nature Neurosci.</i> 2002;5:767-774.	2002
J-879	Popov N, Matthies H (1969): Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. <i>J Neurochem</i> 16:899-907.	1969
J-880	Posner K, Oquendo MA, Gould M, Stacey B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of Suicidal Events in the FDA's Pediatric Suicidal Risk Analysis of Antidepressants. <i>Am J Psychiatry</i> 2007; 164:1035-1043.	2007
J-881	Pugsley TA, Whetzel SZ, Dooley DJ. Reduction of 3,4-diaminopyridine-induced biogenic amine synthesis and release in rat brain by Gabapentin. <i>Psychopharmacology Berlin</i> 1998; 137(1):74-80.	1998
J-882	Putzke JD, Richards JS, Kezar L, Hicken BL, Ness TJ. Long-term use of Gabapentin for treatment of pain after traumatic spinal cord injury. <i>Clin J. Pain</i> 2002; 18(2)(Mar/Apr):116-21.	2002
J-883	Quanbeck, C. Forensic Psychiatric Aspects of Inpatient Violence. <i>Psychiatr Clin N Am</i> 29 (2006) 743-760.	2006
J-884	Quetsch RM, Achor RWP, Litin EM, Faucett RL. Depressive reactions in hypertensive patients: A comparison of these treated with rauwolfia and those receiving no specific antihypertensive treatment. <i>Circulation</i> 1959; 19:366-375.	1959
J-885	Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. <i>Arch Intern Med</i> 2006; 166:	2006

	1021-1026.	
J-886	Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ (2007): GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 32:471-482.	2007
J-887	Rao ML, Clarenbach P, Vahlensieck M, Kratzschmar S. Gabapentin augments whole blood serotonin in healthy young men. J. Neural. Transm. 1998; 73:129-134.	1998
J-888	Rawlins, MD. Spontaneous reporting of adverse drug reactions. I: the data. Br J Clin Pharmacol. 1988 Jul; 26(1):1-5.	1988
J-889	Reeves RR. Nocebo effects with antidepressant clinical drug trial placebos. General Hospital Psychiatry 29 (2007) 275–277.	2007
J-890	Reimann W, Zumstein A, Jackisch R, Starke K, Hertting G. Effect of extracellular dopamine on the release of dopamine in the rabbit caudate nucleus: Evidence for a dopaminergic feedback inhibition. Naunyn-Schmiedeberg's Archives of Pharmacology 1979; 306.	1979
J-891	Reimann W. Inhibition by GABA, baclofen and Gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Europe J Pharmacol 1983; 94:341-344.	1983
J-892	Rice ASC, Maton S. Gabapentin in Post-Herpetic Neuralgia: a Randomized, Double-Blind, Placebo Controlled Study. Pain. 2001; 94(2):215-224.	2001
J-893	Rickels, Pregabalin for the treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat 2005; 62: 1022-30.	2005
J-894	Rihmer Z et al. Bipolar II disorder and suicidal behavior. Psychiatry Clin North Am 1999;22:667-73.	1999
J-895	Rizzo, J., "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs, "Journal of Law and Economics, 42:1, 1999.	1999
J-896	Robert M. Kaplan & Igor Grant, 5.2 Statistics and Experimental Design, in Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Volume 1, (Benjamin I. Sadock & Virginia A. Sadock eds., 7th ed. 2000) 522.	2000
J-897	Robertson MM. Suicide parasuicide and epilepsy. In: Engel J et al. eds. Epilepsy: a Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1997 :2141-51.	1997

J-898	Rock DM, Kelly KM, Macdonald RL. Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons. <i>Epilepsy Res</i> 1993; 16(2):89-98.	1993
J-899	Rogawski MA, Taylor CP. Section 2.4.2. Potential new targets for development of anti-ictal drugs: How to improve efficacy versus tolerability? Ion channels. In: Schmidt D, Loescher W. Critical review: Drug resistance in epilepsy: Putative neurobiologic an.	2006
J-900	Rogawski, M. A. and W. Loscher (2004). "The neurobiology of antiepileptic drugs." <i>Nature Reviews Neurosci</i> 5: 553-564.	2004
J-901	Rogers, AM., et al. Physician knowledge, attitudes, and behavior related to reporting adverse drug events. <i>Arch Intern Med</i> 1988; 148:1596-1600.	1988
J-902	Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, et al (1998): Effects of antidepressant treatment on neuroactive steroids in major depression. <i>Am J Psychiatry</i> 155:910-913.	1998
J-903	Roose SP, Glassman AH, Walsh BT, Woodring S, Vitas-Herne J. Depression, delusions, and suicide. <i>Am J Psychiatry</i> . 1983 Sep;140(9):1159-62.	1983
J-904	Rorarius MGF, Mennander S, Suimien P, et al. Gabapentin for the Prevention of Postoperative Pain After Vaginal Hysterectomy. <i>Pain</i> . 2004; 110: 175-181.	2004
J-905	Rosenblatt JE, Rosenblatt, NC: Gabapentin for bipolar disorder. <i>Currents in Affective Illness</i> 15(6):2-3, 1996.	1996
J-906	Rossi AR., et al. The importance of physician adverse reaction reporting: suprofen and the flank pain syndrome. <i>JAMA</i> 1988; 259:1203-04.	1988
J-907	Rothman DL, Petroff OA, Behar KL, Mattson RH. Localized ¹ H NMR measurements of gamma-aminobutyric acid in human brain in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> 1993; 90(12):5662-5666.	1993
J-908	Rothman KJ, Greenland S. <i>Modern Epidemiology</i> . 2nd ed. Lippincott, Williams and Wilkins, Philadelphia, 1998.	1998
J-909	Rothman, Greenland & Lash <i>Modern Epidemiology</i> , 3rd Edition. Lippincott Williams & Wilkins. 2008. Philadelphia, PA.	2008
J-910	Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Mier L. Gabapentin for the Treatment of Postherpetic Neuralgia: a Randomized Controlled Trial. <i>JAMA</i> . December 2, 1998; 280(21):1837-1842.	1998
J-911	Rowbotham MC. Mechanisms and Pharmacologic Management of Neuropathic Pain. In Dyck PJ, Thomas PK (eds.), <i>Peripheral Neuropathy</i> , Four Edition, Elsevier Saunders, New	2005

	York. 2005, pp. 2637-2652.	
J-912	Ruhe HG, Mason NS, Schene AH (2007): Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331-359.	2007
J-913	Rush AJ (2007): STAR*D: What have we learned? Am J Psychiatry 164:201-204.	2007
J-914	Sachs, GS, et al.: Expert Consensus Guideline Series-medication treatment of bipolar disorder 2000. Postgraduate Med Apr:1-104, 2000.	2000
J-915	Saks MJ, Faigman DL, Kaye DH, Sanders J (Eds). Annotated Reference Manual on Scientific Evidence (2005-2006). St. Paul, Minnesota: Thomson West;526-535.	2005
J-916	Salas, et al. Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology. American Journal of Epidemiology 1999; 149(11):981-983.	1999
J-917	Salzman C. Treatment of the Suicidal Patient with Psychotropic Drugs and ECT, p. 272 in: Harvard Medical School Guide to Suicide Assessment and Intervention (Jacobs D, ed.) 1999.	1999
J-918	Sanacora G, Gueorguieva R, Epperson CN, Wu Y-T, Appel M, Rothman DL, et al (2004): Subtype-specific alterations of GABA and glutamate in major depression. Archives of General Psychiatry 61:705-713.	2004
J-919	Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH (2007): Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61:822-825.	2007
J-920	Sanacora G, Mason GF, Krystal JH. Impairment of GABAergic Function in Depression: New Insights from Neuroimaging. Critical Reviews of Neurobiology 2000;14:23-45.	2000
J-921	Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, et al (1999): Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Archives of General Psychiatry 56:1043-1047.	1999
J-922	Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased cortical GABA concentrations in depressed patients receiving ECT. Amer. J. Psychiat. 2003;160(3):577-579.	2003
J-923	Sanacora G, Mason GF, Rothman DL, Krystal JH (2002): Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake	2002

	inhibitors. American Journal of Psychiatry 159:663-665.	
J-924	Sanacora G, Saricicek A (2007): GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol Disord Drug Targets 6:127-140.	2007
J-925	Sander JM, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry 1991; 54(5):435-439.	1991
J-926	Sander JM, Hart YM. Vigabatrin and behavior disturbances. Lancet 1990; 335(8680): 57.	1990
J-927	Saper CB. Brain stem modulation of sensation, movement and consciousness. Chapter 45 in: Principles of Neural Science, 4th edition, Kandel ER, Schwartz JH, Jessell TM (eds.), McGraw-Hill, New York, 2001.	2001
J-928	Sapolsky RM (2000): The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biological Psychiatry 48:755-765.	2000
J-929	Sartorius A, Mahlstedt MM, Vollmayr B, Henn FA, Ende G (2007): Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. Neuroreport 18:1469-1473.	2007
J-930	Sator-Katzenschlatger SM, Schiesser AQ, Kozek-Langenecker SA, Benetka G, Langer G, Kress HG Does pain relief improve pain behavior and mood in chronic pain patients? Anesth Analg 2003; 97(3)(Sep):791-7.	2003
J-931	Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneimittelforschung 1994; 44(3):261-266.	1994
J-932	Scatton B, Lloyd KG, Zivkovic B, Dennis T, Claustre Y, Dedek J, et al (1987): Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther 241:251-257.	1987
J-933	Schatz RA, Lal H (1971): elevation of brain GABA by Pargyline: A possible mechanism for protection against oxygen toxicity. J Neurochem 18:2553-2555.	1971
J-934	Schatzberg AF, Nemeroff CB. Depression and gamma-aminobutyric acid, page 736 in: The American Psychiatric Publishing Textbook of Psychopharmacology, 3rd Ed. 2004.	2004
J-935	Schatzberg, "The Relationship of Chronic Pain and Depression," J. Clin. Psychiatry 2004; 65 (suppl 12).	2004
J-936	Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE et al. Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRX 2005;2:590-611.	2005

J-937	Schlicker E, Brandt F, Classen K, Gothert M. Serotonin release in human cerebral cortex and its modulation via serotonin receptors. Brain Research 1985; 331:337-341.	1985
J-938	Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneim Forsch - Drug Res 1985; 35(9):1347-1349.	1985
J-939	Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006; (47) (supp. 2):28-33.	2006
J-940	Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 (Supp. 10):S65-S70.	1999
J-941	Schmitz EB, Robertson J, Trimble MR Depression and Schizophrenia in Epilepsy: Social and Biological Risk Factors: Epilepsy Research 1999; 35 :59-68.	1999
J-942	Schnyder U, Valach L, Bichsel K, Michel K. Attempted suicide. Do we understand the patients' reasons? Gen Hosp Psychiatry. 1999 Jan-Feb; 21(1):62-9.	1999
J-943	Scholz, J. and C. J. Woolf (2002) "Can we conquer pain?" Nat Neurosci 5 Suppl: 1062- 7.	2002
J-944	Scott, HS., et al. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA 1990; 263:1785-88.	1990
J-945	Selai C, Bannister D, Trimble M. Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy. Epilepsia 2005; 46(Suppl. 4):50-57.	2005
J-946	Serpell MG, Neuropathic Pain Study Group. Gabapentin in Neuropathic Pain Syndromes: a Randomized, Double-Blind, Placebo-Controlled Trial. Pain. 2002; 99(3):557-566.	2002
J-947	Shank RP, Smith-Swintosky VL, Maryanoff BE. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J. Enzyme Inhib. Med. Chem. 2008;23:271-276.	2008
J-948	Shawn J. Bird and Mark J. Brown, Diabetic Neuropathies, in Neuromuscular Disorders in Clinical Practice. 2002.	2002
J-949	Sherman AD, Petty F (1980): Neurochemical basis of the action of antidepressants on learned helplessness. Behav Neural Biol 30:119-134.	1980
J-950	Sherman AD, Petty F (1982): Additivity of neurochemical changes in learned helplessness and imipramine. Behav Neural Biol 35:344-353.	1982
J-951	Sheth RD, Buckley D, Penney S, Hobbs GR. Vigabatrin in childhood epilepsy: comparable efficacy for generalized and partial seizures. Clin Neuropharmacol 1996; 19 (4):297-304.	1996

J-952	Shiah I, Yatham LN. GABA function in mood disorders: An update and critical review. Life Sciences 1998;63:1289-1303.	1998
J-953	Shimizu S, Honda M, Tanabe M, Oka J-I, Ono H. Endogenous GABA does not mediate the inhibitory effects of Gabapentin on spinal reflexes in rats. J Pharmacol Sci 2004a; 94:137-143.	2004
J-954	Shimizu S, Honda M, Tanabe M, Ono H. GABAB receptors do not mediate the inhibitory actions of Gabapentin on the spinal reflex in rats. J Pharmacol Sci 2004b; 96(4):444-449.	2004
J-955	Short C, Cooke L: Hypomania induced by gabapentin. Br J Psychiatry 166:679-680, 1995.	1995
J-956	Shukla G et al. Psychiatric manifestations in temporal lobe epilepsy: a controlled study. Br J Psychiatry 1979; 135 :411-7.	1979
J-957	Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. Vigabatrin, but not Gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 2003; 44(7):886-892.	2003
J-958	Sills GJ. Not another Gabapentin mechanism! Epilepsy Currents / American Epilepsy Society 2005; 5(2):75-77.	2005
J-959	Sills GJ. The mechanisms of action of Gabapentin and pregabalin. Current Opinion in Pharmacology 2006; 6(1):108-113.	2006
J-960	Silverman MM., Mars, RW. The Prevention of Suicidal Behaviors: an Overview. Suicide and Life Threatening Behavior 1995; 25(1): 10-20.	1995
J-961	Silverman RB, Andruszkiewicz R, Nanavati SM, Taylor CP, Vartanian MG. 3-alkyl-4-aminobutyric acids: The first class of anticonvulsant agents that activates l-glutamic acid decarboxylase. Journal of Medicinal Chemistry 1991;34:2295-2298.	1991
J-962	Silverstone PH, Silverstone T: A review of acute treatments for bipolar depression. Int Clin Psychopharmacol 19(3):113-24, May 2004.	2004
J-963	Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007 Jul;164(7):1029-34.	2007
J-964	Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN. The antiepileptic agent Gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacol 1996; 127(1):1-10.	1996
J-965	Smith L, Price-Jones M, Hughes K, Egebjerg J, Poulsen F, Wiberg FC, Shank RP. Effects of topiramate on kainite- and	2000

	domoate-activated [¹⁴ C]guanidinium ion flux through GluR6 channels in transfected BHK cells using Cytostar-T scintillating microplates. Epi.	
J-966	Smith MT., Edwards RR., et al. Suicidal ideation, plans, and attempts in chronic pain patients: factors associated with increased risk. Pain 2004; 111(1-2):201-8.	2004
J-967	Smith, et al., "Suicidal Ideation in Outpatients With Chronic Musculoskeletal Pain; An Exploratory Study of the Role of Sleep Onset Insomnia and Pain Intensity," Clin J Pain 2004; 20:111-118.	2004
J-968	Smolders I, Khan GM, Lindekens H, Prikken S, Marvin CA, Manil J, Ebinger G, Michotte Y. Effectiveness of vigabatrin against focally evoked pilocarpine-induced seizures and concomitant changes in extracellular hippocampal and cerebellar glutamate, gamma-am.	1997
J-969	Sokolski KN, Green C, Maris DE, DeMet EM: Gabapentin as an adjunct to standard mood stabilizers in outpatients with mixed bipolar symptomatology. Ann Clin Psychiatry 11(4):217-22, 1999.	1999
J-970	Song C, Leonard BE (2005): The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627-647. Epub 2005 Apr 2025.	2005
J-971	Spafford & Zamponi, Functional interactions between presynaptic calcium channels and the neurotransmitter release machinery. Curr. Opin Neurobiology 2003; 13: 308-314.	2003
J-972	Stahl, S. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd ed., Cambridge University Press, New York, 2000, pp. 135-197.	2000
J-973	Starke K, Reimann W, Zumstein A, Hertting G. Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology 1978; 305(1):27-36.	1978
J-974	Stefani A, et al. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacolog.1998; 37:83-91.	1998
J-975	Stefani A, Spadoni F, Bernardi G (1997): Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147:115-122.	1997
J-976	Stein MB et al. Social Anxiety disorder and the risk of depression. Arch Gen Psychiatry 2001; 58:251-56.	2001
J-977	Stenager E et al. Attempted suicide, depression and physical disease: a one year follow up study. Psychother Psychosom. 1994 ;61:65-73.	1994

J-978	Stone, MB, Jones, ML. Clinical Review: Relationship Between Antidepressant Drugs and Suicidality in Adults, U.S. Food and Drug Administration, November 17, 2006.	2006
J-979	Streeter CC, Hennen J, Ke Y, Jensen JE, Sarid-Segal O, Nassar LE, et al (2005): Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment. <i>Psychopharmacology (Berl)</i> :1-11.	2005
J-980	Streeter CC, Jensen JE, Perlmutter RM, Cabral HJ, Tian H, Terhune DB, Ciraulo DA, Renshaw PF. Yoga Asana sessions increase brain GABA levels: A pilot study. <i>Journal of Alternative and Complementary Medicine (New York, NY)</i> 2007; 13(4):419-426.	2007
J-981	Stringer JL, Ariibi AM. Modulation of the in vivo effects of Gabapentin by vigabatrin and SKF89976A. <i>Epilepsy Research</i> 2002; 52(2):129-137.	2002
J-982	Stringer JL, Lorenzo N. The reduction in paired-pulse inhibition in the rat hippocampus by Gabapentin is independent of GABA(B) receptor activation. <i>Epilepsy Research</i> 1999;33(2-3):169-176.	1999
J-983	Strom B and Melmon KL. Chapter 40. The use of pharmacoepidemiology to study beneficial drug effects. In: <i>Pharmacoepidemiology</i> . 3rd Edition. Strom Bed. Wiley & Sons. England. 2002 (electronic version).	2002
J-984	Strom B and Melmon KL. Chapter 40. The use of pharmacoepidemiology to study beneficial drug effects. In: <i>Pharmacoepidemiology</i> . 4th Edition. Strom Bed. Wiley & Sons. England. 2005 (electronic version).	2005
J-985	Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. <i>JAMA</i> , 2004, 292:2643-2626.	2004
J-986	Strom BL. Chapter 2. Study design available for pharmacoepidemiology studies. In: <i>Pharmacoepidemiology</i> . 4 Edition. Strom Bed. Wiley & Sons. England. 2005. (electronic version).	2005
J-987	Strom, BL "Evaluation of Suspected Adverse Drug Reactions – Reply," <i>JAMA</i> 293:1324 – 1325 (2005).	2005
J-988	Su TZ, Lunney E, Campbell G, Oxender DL. Transport of Gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: A comparative study in astrocytes, synaptosomes, and CHO cells. <i>J Neurochem</i> 1995; 64(5):2125-2131.	1995
J-989	Suicide Trends Among Youths and Young Adults Aged 10-24 - United States, 1990-2004. <i>MMWR</i> . September 7, 2007/56(35):905-908.	2007

J-990	Suman-Chauhan N, Webdale L, Hill DR, Woodruff GN. Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993; 244(3):293-301.	1993
J-991	Sung B, Lim G, Mao J (2003): Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 23:2899-2910.	2003
J-992	Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH. Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. British Journal of Pharmacology 2002; 135(1):257-265.	2002
J-993	Sutton KG, Snutch TP. Gabapentin: a novel analgesic targeting voltage- gated calcium channels. Drug Development Research 2002; 54(3):167-172.	2002
J-994	Tabarrok, A.T., "Assessing the FDA via the Anomaly of Off-Label Drug Prescribing," Independent Review, Volume 5(1), Summer 2000.	2000
J-995	Tai Q, Kirshblum S, Chen B, Millis S, Johnston M. Delissa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: A prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002; 25(2)(summer):100-5.	2002
J-996	Takasu K, Ono H, Tanabe M. Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. J. Neurochem. 2008;105:933-942.	2008
J-997	Takeuchi Y, Takasu K, Honda M, Ono H, Tanabe M. Neurochemical evidence that supraspinally administered gabapentin activates the descending noradrenergic system after peripheral nerve injury. Eur. J. Pharmacol. 2007;556(1-3):69-74.	2007
J-998	Tamez-Perez HE, Rodrguez AM, Gomez DO. Use of Gabapentin on Neuropathic Pain. Med. Intern Mex. 1998; 14:251-253.	1998
J-999	Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H. Role of descending noradrenergic system and spinal alpha2-adrenergic receptors in the effects of Gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharma.	2005
J-1000	Tanabe, M., K. Takasu, et al. (2008). "Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury." J Neurosci Res.	2008
J-1001	Taney BL. Psychiatric Diagnoses and Suicide, In Mars, R.W. et al, eds., Comprehensive Textbook of Suicidology. New York: Guilford, 2000:311-41.	2000

J-1002	Tang NK., Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med. 2006 May; 36(5):575-86.	2006
J-1003	Taylor CP (2002) Chapter 8, Sodium and calcium channel blockers, pp. 209-244 in: Marcoux FW, Choi DW (eds.) Handbook of Experimental Pharmacology: CNS Neuroprotection. Heidelberg, Germany: Springer Verlag.	2002
J-1004	Taylor CP, Donevan SD. Summary of preclinical pharmacological studies with gabapentin (CI 0945, PD 0087842 0000) in vitro and in laboratory animals, Section 5 [from May 2001 gabapentin neuropathic pain sNDA application], Pfizer Research Report RR 740-0355.	2001
J-1005	Taylor CP, et al. A summary of mechanistic hypotheses of Gabapentin pharmacology. Epilepsy Research 1998; 29(3):233-249.	1998
J-1006	Taylor CP, Garrido R, Joshi I, Budzyn B, Arneric S. (2006) Immunoreactivity for calcium channel alpha2-delta ($\alpha 2$ - δ) type 1 protein is localized at glutamate synaptic endings in rat brain and neuronal cell cultures. Amer. Acad. Neuropsychopharmacol. Abstra.	2006
J-1007	Taylor CP, Garrido R. Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta ($\alpha 2$ - δ) type 1 protein. Neurosci. 2008;155:510-521.	2008
J-1008	Taylor CP, Narasimhan LS. Sodium channels and therapy of central nervous system diseases. Adv. Pharmacol. 1997;39:47-98.	1997
J-1009	Taylor CP, Offord J, Su T-Z, Baron S, Kinsora J, Vartanian MG, Bian F, Li Z, Dooley D, Wustrow DJ, Belliotti T, Schwarz J, Thorpe A, Donevan S, Field MJ. (2005) Contribution of high-affinity binding at calcium channel $\alpha 2$ -d proteins to the Analgesic, Antic.	2004
J-1010	Taylor CP, Vartanian MG, Andruszkiewicz R, Silverman RB. 3-alkyl GABA and 3-alkylglutamic acid analogues: Two new classes of anticonvulsant agents. Epilepsy Research 1992;11(2):103-110.	1992
J-1011	Taylor CP. Emerging perspectives on the mechanism of action of Gabapentin. Neurology 1994;44(6 Suppl 5):10-16.	1994
J-1012	Taylor CP. Gabapentin: Mechanisms of action. In: RH Levy, RH Mattson, BS Meldrum (editors) Antiepileptic Drugs, 4th Edition, New York, NY, Raven Press 1995, pp 829-41.	1995
J-1013	Taylor CP. Gabapentin: Mechanisms of action. In: RH Levy, RH Mattson, BS Meldrum (editors) Antiepileptic Drugs, 5th Edition, New York, NY, Raven Press 2002, pp 321-34.	2002

J-1014	Taylor CP. (2004) Meeting Report: The biology and pharmacology of calcium channel(α 2- δ) proteins - Pfizer satellite symposium to the 2003 Society for Neuroscience meeting. CNS Drug Rev 10:183-188.	2004
J-1015	Taylor, CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α 2- δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007a;73:137-150.	2007
J-1016	Taylor, CP. (2009). "Mechanisms of analgesia by gabapentin and pregabalin – Calcium channel α 2-d [CaVa2-d] ligands." Pain 142: 13-16.	2009
J-1017	Taylor, CP. and R. Garrido (2008). "Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (α 2- δ) type 1 protein." Neuroscience 155: 510-521.	2008
J-1018	Tayoshi, S et al. Lithium Effects on Brain Glutamatergic and GABAergic Systems of Healthy Volunteers as Measured by Proton Magnetic Resonance Spectroscopy. In Press: Progress Neuropsychopharmacol Biologic Psychiatry 2007.	2007
J-1019	Teasdall RD, Smith BP, Koman LA. Complex regional pain syndrome (reflex sympathetic dystrophy) Clin Sports Med 2004; 23(1):145-55.	2004
J-1020	Thase, M. Chapter 14.1, Mood Disorders: Neurobiology, in: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Vol. I, pp. 1318-1328 (Sadock B, Sadock V, eds., 7th ed. 2000.	2000
J-1021	The Empirical Foundations of Suicidology in Ronald W. Maris, Alan L. Berman & Morton M. Silverman, Comprehensive Textbook of Suicidology (2000).	2000
J-1022	The Theoretical Component in Suicidology in Ronald W. Maris, Alan L. Berman & Morton M. Silverman, Comprehensive Textbook of Suicidology (2000).	2000
J-1023	Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behavior disorders: a retrospective survey. Epilepsy Res. 1996; 25(1):21-27.	1996
J-1024	Thomas S. A phenomenologic study of chronic pain. Western Journal of Nursing Research 2000; 22:683-705.	2000
J-1025	Thompson SO. Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-1355.	1994
J-1026	Thompson, P., Clarkson, P., Karas, R. Statin-Associated Myopathy. JAMA 2003; 289(13):1681-1690.	2003
J-1027	Thorpe A, Taylor CP, Barta NS, Donevan SD (2006) Case histories: Alpha2-delta ligands: Gabapentin and pregabalin, in: Comprehensive Medicinal Chemistry, Vol. 8, eds. Trigg	2006

	DJ, Taylor JB (Elsevier, Oxford) p. 227-246.	
J-1028	Tidemalm, Dan, et al. "Risk of Suicide After Suicide Attempt According to Coexisting Psychiatric Disorder: Swedish Cohort Study with Long Term Follow up." BMJ (2008): Print.	2008
J-1029	Tiippana, E. M., K. Hamunen, et al. (2007). "Do surgical patients benefit from perioperative Gabapentin/pregabalin? A systematic review of efficacy and safety." Anesth Analg 104(6): 1545-56, table of contents.	2007
J-1030	Timmerman W, Bouma M, De Vries JB, Davis M, Westerink BH (2000): A microdialysis study on the mechanism of action of Gabapentin. Eur J Pharmacol 398:53-57.	2000
J-1031	To TP, Lim TC, Hill St, Frauman AG, Cooper N, Kirsa SW, Brown DJ. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord 2002; 40(6)(Jun):282-5.	2002
J-1032	Todorov A, Kolchev C, Todorov A Tiagabine and Gabapentin for the Management of Chronic Pain. Clin. J. Pain. July/August 2005; 21(4):358-361.	2005
J-1033	Tohen M et al. Epidemiology of bipolar disorder. In: Tsuang MT et al, eds. Psychiatric Epidemiology. New York, NY: Wiley-Liss; 2002:427-44.	2002
J-1034	Tollefson GD, Rosenbaum JF, Selective serotonin reuptake inhibitors, pp 219-234 in: The American Psychiatric Press Textbook of Psychopharmacology, 2nd edition. (Schatzberg AF, Nemeroff CB, eds.) 1998.	1998
J-1035	Tondo L et al. Suicidal behavior in bipolar disorder: risk and prevention. CNS Drugs 2003;17:491-511.	2003
J-1036	Traa, B. S., J. D. Mulholland, et al. (2008). "Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia." Pediatr Res 64(1): 81-5.	2008
J-1037	Trescott-A, Boswell M, Atluri S, et al. Opioid Guidelines in the Management of Chronic Non-Cancer Pain. Pain Physician. 2006; 9:1-40.	2006
J-1038	Triggle DJ. Calcium-channel antagonists: mechanisms of action, vascular selectivity, and clinical relevance. Cleve Clin J Med. 1992; 59(6):617-27.	1992
J-1039	Trimble MR. Anticonvulsant-induced psychiatric disorders. The role of forced normalization. Drug Safety 1996; 15(3):159-166.	1996
J-1040	Trimble MR. Biological Psychiatry, Second Edition.	1996
J-1041	Trimble MR. Neuropsychiatric consequences of pharmacotherapy. In: Engel J, Pedley TA, eds, Epilepsy. A comprehensive textbook. Philadelphia, New York:	1997

	Lippincott-Raven, 1997, pp. 2161– 2170.	
J-1042	Trimble MR New antiepileptic drugs and psychopathology. Neuropsychobiology. 1998 Oct;38(3):149-51.	1998
J-1043	Trimble MR, Rusch N, Betts T, Crawford PA. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9:249-254.	2000
J-1044	Tuncer S, Bariskaner H, Reisli R, Sarkiar G, Cicekci F, Otelcioglu S Effect of Gabapentin on postoperative pain: A randomized, placebo-controlled clinical study. Pain Clin. 2005; 17(1):95-9.	2005
J-1045	Tunnicliff G, Malatynska E. Central GABAergic systems and depressive illness. Neurochemical Research 2003;28:965-976.	2003
J-1046	Turan A, Karamanlioglu B, Memis D, et al. Analgesic Effects of Gabapentin After Spinal Surgery. Anesthesiology. 2004; 100(4):935-938.	2004
J-1047	Turan A, Kararanlioglu B, Memis D, et al. The Analgesic Effects of Gabapentin After Total Abdominal Hysterectomy. Anesth. Analg. 2004; 98:1370-3.	2004
J-1048	Turk, D. C., K. S. Swanson, et al. (2008). "Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis." Clin J Pain 24(6): 497-508.	2008
J-1049	Tutka P, Olszewski K, Wozniak M, Kleinrok Z, Czuczwar SJ, Wielosz M. Molsidomine potentiates the protective activity of GYKI 52466, a non-NMDA antagonist, MK-801, a non-competitive NMDA antagonist, and riluzole against electro convulsions in mice. Eur Neu.	2002
J-1050	Tzellos, T. G., G. Papazisis, et al. (2008). "Efficacy of pregabalin and Gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature." Eur J Clin Pharmacol 64(9): 851-8.	2008
J-1051	U.S. Department of Health and Human Services. Mental Health: a Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, Nation.	1999
J-1052	U.S. Dep't of Health, Educ. & Welfare, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service 20 (1964).	1964
J-1053	U.S. Surgeon General, The Health Consequences of Involuntary Exposure to Tobacco Smoke (2006)..	2006
J-1054	Urbani A, Belluzzi O (2000): Riluzole inhibits the persistent sodium current in mammalian CNS neurons. Eur J Neurosci	2000

	12:3567-3574.	
J-1055	Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998): Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proceedings of the Nat.	1998
J-1056	van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE. Randomized controlled trial of Gabapentin in Complex Regional Pain Syndrome type 1. BMC Neurology 2004; 4(1)(29 Sep):13.	2004
J-1057	Van Elstraete, A. C., P. Sitbon, et al. (2008). "Gabapentin prevents delayed and long-lasting hyperalgesia induced by fentanyl in rats." Anesthesiology 108(3): 484-94.	2008
J-1058	van Hooft JA, Dougherty JJ, Endeman D, Nichols RA, Wadman WJ. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449(3):221-228.	2002
J-1059	van Reekum et al., Applying Bradford Hill's Criteria for Causation to Neuropsychiatry: Challenges and Opportunities, The Journal of Neuropsychiatry and clinical Neurosciences 2001; 13:318-325.	2001
J-1060	Vartanian M, Radulovic LL, Kinsora JJ, Serpa KA, Vergnes M, Bertram E, Taylor CP (2006) Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Res. 68:189-205.	2006
J-1061	Vartanian MG, Donevan SD, Weber ML, Stoehr SJ, Dooley DJ, Taylor CP, Donevan SD. Gabapentin does not interact with the GABAB receptor. Soc Neurosci Abstr 2002; 31:603.603.	2002
J-1062	Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, Parker EM, Hunter JC, Higgins GA, Reggiani A, Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor.	2005
J-1063	Venkoba RA. Physical illness, pain and suicidal behavior. Crisis 1990; 11 :48-56.	1990
J-1064	Verkuyl JM, Karst H, Joels M (2005): GABAergic transmission in the rat paraventricular nucleus of the hypothalamus is suppressed by corticosterone and stress. Eur J Neurosci 21:113-121.	2005
J-1065	Verona, E., Sachs-Ericsson, N., Joiner, TE. Suicide Attempts Associated with Externalizing Psychopathology in an Epidemiological Sample. Am J Psychiatry 2004; 161(3): 444-451.	2004

J-1066	Victoroff J. DSM - III -R psychiatric diagnoses in candidates for epilepsy surgery: lifetime prevalence. Neuropsychiatry Neuropsychol Behav Neurol 1994;7:87-97.	1994
J-1067	Victoroff JJ, Benson F, Grafon ST, Engel J Jr, Mazotta JC. Depression in Complex Partial Seizes. Electroencephalography and Cerebra Metabolic Correlates. Arch Neurol 1994 Feb; 51(2):155-163.	1994
J-1068	Vieta E, Goikolea JM, Martinez-Aran A et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive Neurontin for bipolar disorder. J Clin Psychiatry 2006; 67:473-477.	2006
J-1069	Vieta E, Martinez-Aran A, Nieto E, et al. Adjunctive Neurontin treatment of bipolar disorder. Eur Psychiatry 2000; 15:433-437.	2000
J-1070	Vilhjalmsson, R., Krstjandottir, G., et al. Factors associated with suicide ideation in adults. Soc Psychiatry Psychiatry Epidemiol 1998; 33(3): 97-103.	1998
J-1071	Wagstaff AJ, Ormrod D, Spencer CM (2001): Tianeptine: a review of its use in depressive disorders. CNS Drugs 15:231-259.	2001
J-1072	Wamil AW, McLean MJ. Limitation by Gabapentin of high frequency action potential firing by mouse central neurons in cell culture. Epilepsy Res. 1994; 17:1-11.	1994
J-1073	Watson CJ, Venton BJ, Kennedy RT. In vivo measurements of neurotransmitters by microdialysis sampling. Analytical Chemistry 2006; 78(5):1391-1399.	2006
J-1074	Weiner N. Drugs that block adrenergic nerves and receptors. Chapter 9 In: AG Gilman, LS Goodman, A Gilman (ed.). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed., 1980, MacMillan Publishing Co., New York, NY, 1843 pp.	1980
J-1075	Weintraub D, Buschbaum R, Resor SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior 2007; 10:105-110.	2007
J-1076	Weisberg, HI, Hayden, VC, Pontes, VP. Selection Criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant- induced suicidality? Clin Trials 2009; 6: 109-118.	2009
J-1077	Weiss S.R, Gogolak V, Chung S., Deshpande G. Assessing data mining approaches to drug safety. In: Best Practices in Data Mining Thin Tan Meeting. Shady Grove, MD. June 2008. At: http://www.unaryland.edu/datamining.html .	2008
J-1078	Weiss Smith, S. Chapter Title: Pharmacoepidemiology. In: Encyclopedia of Epidemiology. Editor: Boslaugh S. Publisher: Sage Publications Inc. 2007.	2007

J-1079	Werner MU, Perkins FM, Holte K, Pedersen JL, Kehlet H. Effects of Gabapentin in acute inflammatory pain in humans. <i>Reg Anesth Pain Med</i> 2001; 26(4)(Jul/Aug):322-8.	2001
J-1080	White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. <i>Epilepsia</i> 2000;41 Suppl 1, S17-20.	2000
J-1081	White SJ et al. Anticonvulsant drugs and cancer: a cohort study in patients with severe epilepsy. <i>Lancet</i> 1979;2:458-60.	1979
J-1082	White, J. M. (2004). "Pleasure into pain: the consequences of long-term opioid use." <i>Addict Behav</i> 29(7): 13 1-24.	2004
J-1083	Whitworth TL, Quick MW. Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma- aminobutyric acid derivatives. <i>Biochem Soc Transactions</i> 2001; 29(6):736-741.	2001
J-1084	Wiffen PJ, McQuay HJ, Edwards, JE, Moore RA. Gabapentin for Acute and Chronic Pain (Review). <i>Cochrane Database of Systematic Reviews</i> . 2005, Issue 3, Ar. No.: CDOO5452. DOI: 10.1002/1465 1858.CD005452.	2006
J-1085	Wiffen, P. J., H. J. McQuay, et all. (2005). "Gabapentin for acute and chronic pain." <i>Cochrane Database Syst Rev</i> (3): CD005452.	2005
J-1086	Wilde MI, Benfield P (1995): Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. <i>Drugs</i> 49:411-439.	1995
J-1087	Williams et al., Psychology and suicidal behavior: elaborating the entrapment model. In <i>Prevention and Treatment of Suicidal Behavior: From Science to Practice</i> (ed. K Hawton), pp. 71-89. Oxford University Press: Oxford, UK.	2005
J-1088	Wilton, LV. and Shakin, S. A Postmarketing surveillance Study of Gabapentin as Add-on Therapy for 3,100 Patients in England. <i>Epilepsia</i> 2002 Sep; 43(9):983-92.	2002
J-1089	Wodarski, R., A. K. Clark, et al. (2008). "Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats." <i>Eur J Pain</i> .	2008
J-1090	Wohlfarth T, Boer F, van den Brink W. Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents. <i>Am J Psychiatry</i> . 2007 Dec;164(12):1908; author reply 1908-10.	2007
J-1091	Wolf M, Eberhart A, Glossmann H, Striessnig J, Grigorieff N. Visualization of the domain structure of an L-type Ca ²⁺ channel using electron cryo-microscopy. <i>J Mol Biol</i> 2003; 332:171-182.	2003

J-1092	Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. <i>Nature</i> 1983; 306(5944):686-688.	1983
J-1093	Working Group on Meta-Analysis in Environmental Epidemiology (1995). Guidelines for application of meta-analysis in environmental epidemiology. <i>Regulatory toxicology and Pharmacology</i> , 22, 189-197.	1995
J-1094	Wu Y, Wang W, Richerson GB. GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux through reversal of the GABA transporter. <i>J Neurosci</i> 2001; 21(8):2630-2639.	2001
J-1095	Xiong Z-Q, Stringer JL. Effects of felbamate, Gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. <i>Epilepsy Res</i> 1997; 27:187-194.	1997
J-1096	Xu L, Enyeart JA, Enyeart JJ (2001): Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. <i>J Pharmacol Exp Ther</i> 299:227-237.	2001
J-1097	Yaksi, A., L. Ozgonenel, et al. (2007). The efficiency of Gabapentin therapy in patients with lumbar spinal stenosis.” <i>Spine</i> 32(9): 939-42.	2007
J-1098	Yang J, Shen J (2005): In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. <i>Neuroscience</i> 135:927-937.	2005
J-1099	Yoshimoto K, Ueda S, Kato B, Takeuchi Y, Kawai Y, Noritake K, Yasuhara M. Alcohol enhances characteristic releases of dopamine and serotonin in the central nucleus of the amygdale. <i>Neurochem Int</i> , 2000; 37:369-376.	2000
J-1100	Young LT, Robb JC, Hasey GM, MacQueen GM, Patelis-Siotis I, Marriott M, Joffe RT. Gabapentin as an adjunctive treatment in bipolar disorder. <i>J of Affect Disord</i> 1999; 55:73-77.	1999
J-1101	Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with Neurontin. <i>Biol Psychiatry</i> 1997; 42:851-853.	1997
J-1102	Yourick DL, Repasi RT, Rittase WB, Staten LD, Meyerhoff JL. Ifenprodil and arcaine alter amygdala-kindling development. <i>European Journal of Pharmacology</i> 1999; 371(2-3):147-152.	1999
J-1103	Zarate CA, Jr., Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al (2004): An open-label trial of riluzole in patients with treatment-resistant major depression. <i>American Journal of Psychiatry</i> 161:171-174.	2004
J-1104	Zarate CA, Jr., Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al (2005): An open-label trial of the glutamate-modulating agent riluzole in combination with	2005

	lithium for the treatment of bipolar depression. Biological Psychiatry 57:430-43.	
J-1105	Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al (2006): A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.	2006
J-1106	Zheng GZ, Bhatia P, Daanen J, Kolasa T, Patel M, Latshaw S, El Kouhen OF, Chang R, Uchic ME, Miller L, Nakane M, Lehto SG, Honore MP, Moreland RB, Brioni JD, Stewart AO. Structure-activity relationship of triazafluorenone derivatives as potent and selecti.	2005
J-1107	Zielinski JJ. Epilepsy and mortality rate and cause of death. Epilepsia 1974;15:191-201.	1974
J-1108	A.K. MacLeod et al., Hopelessness and Positive and Negative Future Thinking in Parasuicide, 44 Brit. J. Clinical Psychology 495 (2005).	2005
J-1109	A.L. Chapman et al., Factors Associated with Suicide Attempts in Female Inmates, Acgemony of Hopelessness, 35 Suicide & Life-Threatening Behav. iii (2005).	2005
J-1110	A.P. Chioqueta & T.C. Stiles, The Relationship Between Psychological Buffers, Hopelessness, and Suicidal Ideation: Identification of Protective Factors, 28 Crisis 67 (2007).	2007
J-1111	B.R. Sommer et al., Safety and Efficacy of Anticonvulsants in Elderly Patients with Psychiatric Disorders: Oxcarabazepine, Topiramate, and Gabapentin, 6 Expert Opinion in Drug Safety 133 (2007).	2007
J-1112	C. Born et al., Newer Prophylactic Agents for Bipolar Disorder and Their Influence on Suicidality, 9 Archives Suicide Res. 301 (2005).	2005
J-1113	C.A. Langford & B.C. Gilliland, Fibromyalgia, in Harrison's Principles of Internal Medicine (A.S. Fauci et al. eds., 17th ed. 2008).	2008
J-1114	C.L. Ernst & J.F. Goldberg, Anti-suicide Properties of Psychotropic Drugs: A Critical Review, 12 Harv. Rev. Psychiatry 317 (2004).	2004
J-1115	Chou R, Norris S, Carson S, Chan BKS. Drug Class Review for Neuropathic Pain. 2007.	2007
J-1116	D. Jacobs & M. Klein-Benheim, The Psychological Autopsy: A Useful Tool for Determining Proximate Causation in Suicide Cases, 23 Bull. Am. Acad. Psychiatry & Law 165 (1995).	1995
J-1117	D. Lester & R.L. Walker, Hopelessness, Helplessness, and Haplessness as Predictors of Suicidal Ideation, 55 Omega 321 (2007).	2007

J-1118	D. McMillan et al., Can We Predict Suicide and Non-Fatal Self-Harm with the Beck Hopelessness Scale? A Meta Analysis, 37 Psychological Med. 769 (2007).	2007
J-1119	D.G. Blazer, Treatment of Seniors, in American Psychiatry Publishing Textbook of Psychiatry (R.E. Hales et al. eds., 5th ed. 2008).	2008
J-1120	D.G. Jacobs, Review of Navy Investigation of U.S.S. Iowa Explosion, Joint Hearings Before the Investigations Subcommittee and the Defense Policy Panel of the Committee on Armed Services, U.S. House of Representatives (Dec. 21, 1989).	1989
J-1121	D.M. Reith & L. Edmonds, Assessing the Role of Drugs and Suicidal Ideation and Suicidality, 21 CNS Drugs 463 (2007).	2007
J-1122	D.W. Black & G. Winokur, Suicide and Psychiatric Diagnosis, in Suicide Over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients 135 (S.J. Blumenthal & D.J. Kupfer eds. 1990).	1990
J-1123	Dale C. Hesdorffer and Andres M. Kanner, "The FDA Alert on suicidality and antiepileptic drugs: Fire or false alarm?", Epilepsia, 50(5):978-986, 2009 (April 27, 2009).	2009
J-1124	E. Robins et al., Some Clinical Considerations in the Prevention of Suicide Based on a Study of 134 Successful Suicides, 49 Am. J. Pub. Health 888 (1959).	1959
J-1125	E.K. Moscicki, Epidemiology Surveys as Tools for Studying Suicidal Behavior: A Review, 19 Suicide & Life-Threatening Behav. 131 (1989).	1989
J-1126	Ajtai 2008 Hopelessness in Patients Presenting to Their Family Physician.pdf Segatore 1994 Understanding Chronic Pain after Spinal Cord Injury.pdf.	2008
J-1127	G. Ratcliffe, Chronic Pain Conditions and Suicidal Ideation and Suicide Attempts: An Epidemiological Perspective, 23 Clinical J. Pain 204 (2008).	2008
J-1128	G. Ratcliffe, Chronic Pain Conditions and Suicidal Ideation and Suicide Attempts: An Epidemiological Perspective, 23 Clinical J. Pain 204 (2008).	2008
J-1129	G.J. Macfarlane et al., Widespread Body Pain and Mortality: Prospective Population Based Study, 323 BMJ 662 (2001).	2001
J-1130	Gilron I, Orr E, Tu D, Mercer CD, Bond D. A randomized, double-blind, controlled trial of perioperative administration of gabapentin, meloxicam and their combination for spontaneous and movement-evoked pain after ambulatory laparoscopic cholecystectomy. Anesth Analg. 2009 Feb;108(2):623-30.	2009
J-1131	J. Avorn, Drug Warnings That Cause Fits. Communicating Risks in a Data-Poor Environment, 359 New Eng. J. Med. 991	2008

	(2008).	
J-1132	J. Neill, Meta-Analysis Research Methodology, http://wilderdom.com/research/meta-analysis.html , Internet site visited October 31, 2008.	2008
J-1133	J.Arheit-Treichel, Some Chronic Pain Patients at Increased Suicide Risk, 41 Psychiatric News 25 (2006).	2006
J-1134	J.G. Abbey et al., Hopelessness at the End of Life: The Utility of the Hopelessness Scale with Terminally Ill Cancer Patients, 11 Brit. J. Health Psychology 173 (2006).	2006
J-1135	J.K. Hirsch & K.R.Conner, Dispositional and Explanatory Style Optimism as Potential Moderators of the Relationship Between Hopelessness and Suicidal Ideation, 36 Suicide & Life-Threatening Behav. 661 (2006).	2006
J-1136	J.P. Lepine & M. Briley, The Epidemiology of Pain and Depression, 19 (Suppl. 1) Hum. Psychopharmacology S3 (2004).	2004
J-1137	L. Lawhorne, Depression in the Older Adult, 32 Primary Care 787 (2005).	2005
J-1138	M. Burgy, Phenomenological Investigation of Despair and Depression, 41 Psychopathology 147 (2008).	2008
J-1139	M. Miller & D. Hemenway, Guns and Suicide in the United States, 359 New Eng. J. Med. 989 (2008).	2008
J-1140	M. Pompili et al., Depression, Hopelessness, and Suicide Risks Among Patients Suffering from Epilepsy, 43 Annali dell'Institute Superiore di Sanita 425 (2007).	2007
J-1141	M. Pompili et al., Hopelessness and Suicide Risks Emerge in Psychiatric Nurses Suffering from Burnout and Using Specific Defense Mechanisms, 20 Archives Psychiatric Nursing 135 (2006).	2006
J-1142	M. Segatore, Understanding Chronic Pain After Spinal Cord Injury, 26 J. Neuroscience Nursing 230 (1994).	1994
J-1143	M. Theodoulou et al., Pain and Deliberate Self-Harm: An Important Association, 58 J. Psychosomatic Res. 317 (2005).	2005
J-1144	M.D. Rudd, Suicide Warning Signs in Clinical Practice, 10 Current Psychiatry Rep. 87 (2008).	2008
J-1145	M.I. Bennett, Gabapentin Significantly Improves Analgesia in People Receiving Opioids for Neuropathic Cancer Pain, 31 Cancer Treatment Rev. 58 (2005).	2005
J-1146	Medical Research Council Tuberculosis Chemotherapy Trials Committee, The Treatment of Pulmonary Tuberculosis with Isoniazid, 2 Brit. Med. J. 735 (1952).	1952

J-1147	Medical Research Council Whooping-Cough Immunization Committee, The Prevention of Whooping-Cough by Vaccination, 1 Brit. Med. J. 1463 (1950).	1950
J-1148	N. Billig, Attitude and Burden in Families of Depressed Elderly Patients: Strategies for Care, 84 S. Med. J. 225 (1991).	1991
J-1149	P. Sokero et al., Decline and Suicidal Ideation Among Patients with MDD Is Predicted by Decline in Depression and Hopelessness, 95 J. Affective Disorders 95 (2006).	2006
J-1150	P.K. Grewal & J.E. Porter, Hope Theory: A Framework for Understanding Suicidal Action, 31 Death Studies 131 (2007).	2007
J-1151	R. Doll, People of Consequence: Sir Austin Bradford Hill and the Progress of Medical Science, 305 BMJ 1521 (1992).	1992
J-1152	R. Roy, Chronic Pain, Loss and Suffering: A Clinical Perspective (2004).	2004
J-1153	R. Schiffer et al., Neuropsychiatry (2003).	2003
J-1154	R. Weiner, Pain Management: A Practical Guide for Clinicians (6th ed. 2002).	2002
J-1155	R.B. Khan et al., Gabapentin to Control Seizures in Painful AIDS-Related Neuropathy, 52 Neurology A190 (1999).	2004
J-1156	R.E. McKeown et al., U.S. Suicide Rates by Age Group, 1970-2002: An Examination of Recent Trends, 96 Am. J. Pub. Health 1744 (2006).	2006
J-1157	S.A.W. Shakir, Thoughts on Signal Detection in Pharmacovigilance (Abstract), www.haiweb.org/medicineprices/2410/contributions/saadshakir.doc , Site visited 9/08/08.	2008
J-1158	T.W. Meeks et al., Chronic Pain and Depression Among Geriatric Psychiatry Inpatients, 23 Int'l J. Geriatric Psychiatry 637 (2008).	2008
J-1159	Wiffen PJ, McQuay HJ. Rees J, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005452 DOI: 10.1002/14651858.CD005452. Published in Issue 1, 2010.	2010
J-1160	Y. Levi et al., Mental Pain and Its Communication in Medically Serious Suicide Attempts and "Impossible Situation," J. Affective Disorders ePub (Apr. 22, 2008).	2008
J-1161	Z. Bajwa et al., Antiepileptic Drugs in the Treatment of Neuropathic Pain, in UpToDate (B.D. Rose ed. 2008), available at http://www.uptodate.com .	2008
J-1162	Mokhber N. Lane CJ, Azarpazhooh MR, Salari E, Fayazi R, Shakeri MT, Young AH, Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and	2008

	carbamazepine in Iran. Neuropsychiatr Dis Treat. 2008 Feb.;4(1):227-34.	
J-1163	Gorson et al., Gabapentin in the Treatment of Painful Diabetic Neuropathy: A Placebo-Controlled, Double-Blind, Crossover Trial, 66 J. Neurology, Neurosurgery & Psychiatry 251 (Feb. 1999).	Feb-99
J-1164	Di Trapani, G. et al.: Gabapentin in the Prophylaxis of Migraine: A Double-Blind Randomized Placebo-Controlled Study, 151 Clin. Ter. 145 (2000).	2000
J-1165	Spira, P.J. et al.: Gabapentin in the Prophylaxis of Chronic Daily Headache: A Randomized, Placebo-Controlled Study, 61 Neurology 1753 (2003).	2003
J-1166	Zona C. et al. (1998) Riluzole interacts with voltage activated sodium and potassium currents in cultered rat cortical neurons Neuroscience 85:931-938.	
J-1167	Goodman F, Glassman P, Maglione M. Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm .	2006
J-1168	Editorial in JAMA, Dec 2, 1998 Vol 280, No 21 “Symptomatic Treatment of Painful Neuropathy” by Phillip Low, MD and Rose M Dotson MD.	
J-1169	Schatzberg, AF and Nemeroff, C. eds. Textbook of Psychopharmacology, 3rd ed. APA Press, Washington, 2004.	2004
J-1170	Rowbotham, M. et al.: Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial, 280 JAMA 1837 (1998).	1998
J-1171	Maizels, M., “The Patient with Daily Headaches,” American Family Physician, 70(12):2299-2306, Dec. 15, 2004.	12/15/2004
J-1172	Reducing Suicide: A National Imperative, National Academies Press; 1 edition, By Board on Neuroscience and Behavioral Health.	2002
J-1173	Backonja, M. and R.L. Glanzman, Gabapentin Dosing for Neuropathic Pain: Evidence from Randomized, Placebo-Controlled Clinical Trials, Clin. Ther. 2003; 25:81-104.	2003
J-1174	Guille et al., Gabapentin Versus Placebo As Adjunctive Treatment for Acute Mania and Mixed States in Bipolar Disorder, in Am. Psych. Ass’n, New Research Abstracts, available at http://archive.psych.org/edu/other_res/lib_archives/archives/meetings/1999 .	1999
J-1175	Abstract of T. Gordh, A Stubhaug et al., Gabapentin in Chronic Peripheral Postoperative and Posttraumatic Neuropathic Pain, included in “Abstracts of the 10th World Congress on Pain,” IASP, San Diego, Aug 17-22, 2002.	2002

J-1176	“Warner-Lambert Neurontin Promotions Under Investigation By U.S. Attorney”, The Pink Sheet, April 3, 2000.	4/3/2000
J-1177	Davidson JRT, Connor KM, Sutherland SM. Panic Disorder and social phobia: current treatments and new strategies. Cleve Clin J Med 1998;65(Suppl 1):S139-S147.	
J-1178	Mosciki EK. Identification of Suicide Risk Factors Using Epidemiological Studies, Psychiar. Clin. North AM. 1997; 20:499-517.	
J-1179	Schmader, KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002; 18:350-354.	
J-1180	Delgado-Rodriguez M. Systematic reviews of meta-analyses: applications and limitations. J Epidemiol Comm. Health 2006; 60:90-92.	
J-1181	Greenland S. Invited commentary: A critical look at some popular meta-analytic methods. Am J Epi 1994; 140(3):290-295.	
J-1182	Greenland S, Schwartzbaum JA, Finkle WD. Problems due to small samples and sparse data in conditional logistic regression analysis. Am J Epi, 2000; 151(5):531-539.	
J-1183	Greenland S. Multiple-bias modeling for analysis of observational data. JR Statist Soc A 2005; 168(2):267-306.	
J-1184	Greenland S. Meta-analysis. In: Rothman KJ, Greenland S, Editors. Modern Epidemiology, Second Edition. Philadelphia: Lippincot, Williams & Wilkins; 1998: p. 643-673.	
J-1185	Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia. Arch Gen Psychiatry 2003; 60:82-91.	
J-1186	Shapiro S. Meta-analysis/shmeta-analysis. Am J Epi 1994; 140(9):771-778.	
J-1187	Petitti DB. Of babies and bathwater. Am J of Epi 1994; 140(9): 779-782.	
J-1188	Shapiro S. Is there or is there ain’t no baby?: Dr. Shapiro replies to Drs. Petitti and Greenland. Am J Epi 1994; 140(9):788-791.	
J-1189	Harden CL, Pick LH. Alterations in mood and anxiety in epilepsy patients treated with gabapentin [abstract]. Epilepsia 1996; 37 (5): 137.	
J-1190	Harden CL, Lazar LM, Pick LH. et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40: 1129-34.	

J-1191	Dodrill CR, Arnett JL, Hayes AG, et al. Cognitive abilities adjustment with gabapentin: results of multi-site study. <i>Epilepsy Res</i> 1999; 35: 109-2.	
J-1192	Hudson, JI & Pope, HG. Affective Spectrum Disorder: Does Antidepressant Response Identify a Family of Disorders with a Common Pathophysiology? <i>Am J Psychiatry</i> 1990; 147: 552-564.	
J-1193	Bridge, JA, Iyengar, S, et. al., Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressants Treatment: A Meta-analysis of Randomized Controlled Trials. <i>JAMA</i> 2007; 297 (15): 1683-1696.	
J-1194	Kaizar, E., Greenhouse, JB, et.al. Do antidepressants cause suicidality in children? A Bayesian meta-analysis. <i>Clin Trials</i> . 2006; 3: 73-98.	
J-1195	Rowbotham, M. Gabapentin in the Management of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathic Pain of Varying Etiology: Overview of Results from 5 Placebo-Controlled Trials, Fourth International Conference on the Mechanisms and treatment of Neuropathic Pain (2001).	Sep-01
D-7000	Gabapentin Draft Label, Draft 3, 1989 bearing the bates range Pfizer_TMF_CRF_052223 - 38.	8/7/1989
D-7001	Gabapentin Draft Label, Draft 4, 1989 bearing the bates range Pfizer_TMF_CRF_052206 - 22.	9/25/1989
D-7002	Gabapentin Draft Label, Draft 5, 1989.	10/20/1989
D-7003	Neurontin Draft Label 1992.	11/15/1992
D-7004	Neurontin Annotated Label 1992 bearing the bates range Pfizer_LCastro_0039686 - 718.	1/31/1992
D-7005	Neurontin Revised Label 1993 bearing the bates range WLC_CBU_118838 - 57.	1/26/1993
D-7006	Neurontin Revised Label 1993 bearing the bates range WLC_CBU_122636 - 57.	9/2/1993
D-7007	Neurontin Draft Label 1993 bearing the bates range WLC_CBU_120352 - 407.	12/29/1993
D-7008	Neurontin Approved Label 1993.	12/30/1993
D-7009	Neurontin Approved Label 1994.	January 1994
D-7010	Neurontin Approved Label 1994.	December 1994

D-7011	Neurontin Approved Label 1997.	January 1997
D-7012	Neurontin Approved Label 1998.	March 1998
D-7013	Neurontin Approved Label 1998.	October 1998
D-7014	Neurontin Draft Label 1999 bearing the bates range Pfizer_CTaylor_0012930 - 976.	1999
D-7015	Neurontin Approved Label 2000.	June 2000
D-7016	Neurontin Approved Label 2000.	November 2000
D-7017	Neurontin Approved Label 2000.	10/12/2000
D-7018	Neurontin Annotated Label with Proposed Revisions 2001 bearing the bates range Pfizer_LAlphs_0080550 - 643.	August 2001
D-7019	Neurontin Approved Label 2001.	July 2001
D-7020	Neurontin Draft Label 2002 bearing the bates range Pfizer_LKnapp_0066072 - 107.	January 2002
D-7021	Neurontin Revised Draft Label, Draft 2, 2002 bearing the bates range Pfizer_RGlanzman_0057487 - 523.	5/16/2002
D-7022	Neurontin Approved Label 2002.	5/24/2002
D-7023	Neurontin Revised Label 2003 bearing the bates range Pfizer_AMishra_0005337 - 63.	September 2003
D-7024	Neurontin Revised Label 2004.	May 2004
D-7025	Neurontin Approved Label 2005.	February 2005
D-7026	Neurontin Approved Label 2005.	December 2005
D-7027	Neurontin Approved Label 2007.	January 2007
D-7028	Memo from Jan Turner to John Howard, Lena Ulrich, and Harry Okerfell bearing the bates range WLC_CBU_119977 - 120015.	12/21/1993
D-7029	Conditional Approval Letter from Robert Temple to Janeth Turner bearing the bates range WLC_CBU_119980 - 120015.	12/21/1993

D-7030	Original Approval Letter (NDA 20-235) bearing the bates range Pfizer_LCastro_0035910 - 46.	12/30/1993
D-7031	Original Approval Letter (NDA 20-235).	4/8/1994
D-7032	Supplement 6 Non-Approval Letter (NDA 20-235) bearing the bates range WLC_FRANKLIN_0000090128 - 30.	8/26/1997
D-7033	Supplement 011 - Approval Letter (NDA 20-235).	9/29/1998
D-7034	Original Approval Letter (NDA 20-882) bearing the bates range WLC_CBU_140528 - 30.	10/9/1998
D-7035	Supplement 015 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_LCastro_0072758 - 61.	10/12/2000
D-7036	Supplement 022 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_JSu_0031427 - 29.	1/30/2002
D-7037	Original Approval Letter (NDA 21-397) bearing the bates range Pfizer_JSu_0019183 - 85.	5/24/2002
D-7038	Supplement 023 - Approval Letter (NDA 20-235) bearing the bates range Pfizer_TMF_CRF_001074 - 76.	8/27/2002
D-7039	Original Approval Letter (NDA 21-397, 21-423, 21-424) bearing the bates range Pfizer_ELuczak_0000005 - 6.	12/12/2003
D-7040	Original Approval Letter (NDA 20-882) bearing the bates range Pfizer_BParsons_0106370 - 72.	4/30/2004
D-7041	Supplement 029 - Approval Letter (NDA 20-235).	2/28/2005
D-7042	Supplement 035 - Approval Letter (NDA 20-235).	5/3/2005
D-7043	Letter from Mary Ann Evertsz to Russell Katz bearing the bates range Pfizer_MEvertsz_0079493 - 94.	12/21/2005
D-7044	Summary of Propsed Labeling bearing the bates range Pfizer_CGrogan_0012493 and 0012541.	1999
D-7045	Neurontin Indication Status Spreadsheets bearing the bates range Pfizer_MDL_0008198 - 408.	1/24/2007
D-7046	NDA Reviewer's Guide: Content and Format.	7/16/1989
D-7047	NDA 20-235 Cover Letter bearing the bates range Pfizer_LCastro_0039684 - 85.	1/15/1992
D-7048	Epilepsy NDA Index bearing the bates range Pfizer_LCastro_0066749 - 808.	
D-7049	Neurontin IND/NDA Periodic and Annual Reports.	1/14/94 - 8/18/05

D-7050	MedWatch Reports.	1994-2005
D-7051	NDA Narratives in Epilepsy NDA.	
D-7052	FDA letter to Janeth Turner.	11/8/1991
D-7053	Epilepsy ISE bearing the bates range Pfizer_Raltevogt_0000008 - 259.	11/15/1991
D-7054	Epilepsy ISS bearing the bates range Pfizer_MPatel_0239370 - 40396.	11/19/1991
D-7055	Appendix B.2, Epilepsy ISS bearing the bates range Pfizer_MPatel_0239655 - 64.	9/19/1991
D-7056	Appendix B.5 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239680 - 99.	9/19/1991
D-7057	Appendix B.13 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239801 - 34.	9/20/1991
D-7058	Appendix B.30, Epilepsy ISS bearing the bates range Pfizer_MPatel_0239956 - 58.	9/20/1991
D-7059	Appendix B.33 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239968 - 76.	11/18/1991
D-7060	Appendix B.34 Epilepsy ISS bearing the bates range Pfizer_MPatel_0239977 - 96.	11/18/1991
D-7061	Appendix C.1 to Epilepsy ISS bearing the bates range Pfizer_MPatel_0240009 - 52.	11/26/1991
D-7062	Appendix C.3 to Epilepsy ISS bearing the bates range Pfizer_MPatel_0240057 - 141.	11/26/1991
D-7063	Appendix C.4, Epilepsy ISS bearing the bates range Pfizer_MPatel_0132429 - 60.	1/15/1992
D-7064	Table 14, Epilepsy ISS bearing the bates range WLC_CBU_117908.	11/20/1991
D-7065	Table 15, Epilepsy ISS bearing the bates range WLC_CBU_117910.	11/20/1991
D-7066	Table 41, Epilepsy ISS bearing the bates range WLC_CBU_117990.	11/20/1991
D-7067	Epilepsy ISS, page 135 bearing the bates range WLC_CBU_117998.	11/20/1991
D-7068	First Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0149430 - 72.	5/29/1992
D-7069	Appendix C.4, First Safety Update (Epilepsy NDA) bearing the bates range Pfizer_LAlphs_0066259 - 315.	5/26/1992

D-7070	First Safety Update (Epilepsy NDA) Table 8 bearing the bates range Pfizer_MPatel_0153669.	5/29/1992
D-7071	First Safety Update (Epilepsy NDA) Table 9 bearing the bates range Pfizer_MPatel_0153670.	5/29/1992
D-7072	Second Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0148429 - 85.	10/30/1992
D-7073	Appendix C, Second Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MPatel_0155170 - 201.	10/30/1992
D-7074	Third Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_120469 - 518.	5/12/1993
D-7075	Appendix B.3, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MClaussen_0011908 - 09.	4/1/1993
D-7076	Appendix B.6, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MEvertsz_0021265 - 308.	4/14/1993
D-7077	Appendix B.7, Third Safety Update (Epilepsy NDA) bearing the bates range Pfizer_MClaussen_0011956 - 80.	4/14/1993
D-7078	Third Safety Update (Epilepsy NDA)--Review and Analysis of Clinical Data bearing the bates range Pfizer_LAlphs_0059899 - 917.	5/12/1992
D-7079	Fourth Safety Update (Epilepsy NDA) bearing the bates range Pfizer_RAltevogt_0002091 - 138.	2/11/1994
D-7080	Appendices to Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_064286 - 648.	2/11/1994
D-7081	Appendix B.1 Fourth Safety Update (Epilepsy NDA) bearing the bates range Pfizer_LAlphs_0081418 - 564.	11/16/1993
D-7082	Appendix B.9, Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_057070 - 156.	11/15/1993
D-7083	Appendix B.10, Fourth Safety Update (Epilepsy NDA) bearing the bates range WLC_CBU_057157 - 63.	11/16/1993
D-7084	Fourth Safety Update (Epilepsy NDA)--Review and Analysis of Clinical Data bearing the bates range Pfizer_LLaMoreaux_0031627 - 34.	12/15/1993
D-7085	PHN Safety Update bearing the bates range Pfizer_LCastro_0024697 - 810.	11/28/2001
D-7086	PHN ISE bearing the bates range Pfizer_Azeuscher_0005442 - 728.	12/13/2001
D-7087	PHN ISS bearing the bates range Pfizer_AGarrity_0007313 - 9693.	12/13/2001
D-7088	Appendix A.9 Pain ISS bearing the bates range Pfizer_AGarrity_0007565.	12/13/2001

D-7089	Pain ISE bearing the bates range Pfizer_Sdofit_0001870 - 944.	12/8/2004
D-7090	Neuropathic Pain ISS bearing the bates range Pfizer_LLaMoreaux_009076 - 145.	7/9/2001
D-7091	Memorandum with attachments from Meisenhelder to Wallace.	7/20/1987
D-7092	Gabapentin NDA/FDA Questions/Requests: Responses to FDA Requests Book 1 bearing the bates range Pfizer_LAlphs_0082420 - 908.	12/9/1992
D-7093	Record of FDA Contact to discuss December 15, 1992 Advisory Committee Meeting to review the Gabapentin NDA bearing the bates range WLC_JTurner_000698 - 701.	10/20/1992
D-7094	Letter to Leber bearing the bates range Pfizer_LAlphs_0087261 - 62.	10/19/1992
D-7095	Letter to Paul Leber bearing the bates range Pfizer_CPacella_0015510 - 11.	10/30/1992
D-7096	Gabapentin NDA/FDA Questions/Requests: Responses to FDA Requests Book 2 bearing the bates range Pfizer_LAlphs_0082979 - 98.	11/19/1992
D-7097	Response to FDA Question 101 bearing the bates range Pfizer_LAlphs_0083351 - 56.	12/2/1992
D-7098	Record of FDA Contact bearing the bates range NDA20235_MISC_001_0102 - 236.	12/7/1992
D-7099	Summary Basis of Approval of Gabapentin bearing the bates range Pfizer_LAlphs_0020290 - 383.	1/20/1993
D-7100	Memorandum to Gabapentin task force bearing the bates range WLC_JTurner_002441 - 47.	3/10/1993
D-7101	Combined Medical Statistical Review NDA-20-235 bearing the bates range Pfizer_LAlphs_0084359 - 479.	10/13/1993
D-7102	Supervisory Overview of Safety & Efficacy Data for NDA 20-235 bearing the bates range Pfizer_LLaMoreaux_0031287 - 304.	10/11/1993
D-7103	Epilepsy Pediatric ISS bearing the bates range WLC_CBU_061841 - 2079.	12/3/1999
D-7104	Gabapentin NDA/FDA Questions and Requests. Item 8 & 10: Clinical and Statistical bearing the bates range WLC_JTurner_000583 - 602.	10/19/1993
D-7105	Record of FDA Contact bearing the bates range WLC_JTurner_000702 - 703.	10/20/1993
D-7106	Cover Letter Providing Neurontin Promotion Materials to Paul Leber from Janeth Turner bearing the bates range NDA20235_MISC_008_004 - 5.	12/10/1993

D-7107	Approvable Action Memorandum for NDA 20-235 from Paul Leber bearing the bates range Pfizer_LAlphs_0059749 - 54.	12/13/1993
D-7108	Record of FDA Contact bearing the bates range WLC_JTurner_000813 - 15.	12/22/1993
D-7109	Fax from Jan Turner to Chamberlain bearing the bates range WLC_JTurner_002828 - 29.	12/22/1993
D-7110	Letter from Robert Temple to Janeth Turner bearing the bates range Pfizer_JMarino_0004515 - 49.	12/30/1993
D-7111	Memorandum from Janeth Turner to Distribution bearing the bates range Pfizer_LLaMoreaux_0031285 - 498.	7/28/1994
D-7112	Letter from Russell Katz to Janeth Turner bearing the bates range Pfizer_MPatel_0202536 - 39.	10/12/2000
D-7113	Email from Drusilla Scott to Anne Giordani et al. bearing the bates range Pfizer_LKnapp_0053774 - 79.	5/18/2001
D-7114	Email from Paula Sparks bearing the bates range Pfizer_AGarrrity_0002518.	8/7/2001
D-7115	Center for Drug Evaluation and Research. Division Director Review and Basis for Approval Action for NDAs 21-397, 21-423, and 21-424. Dr. Cynthia McCormick.	5/22/2002
D-7116	Minutes of Teleconference with FDA bearing the bates range Pfizer_LCastro_0011772 - 76.	5/22/2002
D-7117	Review and Evaluation of Clinical Data for NDAs 21-397, 21-423, and 21-424 by Sharon Hertz.	5/24/2002
D-7118	"Gabapentin & Suicide" report by Tina Ho bearing the bates range Pfizer_BParsons_0123117 - 27.	7/1/2004
D-7119	Gabapentin: Response to FDA Requests on Suicide and Suicide Attempts for Phase 2-4 Studies with Comparators, September 2004 bearing the bates range Pfizer_MPatel_0064566 - 67.	9/1/2004
D-7120	Appendix I to September 2004 Response (Gabapentin Clinical Study & Solicited Cases Reporting Completed Suicide) bearing the bates range Pfizer_GGribko_0011915 - 12475.	5/30/2004
D-7121	Letter from Janeth Turner to FDA Document and Records Section.	1/15/1992
D-7122	Explanation of Changes in Neurontin Label bearing the bates range WLC_JTurner_001685 - 87.	1/1/1993
D-7123	Record of FDA Contact bearing the bates range Pfizer_LAlphs_0087185 - 86.	1/28/1993
D-7124	Record of Contact bearing the bates range WLC_JTurner_000900 - 01.	4/6/1993

D-7125	Letter from Janeth Turner to Paul Leber bearing the bates range Pfizer_LCastro_0004858 - 947.	5/15/1993
D-7126	Record of FDA Contact bearing the bates range WLC_JTurner_002804.	9/10/1993
D-7127	Record of FDA Contact bearing the bates range WLC_JTurner_000948 - 49.	9/17/1993
D-7128	Record of FDA Contact bearing the bates range WLC_JTurner_000717 - 18.	10/6/1993
D-7129	Record of FDA Contact bearing the bates range WLC_JTurner_000688 - 89.	10/15/1993
D-7130	Record of FDA Contact bearing the bates range WLC_JTurner_000694 - 95.	10/19/1993
D-7131	Record of FDA Contact bearing the bates range WLC_Turner_000794 - 95.	12/16/1993
D-7132	Letter from Janeth Turner to Paul Leber bearing the bates range WLC_CBU_119649 - 720.	12/23/1993
D-7133	Record of FDA Contact bearing the bates range WLC_JTurner_000826 - 28.	12/30/1993
D-7134	Letter from Tim Paget to Stuart Dombey bearing the bates range WLC_CBU_102997- 3014.	5/22/1995
D-7135	Minutes of Meeting with FDA.	12/18/1997
D-7136	Letter from Janeth Turner to Michael Weintraub.	1/6/1998
D-7137	Neurontin PSUR for period 5/22/1995 - 11/22/1996.	6/11/1996
D-7138	Neurontin PSUR for period 2/2/1997 - 12/31/1997.	1997
D-7139	Neurontin PSUR for period 8/1/1998 - 1/21/1999.	1999
D-7140	Neurontin PSUR for period 2/2/1999 - 7/31/1999.	1999
D-7141	Neurontin PSUR for period 8/1/1999 - 1/31/2000.	2000
D-7142	Neurontin PSUR for period 8/1/2000 - 1/31/2001.	2001
D-7143	Neurontin PSUR for period 2/1/2001 - 7/31/2001.	2001
D-7144	(PSUR) Periodic Safety Update Report.	3/26/1999

D-7145	(PSUR) Periodic Safety Update Report (5-year) bearing the bates range Pfizer_MPatel_0022406 - 23226.	3/21/2003
D-7146	(PSUR) Periodic Safety Update Report (1-year) bearing the bates range Pfizer_LLaMorauX_0011734 - 817.	3/24/2004
D-7147	Psychiatric Event from 2004-2005 PSUR bearing the bates range Pfizer_LKnapp_0063282 - 83.	2005
D-7148	Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1 January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEvertz_00131185 - 00131202.	2000
D-7149	Parke-Davis Record of FDA Contact bearing the bates range WLC_JTurner_000459.	3/11/1992
D-7150	Parke-Davis Marketing Assessment: Neurontin in Psychiatric Disorders bearing the bates range V090836.	5/18/1995
D-7151	Letter and comments bearing the bates range Pfizer_LLaMoreaux_0025272.	10/20/1999
D-7152	Letter from Dr. Dieck to Dr. Gribko bearing the bates range Pfizer_GGribko_0025081 - 87.	7/20/2000
D-7153	Email from Allison Fannon to Leslie Tive et al. bearing the bates range Pfizer_LeslieTive_0079307.	11/1/2000
D-7154	Email from Allison Fannon to Leslie Tive et al. bearing the bates range Pfizer_LKnapp_0137046 - 84.	5/21/2002
D-7155	Letter from Drusilla Scott to Russell Katz bearing the bates range Pfizer_AGarrity_0002519 - 20.	8/6/2001
D-7156	Letter from Drusilla Scott to Cynthia McCormick bearing the bates range Pfizer_LKnapp_0025817 - 18.	10/22/2001
D-7157	Summary of Neurontin Pre-NDA Meeting for the "Management of Neuropathic Pain" bearing the bates range Pfizer_AGarrity_0002490 - 97.	5/14/2001
D-7158	Minutes of Meeting with FDA and addendum bearing the bates range Pfizer_LCastro_0005616 - 28.	5/14/2001
D-7159	Letter from Drusilla Scott to FDA with draft labeling bearing the bates range Pfizer_LCastro_0072351 - 403.	2/11/2002
D-7160	Pfizer Pharmaceuticals' search of adverse events bearing the bates range Pfizer_CPacella_0029534-0029639; 0029859-0029864; 0129716-0129720; 0129799-0129801; 0129813-0129818; 0129829-0129834; 0130032-0130038.	3/31/2002

D-7161	Email from Lester Reich to Manfred Hauben and attachment bearing the bates range Pfizer_MHauben_0000122 - 25.	3/15/2001
D-7162	Email from Chris Pacella to Cynthia de Luise bearing the bates range Pfizer_Cpacella_0029869 - 71.	10/24/2002
D-7163	Email from Tina Ho to Cathy Sigler, et al. bearing the bates range Pfizer_THO_0012051 - 66.	1/8/2003
D-7164	Email from Cathy Sigler to Tina Ho bearing the bates range Pfizer_THO_0001633.	1/9/2003
D-7165	Email from Lesia Tontisakis to Michael Campbell et al. bearing the bates range Pfizer_THO_0001634 - 35.	1/16/2003
D-7166	Email and Attachment from Cathy Sigler to Christopher Pacella bearing the bates range Pfizer_CPacella_0022941 - 43.	1/21/2003
D-7167	Email from Julia Su to Claire Wohlhuter bearing the bates range Pfizer_SDoft_0055892 - 93.	10/9/2003
D-7168	Email from Suzanne Doft to Jill Bruzga, et al. bearing the bates range Pfizer_SDoft_0056764.	10/9/2003
D-7169	Email from Ed Whalen to Claire Wohlhuter, et al. bearing the bates range Pfizer_SDoft_0055890.	10/9/2003
D-7170	Email from Tina Ho to Claire Wohlhuter bearing the bates range Pfizer_SDoft_56200.	10/9/2003
D-7171	Email from Bruce Parsons to Claire Wohlhuter bearing the bates range Pfizer_BParsons_0134014.	10/14/2003
D-7172	Email from Linda LaMoreaux to Julia Su bearing the bates range Pfizer_JSu_0026449.	11/6/2003
D-7173	Email from Manini Patel to Lucy Castro, et al. bearing the bates range Pfizer_BParsons_0155116 - 17.	4/21/2004
D-7174	FDA Contact Report April 26, 2004 bearing the bates range Pfizer_BParsons_0141815 - 16.	4/26/2004
D-7175	FDA Contact Report bearing the bates range Pfizer_LCastro_0019922 - 23.	4/27/2004
D-7176	Email from Manini Patel bearing the bates range Pfizer_LCastro_0020155.	4/30/2004
D-7177	Proposal for Search Methodology and Information to be Provided bearing the bates range Pfizer_BParsons_0141988 - 89.	4/30/2004
D-7178	FDA Contact Report bearing the bates range Pfizer_SDoft_001125 - 26.	5/6/2004
D-7179	Suicide and Suicide Related Events Analysis Plan Proposal bearing the bates range Pfizer_LCastro_0023878 - 79.	5/17/2004

D-7180	Email from Manini Patel bearing the bates range Pfizer_MPatel_0007960.	5/17/2004
D-7181	Email from Jacqueline Ware bearing the bates range Pfizer_SDoft_0000886 - 89.	5/21/2004
D-7182	Detailed Analysis Plan bearing the bates range Pfizer_MPatel_0008631 - 36.	5/28/2004
D-7183	Email from Lucy Castro bearing the bates range Pfizer_MPatel_0008627 - 30.	5/28/2004
D-7184	Email from Jacqueline Ware bearing the bates range Pfizer_LCastro_0031551 - 58.	6/10/2004
D-7185	Letter from Jacqueline Ware to Manini Patel, et al. bearing the bates range Pfizer_LCastro_0031246 - 52.	6/28/2004
D-7186	Email from Jacqueline Ware to Manini Patel, et al. bearing the bates range Pfizer_LCastro_0036078 - 86.	7/16/2004
D-7187	Adverse Event Listing for FDA Request.	7/29/2004
D-7188	Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_MPatel_0023743 - 44.	8/6/2004
D-7189	Proposed Suicide Analysis Plan bearing the bates range Pfizer_MPatel_0023745 - 52.	8/6/2004
D-7190	September 2004 Submission (with appendices) bearing the bates range Pfizer_MEvertsz_0141890 - 3416.	9/10/2004
D-7191	September 2004 Submission bearing the bates range Pfizer_MPatel_039110 - 68.	9/9/2004
D-7192	Appendix B1.4 (September 2004 Submission) bearing the bates range Pfizer_MPatel_0172206 - 09.	9/9/2004
D-7193	Appendix D to September 2004 Submission.	
D-7194	Letter from Jane Axelrad to Keith Altman.	11/5/2004
D-7195	Parsons November 16, 2004 Response to FDA bearing the bates range Pfizer_Regulatory_000955 - 88.	11/19/2004
D-7196	November 2004 Submission bearing the bates range Pfizer_MPatel_0045143 - 76.	11/19/2004
D-7197	Letter from Russell Katz to Manini Patel bearing the bates range Pfizer_LKnapp_0062278 - 85.	3/16/2005
D-7198	Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_LKnapp_0062717 - 23.	5/5/2005
D-7199	Letter from FDA to all AED Sponsors about March 16, 2005 Request bearing the bates range Pfizer_CTaylor_0015011 -	7/11/2005

	18.	
D-7200	Letter from Manini Patel to Russell Katz bearing the bates range Pfizer_Regulatory_000486 - 95.	10/25/2005
D-7201	Courtney Calder email to Molly Powers bearing the bates range Pfizer_Regulatory_000001.	10/20/2005
D-7202	Courtney Calder email to Manini Patel bearing the bates range Pfizer_Regulatory_000002.	10/27/2005
D-7203	Email from Manini Patel to Courtney Calder bearing the bates range Pfizer_Regulatory_000031 - 32.	11/18/2005
D-7204	Email from Courtney Calder to Manini Patel bearing the bates range Pfizer_Regulatory_000003.	11/22/2005
D-7205	Letter from Russell Katz to Manini Patel bearing the bates range Pfizer_Regulatory_000473 - 75.	12/28/2005
D-7206	Letter from Russell Katz to Mary Ann Evertsz bearing the bates range Pfizer_MEvertsz_0109461 - 63.	5/3/2006
D-7207	Letter from Mary Ann Evertsz to Russell Katz bearing the bates range Pfizer_MEvertsz_0125701 - 05.	6/22/2006
D-7208	Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.	3/21/05
D-7209	Letter from Russell Katz to Andrew Finkelstein.	4/12/2005
D-7210	Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.	4/15/05
D-7211	Letter from Andrew Finkelstein, Finkelstein & Partners, to FDA.	10/14/05
D-7212	Plaintiff Lawyer Ads.	N/A
D-7213	Greylock McKinnon Associates Bill for Charles King.	N/A
D-7214	Retention Letter from Greylock McKinnon Associates to Andrew Finkelstein.	4/4/2006
D-7215	Complete June 2006 Submission bearing the bates range Pfizer_Regulatory_000510 - 954.	June 2006
D-7216	June 2006 Submission correspondence bearing the bates range Pfizer_MEvertsz_0079431 - 35.	6/22/2006
D-7217	Advisory Committee discussion.	7/30/2007
D-7218	Presentation slides.	7/30/2007

D-7219	Briefing document provided to the Advisory Committee.	7/30/2007
D-7220	Letter from Robin Pitts to Cynthia McCormick.	5/18/2001
D-7221	Letter to DDMAC from Lucy Castro bearing the bates range Pfizer_LCastro_0085961.	7/9/2001
D-7222	Email from Burch to RON Specialty Sales Force bearing the bates range Pfizer_MBrown_00374 - 75.	7/9/2001
D-7223	Letter to DDMAC from Lucy Castro bearing the bates range Pfizer_LCastro_0085964 - 65.	7/31/2001
D-7224	Memorandum from Rick Burch to RON Sales Force bearing the bates range Pfizer_RGlanzman_0065616 - 17.	7/9/2002
D-7225	Letter to DDMAC from Manini Patel bearing the bates range Pfizer_MPatel_0145892.	7/12/2002
D-7226	Marketing Policies at Parke-Davis bearing the bates range WLC_FRANKLIN_0000128133 - 53.	1993
D-7227	Memorandum from R.W. Doyle to Distribution bearing the bates range WLC_FRANKLIN_0000128131 - 32.	12/6/1994
D-7228	Memorandum from R.W. Doyle to Distribution bearing the bates range WLC_FRANKLIN_0000097026 - 28.	7/22/1996
D-7229	Standard Operating Procedure for Consultant Meetings bearing the bates range WLC_FRANKLIN_0000111217 - 20.	1997
D-7230	Standard Operating Procedure for Continuing Medical Education Grants bearing the bates range WLC_FRANKLIN_0000111224 - 26.	1997
D-7231	Standard Operating Procedure for Speakers Bureau/Promotional Events bearing the bates range WLC_FRANKLIN_0000111221 - 23.	1997
D-7232	Standard Operating Procedure for the Utilization of Medical Groups at Customer Business Units bearing the bates range WLC_FRANKLIN_0000111227 - 29.	1997
D-7233	Memorandum from Karen Katen to Joe Feczko, et al. bearing the bates range Pfizer_LeslieTive_0063878 - 80.	11/10/2000
D-7234	Memorandum from Pat Kelly to PPG - Marketing Personnel bearing the bates range Pfizer_LeslieTive_0063876 - 78.	3/1/2001
D-7235	Standard Response Letter bearing the bates range Pfizer_JSu_0018794.	N/A
D-7236	Bipolar Standard Response Document.	11/28/2000
D-7237	Neurontin Speaker Training Guidelines bearing the bates range Pfizer_AZeuscher_0024845 - 46.	N/A

D-7238	Neurontin Fact Sheet bearing the bates range Pfizer_SDoft_0015171 - 74.	N/A
D-7239	Listing of Neurontin Worldwide Approvals and Indications bearing the bates range Pfizer_MDL_0008409 - 74.	2007
D-7240	Advisory Committee Meeting Transcript.	10/24/1991
D-7241	FDA Briefing Document from 1992 Advisory Committee Meeting.	6/1/1992
D-7242	Parke-Davis briefing document to FDA for Peripheral and Central Nervous System (PCNS) Advisory Committee Meeting bearing the bates range Pfizer_LAlphs_0041754 - 820.	11/16/1992
D-7243	Briefing Materials for Dec. 15, 1992 Peripheral and Central Nervous System (PCNS) Drugs Advisory Committee Meeting on NDA 20-235.	12/1/1992
D-7244	Peripheral and Central Nervous System (PCNS) Advisory Committee Meeting Transcript.	12/15/1992
D-7245	December 1992 Advisory Committee Meeting Transcript Vol. II.	12/30/1992
D-7246	May 16, 2002 Advisory Committee Transcript bearing the bates range Pfizer_LCastro_0083167 - 541.	5/16/2002
D-7247	CDER Office of Translational Sciences & Office of Biostatistics. Statistical Review of Evaluation titled Antiepileptic Drugs and Suicidality.	5/23/2008
D-7248	Information for Healthcare Professionals - Suicidality and Antiepileptic Drugs (FDA Alert).	1/31/2008
D-7249	Suicidal Thoughts and Behavior Antiepileptic Drugs (FDA Alert).	12/16/2008
D-7250	Pfizer Slide presentation to Columbia University Antiepileptic Drug Meeting.	6/2/2008
D-7251	FDA. Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee July 10, 2008. Questions 2008-437b-01-FDA-Katz.pdf.	6/10/2008
D-7252	Russell Katz Memorandum. Briefing Document for the July 10, 2008 FDA Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality.	6/12/2008
D-7253	FDA Amicus Brief.	7/1/2008
D-7254	Pfizer Lyrica & Neurontin slide presentation presented at FDA Advisory Committee.	7/10/2008

D-7255	FDA Advisory Committee meeting slide presentation by Dr. J Cramer.	7/10/2008
D-7256	Pfizer Briefing Documents dated July 10, 2008.	7/10/2008
D-7257	Joint Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee and the Psychopharmacologic Drugs Advisory Committee Transcript.	7/10/2008
D-7258	GlaxoSmithKline Lamictal slide presentation at FDA Advisory Committee Meeting on July 10, 2008.	7/10/2008
D-7259	Letter from Katz to Clark.	12/16/2008
D-7260	Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1 January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEvertsz_0013185 - 202.	February 2000
D-7261	Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067211 - 55.	10/7/2004
D-7262	Pfizer Worldwide Development Safety and Risk Management: Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067016 - 50.	August 2005
D-7263	Attachment 1 (List of Procedural Documents) to Master Document on Pharmacovigilance bearing the bates range Pfizer_ELuczak_0067051 - 57.	August 2005
D-7264	Pfizer U.S. Medical Information, Standard Response Document, Suicidal and Suicide Gesture bearing the bates range Pfizer_BParsons_008288 - 92.	11/11/2003
D-7265	Letter from Medicines Control Agency to Parke-Davis bearing the bates range WLC_CBU_103013-14.	4/28/1995
D-7266	Memorandum from Joe Feczko to PPG - US Medical Personnel bearing the bates range Pfizer_LCastro_0000054 - 58.	12/7/2000
D-7267	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pifzer_CPacella_0022305 - 11.	5/9/2001
D-7268	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0047972 - 79.	7/19/2001
D-7269	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_Cpacella_0022322 - 29.	10/18/2001
D-7270	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022606 - 12.	1/17/2002
D-7271	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LTive_0009939 - 43.	4/18/2002

D-7272	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0047987 - 92.	7/18/2002
D-7273	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0166311 - 14.	7/25/2002
D-7274	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0022069 - 72.	10/14/2002
D-7275	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0022344 - 50.	10/17/2002
D-7276	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_RGlanzman_0022073 - 75.	10/23/2002
D-7277	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0048002 - 08.	1/16/2003
D-7278	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_CPacella_0061212 - 17.	7/17/2003
D-7279	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_MEvertsz_0015747 - 48.	3/1/2004
D-7280	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LCastro_0084739 - 41.	3/4/2004
D-7281	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_MEvertsz_0015747 - 48.	3/10/2004
D-7282	Product Maintenance & Pharmacovigilance Minutes bearing the bates range Pfizer_LCastro_0084739 - 41.	3/25/2004
D-7283	Risk Management Working Group Minutes bearing the bates range Pfizer_RGlanzman_0036788 - 92.	6/12/2001
D-7284	Risk Management Working Group Minutes bearing the bates range Pfizer_LKnapp_0025486 - 90.	9/24/2001
D-7285	Risk Management Working Group Minutes bearing the bates range Pfizer_LCastro_0076898 - 900.	1/16/2002
D-7286	Email string from Linda LaMoreaux to Julia Su bearing the bates range Pfizer_JSu_0017563 - 70.	11/11/2003
D-7287	Plots of PRR over time.	11/12/2007
D-7288	Brock's handwritten notes.	
D-7289	International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; Guideline for Industry: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (E2A).	10/27/1994
D-7290	International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials (E8).	7/17/1997

D-7291	International Conference on Harmonization (ICH); Guideline for Industry: The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions (ICH E1A).	10/27/1994
D-7292	International Conference on Harmonisation Tripartite Guideline - Revision Of The ICH Guideline On Clinical Safety Data Management: Data Elements For Transmission Of Individual Case Safety Reports (E2b(R)).	5/12/2005
D-7293	International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Pharmacovigilance Planning (E2e).	11/18/2004
D-7294	International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Structure And Content Of Clinical Study Reports (E3).	11/30/1995
D-7295	International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use; ICH Harmonised Tripartite Guideline: Guideline For Good Clinical Practice (E6(R1)).	April 1996
D-7296	Neurontin Periodic Adverse Drug Experience Reports and Periodic Reports.	N/A
D-7297	Email from Maribeth to Carriero bearing the bates range Pfizer_LKnapp_0062000 - 02.	5/13/2005
D-7298	MedDRA Release Archive.	N/A
D-7299	Review of the Neuropsychiatric Adverse Events Reported in Association with the Use of Gabapentin During the Period 1: January 1996 to 31 December 1999, Warner-Lambert's Drug Safety Surveillance bearing the bates range Pfizer_MEverts_00131185 - 202.	February 2000
D-7300	Appendix 5, Pfizer Safety and Risk Management Literature Review: Gabapentin Use Among Persons with a History of Psychotic Disorder bearing the bates range Pfizer_Regulatory_261.	December 2005
D-7301	Statement by Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration Before the Subcommittee on Oversight and Investigations Committee on Energy and Commerce U.S. House of Representatives.	12/11/2002
D-7302	Summary of Minutes of Joint Meeting of Endocrine and Metabolic Drugs AC and Drug Safety and Risk Management AC.	7/30/2007
D-7303	Report by Kenneth Petronis, Literature Review: Gabapentin Use Among Persons with a History of a Psychotic Disorder	12/1/2005

	bearing the bates range Pfizer_Regulatory_000260 - 61.	
D-7304	Tabular Summary of the Indications and Medical History in Cases Reporting Patients Who Committed Suicide or Attempted Suicide While Receiving Gabapentin, by Jigna Shaw, Pharm. D. bearing the bates range Pfizer_MEvertsz_0091472 - 78.	7/28/2006
D-7305	Bipolar and Gabapentin Sensitivity Analysis.	N/A
D-7306	Pfizer Response to CHMP's List of Questions bearing the bates range Pfizer_LKnapp_0127238.	April 2005
D-7307	FDA Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products; www.fda.gov/cderiguide/1397fnl.pdf .	5/12/2008
D-7308	U.S. FDA, Reviewer Guidance: Evaluating the Risks of Drug Exposure in Human Pregnancies.	April 2005
D-7309	Response Assessment Report on List of Outstanding Issues Neurontin and associated trade names (Gabapentin) EMEA/H/A-30/616 MAH: Pfizer Ltd. UK bearing the bates range Pfizer_Regulatory_000262 - 73.	4/10/2004
D-7310	Rapporteurs' Joint Response Assessment Report in the Referral under Article 30 of Directive 2001/83/EC concerning Neurontin (and associated names) (INN: Gabapentin) EMEA/H/A-30/616 bearing the bates range Pfizer_MPatel_0208552 - 647.	6/2/2005
D-7311	Response to EMEA List of Outstanding Issues dated 23 June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin), EMEA Procedure No: EMEA/H/A-30/616 bearing the bates range Pfizer_MEvertsz_0084390 - 479.	12/14/2005
D-7312	Appendix 4, Response to EMEA List of Outstanding Issues dated 23 June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin), EMEA Procedure No.: EMEA/H/A-30/616 bearing the bates range Pfizer_JMohan_0000479.	12/14/2005
D-7313	European Union Referral, Response to EMEA, List of Outstanding Issues dated 23, June 2005, Article 30 Referral, Neurontin (and associated names) (INN: Gabapentin) EMEA Procedure No.: EMEA/H/A-30-616 bearing the bates range Pfizer_MEvertsz_0084480 - 569.	12/14/2005
D-7314	Joint Response Assessment Report on List of Outstanding Issues Neurontin and associated trade names (Gabapentin) EMEA/H/A-30/616 MAH: Pfizer Ltd. UK bearing the bates range Pfizer_MPatel_0252359 - 95.	1/12/2006

D-7315	EMA Guidance on Use of Statistical Signal Detection Methods.	11/16/2006
D-7316	CHMP List of Questions bearing the bates range Pfizer_MPate1_0074999 - 5036.	10/27/2004
D-7317	CHMP Day 180 List of Outstanding Issues Neurontin and Associated names (Gabapentin) EMA/H/A-30/616 bearing the bates range Pfizer_EGarofalo_001107 - 31.	6/17/2005
D-7318	CHMP 90-Day List of Remaining Issues bearing the bates range Pfizer_Regulatory_000033 - 36.	1/24/2006
D-7319	CHMP Summary on Referral Opinion bearing the bates range Pfizer_Regulatory_000062.	8/4/2006
D-7320	Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0029393 - 96.	7/30/2002
D-7321	Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0061978 - 81.	10/15/2002
D-7322	Memorandum from Christopher Pacella to Distribution bearing the bates range Pfizer_CPacella_0061982 - 84.	10/23/2002
D-7323	Email from Christopher Pacella to Phillip Arena et al. bearing the bates range Pfizer_CPacella_0061231.	7/12/2002
D-7324	UK Summary of Product Characteristics 2004 bearing the bates range Pfizer_MPate1_0042959 - 70.	January 2004
D-7325	UK Summary of Product Characteristics for Neurontin Capsules and Tablets.	12/8/2006
D-7326	Proposed Summary of Product Characteristics (International Label) bearing the bates range Pfizer_Regulatory_000228 - 46.	January 2006
D-7327	Summary of Product Characteristics 2006 bearing the bates range Pfizer_Regulatory_000215 - 27.	3/22/2006
D-7328	Neurontin SPC viewed online at http://vwww.nelm.nhs.uk/Record20Viewinq/viewRecord.aspx?id=580399 .	5/12/2008
D-7329	Pfizer Inc Core Data Sheet bearing the bates range Pfizer_CPacella_0030209 - 20.	1/30/2003
D-7330	JNDA Summary of Clinical Safety bearing the bates range Pfizer_LAlphs_0002867 - 3074.	2001
D-7331	Investigator's Brochure Addendum for Epilepsy Studies in Japan bearing the bates range Pfizer_Mpatel_0017578 - 672.	July 2004
D-7374	FDA Talk Paper on Antidepressants.	3/22/2004
D-7375	Statement from American Epilepsy Society.	12/5/2008

D-7376	Worsening Depression and Suicidality in Patients Being Treated with Antidepressants.	3/22/2004
D-7377	Gabapentin Comprehensive Summary bearing the bates range Pfizer_LAlphs_0061807 - 1963.	11/18/1991
D-7378	Charlie Taylor 2003 MOA Report bearing the bates range Pfizer_CTaylor_0001365 - 76.	2003
D-7379	An Update on the Possible Mechanisms of Action of Gabapentin. By: Charles Taylor bearing the bates range Pfizer_CTaylor_0008905 - 23.	
D-7380	Clinical Development in the Slipstream of Gabapentin bearing the bates range Pfizer_CTaylor_0000204 - 220.	
D-7381	PowerPoint presentation entitled: Drug Target A2D--The Biology and Pharmacology of Calcium Channel A2D Proteins bearing the bates range Pfizer_CTaylor_0000094 - 121.	
D-7382	Report by Dr. Stephen Brown, "Gabapentin and Psychosis" bearing the bates range MDL_LABL_0000002 - 04.	5/27/1995
D-7383	Report from Dr. Stephen Brown to Dr. Tim Paget bearing the bates range Pfizer_CPacella_0009440 - 49.	8/15/1995
D-7384	Medicines Control Agency Draft Response bearing the bates range Pfizer_LKnapp_0135264 - 65.	February 2000
D-7385	Email from James Leonard to Elizabeth Garofalo bearing the bates range Pfizer_LKnapp_0135257 - 58.	2/8/2000
D-7386	Email from Fiona Sellwood to Thomas Bradley et al. bearing the bates range Pfizer_CPacella_009588 - 89.	3/17/2000
D-7387	Email from Patricia Carlson to Fiona Sellwood bearing the bates range Pfizer_CPacella_009561 - 62.	3/29/2000
D-7388	Email from Patricia Carlson to James Leonard et al. bearing the bates range Pfizer_CPacella_009559 - 60.	3/29/2000
D-7389	Suicide Rates in Neurontin-Treated Populations bearing the bates range Pfizer_MPatel_0039743.	9/9/2004
D-7390	Email from Larry Alps to Cathy Sigler bearing the bates range Pfizer_LeslieTive_0041009-17.	2/5/2003
D-7391	Email from Dr. Alexander Ruggieri to Dr. Steven Galson.	2/8/2008
D-7392	Email from Donald Dobbs to Dr. Alexander Ruggieri.	4/1/2008
D-7393	Letter from Dr. Roder to Prof. Heller bearing the bates range Pfizer Leslie Tive 0020885-921.	2/14/2002
D-7394	Letter from Dr. Roder to Dr. Waldhausl bearing the bates range Pfizer Leslie Tive 0020844-79.	10/21/2002

D-7395	Memorandum from Dr. Roder to Leslie Tive bearing the bates range Pfizer_LeslieTive_0020834 - 79.	3/31/2003
D-7396	FDA Staff Manual Guides, Vol. II, § 1410.10.	
D-7397	Excerpts from Pfizer 2000 SEC form 10K.	3/28/2001
D-7398	Excerpts from Pfizer 2002 SEC form 10K.	3/27/2003
D-7399	COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms (2nd Edition).	8/23/1985
D-7400	COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms (5th Edition).	1995
D-7401	Pharmacist's Letter/Prescriber's Letter bearing the bates range Pfizer_JSu_0017853 - 56.	8/1/2003
D-7402	Office of Drug Safety Annual Report: 2002.	4/9/2004
D-7403	The FDA Guidance to Industry, Good Pharmacovigilance Practices and Pharmacoepidemiology Assessment.	March 2005
D-7404	FDA Guidance for Industry: E2E Pharmacovigilance Planning.	April 2005
D-7405	Adverse Event Reporting System (AERS) Office of Pharmacoepidemiology and Statistical Science Brief Description with Caveats of System.	7/18/2005
D-7406	Druglogic Qscan 3.2 User's Guide. User Manual. Version 3.2.2006.	2006
D-7407	The Guide to Off-Label Prescription Drugs: New Uses for FDA-Approved Prescription Drugs.	2006
D-7408	FDA's Guidance for Industry, Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products -- Content and Format.	January 2006
D-7409	Letter to Editor of Drug Safety.	2007
D-7410	MedDRA Term Selection: Points to Consider. Release 3.10 (Based on MedDRA Version 11.0. April 1,2008.).	2008
D-7411	Affidavit of Dr. Cynthia McCormick, M.D. with exhibits.	9/13/2007
D-7412	Alexander Ruggieri, M.D. Expert Report.	12/20/2007
D-7413	Affidavit of Alexander Ruggieri, M.D.	4/15/2008

D-7414	Alexander Ruggieri, M.D. Supplemental Expert Report.	11/8/2008
D-7415	Alexander Ruggieri, M.D. CV.	12/20/2007
D-7416	Charles P. Taylor, Ph.D. Expert Report.	12/20/2007
D-7417	Charles P. Taylor, Ph.D. CV.	
D-7418	Gerard Sanacora, Ph.D. M.D. Expert Report.	12/20/2007
D-7419	Gerard Sanacora, Ph.D. M.D. Supplemental Expert Report.	11/10/2008
D-7420	Charles P. Taylor, Ph.D. Supplemental Expert Report.	11/8/2008
D-7421	Gerard Sanacora, Ph.D. M.D. CV.	6/15/2007
D-7422	Janet Arrowsmith-Lowe, M.D. Expert Report.	12/20/2007
D-7423	Janet Arrowsmith, M.D. Supplemental Expert Report.	11/7/2008
D-7424	Janet Arrowsmith-Lowe, M.D. Expert Report.	5/12/2008
D-7425	Janet Arrowsmith-Lowe, M.D. Supplemental Expert Report.	11/18/2008
D-7426	Janet Arrowsmith-Lowe, M.D. CV.	November 2008
D-7427	Sheila Weiss Smith, Ph.D. Expert Report.	12/20/2007
D-7428	Sheila Weiss Smith, Ph.D. Supplemental Expert Report.	11/7/2008
D-7429	Sheila Weiss Smith, Ph.D. CV.	
D-7430	Robert D. Gibbons, Ph.D. Expert Report.	5/19/2008
D-7431	Robert D. Gibbons, Ph.D. Supplemental Expert Report.	7/11/2008
D-7432	Robert D. Gibbons, Ph.D. Supplemental Expert Report.	11/5/2008
D-7433	Robert D. Gibbons, Ph.D. Supplemental Expert Report.	3/19/2009

D-7434	Robert D. Gibbons, Ph.D. CV.	
D-7435	Atul C. Pande, M.D. CV bearing the bates range Pfizer_APande_0000352 - 54.	3/7/2007
D-7436	Janeth Turner CV.	
D-7437	Gary Brenner Ph.D., CV.	11/1/2008
D-7438	Gary Brenner Ph.D., Expert Report.	11/10/2008
D-7439	Edward Boyer, M.D. CV.	11/8/2008
D-7440	Edward Boyer, M.D. Expert Report.	11/10/2008
D-7441	Anthony Rothschild, M.D. CV.	4/30/2008
D-7442	Anthony Rothschild, M.D. Expert Report.	11/10/2008
D-7443	Anthony Rothschild, M.D. Expert Report.	12/19/2007
D-7444	Douglas Jacobs, M.D. CV.	12/19/2007
D-7445	Douglas Jacobs, M.D. Expert Report.	11/3/2008
D-7446	Douglas Jacobs, M.D. Expert Report.	12/20/2007
D-7447	Henry Grabowski, Ph.D. CV.	
D-7448	Henry Grabowski, Ph. D Expert Report.	11/18/2008
D-7449	Manfred Hauben, M.D., M.P.H., D.T.M.&H CV.	
D-7450	Lloyd Knapp, Pharm.D CV.	December 2005
D-7451	Bentson McFarland M.D., Ph.D, Expert Report.	11/5/2007
D-7452	Sander Greenland, M.A., M.S., Ph.D. Expert Report.	10/19/2007
D-7453	Richard Mattson, M.D. CV.	

D-7454	Declaration of Richard Mattson.	June 2007
D-7455	Declaration of Miroslav Backonja, M.D.	12/10/2008
D-7456	Declaration of Dr. Kenneth Gorson.	10/30/2006
D-7457	Declaration of Dr. Edward Vieta.	12/4/2008
D-7458	Declaration of Robert Gerner, M.D.	6/12/2008
D-7459	Declaration of Carol A. Janney, M. S.	7/26/2008
D-7460	Declaration of Dr. Ninan T. Mathew.	5/23/2007
D-7461	Dr. Mark Mengel, M.D., M.P.H. CV.	6/1/2008
D-7462	Deposition of Benston McFarland.	11/5/2007
D-7463	Figure A "Modulation of K ⁺ -induced synaptosomal calcium influx by Gabapentin." 875 Brain Res. 157, 158 (2000).	2000
D-7464	Figure A, "Stimulus-Dependent Modulation of [3H] Noreinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin," 295 J. Pharmacology and Experimental Therapeutics 1086, 1089 (2000).	2000
D-7465	Figure 3, "Inhibition of Neuronal Ca ²⁺ Influx by Gabapentin and Subsequent Reduction of Neurotransmitter Release from Rat Neocortical Slices," 130 Brit. J. Pharmacology 900, 902 (2000).	2000
D-7466	Figure A, "Stimulus-Dependent Modulation of [3H] Noreinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin," 295 J. Pharmacology and Experimental Therapeutics 1086, 1089 (2000).	2000
D-7467	Figure 1, "Gabapentin Inhibits the Substance P-Facilitated K ⁺ Evoked Release of [3H] Glutamate from Rat Caudal Trigeminal Nucleus Slices," 93 Pain, 191, 193 (2001).	2001
D-7468	Figure from "Pregabalin and Gabapentin Reduce Release of Substance Pand CGRP from Rat Spinal Tissues Only After Inflammation or Activation of Protein Kinase C," 105 Pain 133, 136 (2003).	2003
D-7469	Figure titled "Gabapentin Reduces DAP-Stimulated but not Basal Monoamines" from Pugsley TA, Whetzel SZ, Dooley DJ, Psychopharmacology 137:74-80.	1998

D-7470	Figure titled "Neurontin/Gabapentin Prescriptions and Promotional Expenditures".	
D-7471	Over-the-Counter Labeling Rule.	12/6/2002
D-7472	Letter to Dr. Robert Gibbons from Archives of General Psychiatry.	4/29/2009
D-7473	Research Report 4192-0166.	May 1984
D-7474	Research Report 720-02801, Study Protocol 945-5-1 Appendix A.2.	1/14/1987
D-7475	Research Report 720-02455.	4/28/1989
D-7476	Research Report 877-078 bearing the bates range Pfizer_LAlphs_0016276 - 514.	2/14/1990
D-7477	Research Report 4301-00066, Study Protocol 879-200 bearing the bates range Pfizer_LeslieTive_0045750 - 6674.	6/25/1990
D-7478	Research Report Memo 4301-00121, Study Protocol 877-035 bearing the bates range Pfizer_LAlphs_0016093 - 275.	2/13/1991
D-7479	Research Report 4301-00024, Study Protocol 877-210P.	5/6/1991
D-7480	Research Report 4301-00024: Appendix A.2 (Protocol 877-210 and Amendments 1 and 2, Blank CRFS).	2/1/1986
D-7481	Research Report 720-02455 Correction Memorandum.	7/8/1991
D-7482	Research Report 720-02455 Correction Memorandum.	8/27/1991
D-7483	Research Report 720-04231, Study Protocol 945-094 bearing the bates range Pfizer_MEvertsz_0052019 - 3246.	7/13/1991
D-7484	Research Report 720-02883, Study Protocol 945-13 bearing the bates range Pfizer_LAlphs_0031572 - 2276.	8/16/1991
D-7485	Research Report 4301-00077, Study Protocol 945-006.	9/12/1991
D-7486	Research Report 4301-00077, Study Protocol 945-006 Appendix A.2.	11/10/1986
D-7487	Research Report 4301-00103, Study Protocol 945-9/10 bearing the bates range Pfizer_LAlphs_0022558 - 609.	9/12/1991
D-7488	Research Report 4301-00103: Appendix A.2 (Protocol 945-9/10 and Amendments) bearing the bates range Pfizer_LAlphs_0022558 - 609.	11/10/1986

D-7489	Research Report 4301-00126, Study Protocol 945-11 bearing the bates range Pfizer_LAlphs_0030388 - 692.	9/13/1991
D-7490	Research Report 720-02801, Study Protocol 945-005.	9/13/1991
D-7491	Research Report 720-02801, Study Protocol 945-005 Appendix A.2.	1/14/1987
D-7492	Research Report 720-02957.	2/3/1992
D-7493	Research Report 720-03092.	5/21/1992
D-7494	Research Report 720-03079.	5/26/1992
D-7495	Research Report 745-02070 bearing the bates range Pfizer_MPatel_0008714 - 34.	3/11/1993
D-7496	Research Report 720-03322 (Fourth Safety Update).	12/14/1993
D-7497	Research Report 720-03362.	4/19/1994
D-7498	Research Report 720-03362: Correction Memorandum.	7/8/1996
D-7499	Research Report 720-03381.	5/31/1994
D-7500	Research Report 720-03366, Study Protocol 945-210G bearing the bates range Pfizer_LAlphs_0016627 - 99.	9/1/1994
D-7501	Research Report 995-0070 Appendix A.3.	4/22/1996
D-7502	Research Report 720-03908, Study Protocol 945-210.	4/24/1996
D-7503	Research Report 720-03908, Study Protocol 945-210 Appendix A.2.	4/24/1996
D-7504	Research Report 720-03495 Study Protocol 945-082 bearing the bates range WLC_CBU_112771 - 887.	7/9/1996
D-7505	Research Report 720-03675, Study Protocol 945-088.	7/10/1996
D-7506	Research Report 720-03365, Study Protocol 945-213 bearing the bates range Pfizer_LAlphs_0036546 - 807.	11/26/1996
D-7507	Gabapentin monotherapy: an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures.	1997

D-7508	Gabapentin monotherapy: II. A 26-Week, Double-Blind, Dose-Controlled, Multicenter Study of Conversion from Polytherapy in Outpatients with Refractory Complex Partial or Secondarily Generalized Seizures.	1997
D-7509	Research Report 720-03779, Study Protocol 945-077 bearing the bates range Pfizer_LCastro_0057483 - 8337.	3/4/1997
D-7510	Research Report Memo 720-03847 Safety Protocol 945-077 bearing the bates range Pfizer_MPatel_0088542 - 60.	3/4/1997
D-7511	Research Report 720-03480 Neurontin Investigator's Brochure bearing the bates range WLC_CBU_030414 - 79.	4/21/1997
D-7512	Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_TMF_CRF_006931.	3/9/1998
D-7513	Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_TMF_CRF_006868.	3/27/1998
D-7514	Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_LAlphs_0048193.	2/15/1999
D-7515	Research Report 720-03480 Correction Memorandum bearing the bates range Pfizer_LAlphs_0048190.	3/30/2000
D-7516	Research Report 720-03891, Study Protocol 945-086/186.	11/20/1997
D-7517	Research Report 995-00057, Study Protocols 945-193 and 945-200 bearing the bates range Pfizer_LeslieTive_0069995 - 70300.	7/20/1998
D-7518	Research Report 995-00070, Study Protocol 945-211.	12/29/1998
D-7519	Research Report 995-00072, Study Protocol 945-195.	2/19/1999
D-7520	Research Report 720-03851, Study Protocol 945-203.	3/19/1999
D-7521	Research Report 720-03851, Study Protocol 945-203 Appendix B.82 bearing the bates range Pfizer_EDukes_0009835 - 37.	2/13/1998
D-7522	Research Report 720-03851, Study Protocol 945-203 Appendix B.86.	2/13/1998
D-7523	Research Report 720-03851, Study Protocol 945-203 Appendix C.92.	2/13/1998
D-7524	Research Report 720-04174, Study Protocol 945-209.	3/26/1999
D-7525	Research Report 720-04174, Study Protocol 945-209 Appendix C.46 bearing the bates range Pfizer_LKnapp_0001212.	11/4/1998

D-7526	Research Report 720-03851, Study Protocol 945-204.	4/9/1999
D-7527	Research Report 995-00074, Study Protocol 945-220 bearing the bates range Pfizer_LTive_0015139 - 294.	8/24/1999
D-7528	Research Report 720-04130, Study Protocol 945-224.	2/7/2000
D-7529	Research Report 720-04130, Study Protocol 945-224 Appendix 2.	2/23/1998
D-7530	Research Report for Study 945-092 bearing the bates range Pfizer_LCastro_0021988 - 0023071.	3/31/2000
D-7531	Research Report 430-00124, Study Protocol 945-430-295.	4/3/2000
D-7532	Research Report 720-04378, Study Protocol 1032-001.	4/4/2000
D-7533	RR 720-04223, Study Protocol 945-213.	4/20/2000
D-7534	Research Report 430-00125, Study Protocol 945-430-306.	5/5/2000
D-7535	Research Report 430-00125, Study Protocol 945-430-306.	2/3/1999
D-7536	Research Report 720-04455, Study Protocol 1035-001.	6/28/2000
D-7537	Research Report 720-04481, Study Protocol 1032-004.	8/16/2000
D-7538	Research Report No. 720-04479, Study Protocol 1032-002.	10/31/2000
D-7539	Research Report 720-04483, Study Protocol 1035-001B.	10/31/2000
D-7540	Research Report 995-00085, Study Protocol 945-217 bearing the bates range Pfizer_LeslieTive_0020213 - 69.	11/19/2000
D-7541	Research Report 720-04471, Study Protocol 1035-002.	12/20/2000
D-7542	Research Report 720-30049, Study Protocol 1035-003 bearing the bates range Pfizer_LAlphs_0078114.	1/2/2001
D-7543	Research Report 720-30049, Study Protocol 1035-003, p. 8 bearing the bates range Pfizer_LAlphs_0078121.	1/2/2001
D-7544	Research Report 744-00621 bearing the bates range Pfizer_SDoft_0001945 - 2002.	7/6/2001
D-7545	Research Report 720-9450222, Study Protocol 945-421-222.	9/18/2001

D-7546	Research Report 934-0324, Study Protocol 934-324 bearing the bates range Pfizer_MPatel_0193581 - 4549.	3/12/2002
D-7547	Research Report 934-0325, Study Protocol 934-325 bearing the bates range Pfizer_MPatel_0195037 - 6187.	10/2/2002
D-7548	Research Report 720-30154, Study Protocol 945-411 bearing the bates range Pfizer_MPatel_0140560 - 703.	11/5/2002
D-7549	Research Report 957-0233, Study Protocol 934-335 bearing the bates range Pfizer_MPatel_0194550 - 5036.	4/22/2003
D-7550	Final Taiwan Report, Study Protocol 945-468-429 bearing the bates range Pfizer_BParsons_0119335 - 120449.	5/13/2003
D-7551	Study Protocol 945-420-276 bearing the bates range Pfizer_LKnapp_0108138 - 398.	5/14/2003
D-7552	Final Report, Study Protocol 945-475-283 bearing the bates range Pfizer_MPatel_0245758 - 882.	12/19/2003
D-7553	Research Report 724-20013, Study Protocol 945-439.	8/18/2004
D-7554	Research Report 720-03930 bearing the bates range Pfizer_EGarofalo_0000498 - 517.	
D-7555	Behavioral Disturbance with Gabapentin (Trimble, M. Institute of Neurology, London, Report for Parke, Davis & Company) bearing the bates range Pfizer_CPacella_0009404 - 21.	1995
D-7556	Psychosis with Gabapentin (Trimble, M. Institute of Neurology, London, Report for Warner Lambert) bearing the bates range WLC_CBU_102999 - 3014.	5/20/1995
D-7557	Summary of post-marketing reports for gabapentin through 3/31/02 Pfizer_CPacella_0061232 - 1257	3/31/2002
D-7558	Information for Healthcare Professionals Suicidal Behavior and Ideation and Antiepileptic Drugs. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm .	12/16/2008
D-7559	Statistical review and evaluation. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf .	5/23/2008
D-7560	Gibbons R.D., Duan N., Meltzer D., Pope, A., Penhoet E.D., Dubler N.N., Francis C.K., Gill, B., Guinan E., Henderson M., Ildstad S.T., King, P.A., Martinez-Maldonado M., McClain G.E., Murray J.E., Nelkin D. Spellman M.W, and Pitluck S. Waiting for Organ Transplantation: Results of an analysis by an Institute of Medicine Committee, Biostatistics, 4, 207-222, 2003.	2003
D-7561	Cynthia G. McCormick, M.D., FDA Division of Neuropharmacological Drug Products, Review of Third	1992

	Safety Update (5/12/92).	
D-7562	Cynthia G. McCormick, M.D., FDA Division of Neuropharmacological Drug Products, Review of Fourth Safety Update (12/15/93).	1993
D-7563	Cynthia G. McCormick, M.D., Combined Medical-Statistical Review of NDA 20-235 (10/13/93).	1993
D-7564	Brent D. Antidepressants and suicidal behavior: cause or cure? Am J Psychiatry. 2007 Jul; 164(7):989-91.	2007
D-7565	Böhning D, Schlattmann P, Lindsay BG. Re: "A statistical method for evaluating suicide clusters and implementing cluster surveillance". Am J Epidemiol. 1992 Jun; 135(11):1310-4.	1992
D-7566	Charles Taylor 8/27/09 Deposition Exhibit 1.	
D-7567	Charles Taylor 8/27/09 Deposition Exhibit 2.	
D-7568	Charles Taylor 8/27/09 Deposition Exhibit 3.	
D-7569	Charles Taylor 8/27/09 Deposition Exhibit 4.	
D-7570	Charles Taylor 8/27/09 Deposition Exhibit 5.	
D-7571	Charles Taylor 8/27/09 Deposition Exhibit 6.	
D-7572	Charles Taylor 8/27/09 Deposition Exhibit 7.	
D-7573	Charles Taylor 8/27/09 Deposition Exhibit 8.	
D-7574	Charles Taylor 8/27/09 Deposition Exhibit 9.	
D-7575	Charles Taylor 8/27/09 Deposition Exhibit 10.	
D-7576	Charles Taylor 8/27/09 Deposition Exhibit 11.	
D-7577	Charles Taylor 8/27/09 Deposition Exhibit 12.	
D-7578	Charles Taylor 8/27/09 Deposition Exhibit 13.	
D-7579	Charles Taylor 8/27/09 Deposition Exhibit 14.	

D-7580	David Franklin 12/18/09 Deposition Exhibit 1.	
D-7581	David Franklin 12/18/09 Deposition Exhibit 2.	
D-7582	David Franklin 12/18/09 Deposition Exhibit 3.	
D-7583	David Franklin 12/18/09 Deposition Exhibit 4.	
D-7584	David Franklin 12/18/09 Deposition Exhibit 5.	
D-7732	Final Study Report: Gabapentin Protocol A945-1008 A 15 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Neurontin for Efficacy and Quality of Life in Patients with Painful, Diabetic Peripheral Neuropathy Pfizer_LKnapp_0062214 - 76.	2005
D-7733	Email from John Marino to Allison Fannon et al. bearing bates range Pfizer_CGrogan_0012251 - 52.	6/30/2001
D-7734	Memorandum from R.W. Doyle to Distribution, re: Marketing Policies & Procedures, dated Dec. 6, 1994.	12/6/1994
D-7735	Document titled Promostudy Report, RE: Neurontin Merritt-Putnam Symposium, Mar. 1995.	Mar-95
D-7736	Document titled "Medical Education, Non-Speakers Bureau, Independent Programs, Grants and Promotional Programs, dated Jan. 1, 1996.	1/1/1996
D-7737	Contract Addendum.	7/8/1996
D-7738	Draft Internal PD Memorandum from P. Reichenberger to all TMs and ABMs, re: Emerging Applications Programs, dated Aug. 26, 1996.	8/26/1996
D-7739	Letter from Tracie L. Kelley (MES) to John Knoop (PD), dated Feb. 27, 1997.	2/27/1997
D-7740	Memo re: Neurontin for Neuropathic Pain in Diabetic Neuropathy.	5/20/1997
D-7741	ltr from Vervack to Aquino.	4/20/2000
D-7742	Memorandum from Pat Kelly to PPG - US Marketing Personnel, dated Mar. 2001, bearing the bates range Pfizer_DProbert_0019738-42.	3/1/2001
D-7743	E-mail from Marino Garcia to Angela Crespo, et al., re: Please Read - Article: "Emerging Therapies in Chronic Pain", dated Apr. 27, 2001, bearing the bates range Pfizer_LCastro_0004053-054.	4/27/2001

D-7744	Email From: Burch To: DL-K All Managers, DL-K All Reps Cc: several recipients.	7/10/2001
D-7745	Email from Marino Garcia to Timothy Hsu and Robert Glanzman, re: Neurontin For Ne Pain in Germany, dated July 18, 2001 bearing the bates range Pfizer_RGlanzman_0037380-381.	7/18/2001
D-7746	Submission cover letter with attachments from Beate Roder to the journal Diabetic Medicine, dated Feb. 14, 2002, bearing the bates range Pfizer_LeslieTive_0020880-0020921.	2/14/202
D-7747	Press release titled "PFIZER RECEIVES FDA APPROVAL TO MARKET NEURONTIN FOR POST-HERPETIC NEURALGIA", dated May 28, 2002, bearing the bates range Pfizer_KSiegler_0004997-998.	5/28/2002
D-7748	Email from Allison Fannon to Howard Bockbrader, Brian Corrigan re: Gabapentin Pk/pd Abstract and manuscript, dated June 10, 2002, bearing the bates range Pfizer_RGlanzman_014062-063.	6/10/2002
D-7749	Email from Steve Piron to John Marino, et al., re: NEU-0032591_DDMAC Materials, dated June 13, 2002, bearing the bates range Pfizer_CGrogan_0007124-169.	6/13/2002
D-7750	Email from Leslie Tive to Allison Fannon, re: Key Messages, dated Oct. 17, 2002, bearing the bates range Pfizer_RGlanzman_0125037-039.	10/17/2002
D-7751	Email from Robert Glanzman to Allison Fannon, Suzanne Doft and Angela Crespo, re: Key Messages, dated Oct. 17, 2002, bearing the bates range Pfizer_RGlanzman_0161613-614.	10/17/2002
D-7752	Submission cover letter with attachments from Beate Roder to the journal DIABETOLOGIA, dated Oct. 21, 2002, bearing the bates range Pfizer_LeslieTive_0020840-0020879.	10/21/2002
D-7753	Email from Bruce Parsons to Mariann Caprino and Jennifer Stamp, DL-Neurontin MM PM & PP, DL-PPG Neurology Group, AA DDEV 945 Neuro Team List, re: Neurontin: NeP Dosing Manuscript Printed Copy Available, dated Jan. 27, 2003, bearing the bates range Pfizer_BParsons_0181880-883.	1/27/2003
D-7754	Letter from Rober M. Sutherland M.D., Co-Director Center for Pain Medicine, Allegheny General Hospital to Carlos Gorrio, Territory Manager, Parke Davis, Northeast Customer Business Unit, re: June 4, 1995 letter from Sherwood Richardson to Anthony Wild, dated June 8, 1995.	6/8/1995
D-7755	Email chain sent from Janney Carol to Atul Pande and Debra Gmerek, re: 945-209, dated Feb., 1998.	February 1998
D-7756	Parke-Davis Investigator's Meeting Protocol 945-209, The Ritz Carlton, Chicago, IL., Meeting Minutes, dated Mar. 8-9, 1996.	March 1996

D-7757	Email from Hank McRorie to DL-All_Field_Force, dated Nov. 30, 2000, bearing the bates range Pfizer_MBrown_0000336-38.	11/30/2000
D-7758	NDA 21-397 Item 6 Table of Contents - Human Pharmacokinetics and Bioavailability.	
D-7759	Pfizer RR: RR-Reg 740-03550, bearing bates range Pfizer_LCastro_0007627-94.	
D-7760	Proceedings of the Third International Conference on Bipolar Disorder 1999.	1999
D-7761	Atul Pande presentation slides titled "Combination Treatment in Bipolar Disorder" (http://www.wpic.pitt.edu/stanley/3rdbipconf/pptslides/pande_files/slide0030.htm , accessed 10/24/2008).	1999
D-7762	Transcript of A. Pande's Presentation at the Third International Conference on Bipolar Disorder, "New Pharmacotherapies."	June 1999
D-7763	Chart Titled "Neurontin / Gabapentin Prescriptions and Promotional Expenditures" (Dec. 15, 2008, Michael C. Keeley Expert Report, p. 28).	
D-7764	Memorandum from B. Roder to L. Tive re: Publication of 945-224 results, bearing bates range Pfizer_LeslieTive_0020834-921.	March 2003
D-7765	Response to FDA Regarding Suicide and Suicide Attempt in Neurontin (gabapentin) Clinical Trials and Postmarketing Surveillance, bearing bates range Pfizer_Regulatory_001621-79.	
D-7766	FDA Ctr. for Drug Eval. And Research, Div. of Neuropharmacological Drug Products, Review and Eval. Of Clinical Data, NDA Supp. 20-235 (Safety Update #4). Review of the World Literature, dated Dec. 15, 1993.	12/15/1993
D-7767	Research Protocol-945-224-A Double Blind Placebo-Controlled Trial with 3 Doses of Gabapentin for Treatment of Painful Diabetic Neuropathy.	
D-7768	21 C.F.R. 314.105.	
D-7769	21 U.S.C. 301.	
D-7770	21 U.S.C. 352.	
D-7771	21 U.S.C. 355.	
D-7772	21 U.S.C. 393.	

D-7773	51 Fed. Reg. 43900.	
D-7774	71 Fed. Reg. 3922-29 (Jan. 24, 2006).	
D-7775	21 C.F.R. 201.57 (April 2002).	
D-7776	21 C.F.R. 202.1.	
D-7777	21 C.F.R. 312.20.	
D-7778	21 C.F.R. 312.22.	
D-7779	21 C.F.R. 314.50.	
D-7780	21 C.F.R. 314.80.	
D-7781	Daubert Hearing Transcript (6-20-08).	6/20/08
D-7782	Daubert Hearing Transcript(7-23-08).	7/23/08
D-7783	Daubert Hearing Transcript (6-19-08).	6/19/08
D-7784	Robert D. Gibbons, Ph.D. Supplemental Expert Report.	12/15/2008
D-7785	Robert D. Gibbons, Ph.D. Supplemental Expert Report.	1/5/2010
D-7786	Henry Grabowski, Ph. D Supplemental Expert Report.	3/13/2008
D-7787	Henry Grabowski, Ph. D Supplemental Expert Report.	4/14/2008
D-7788	Levetiracetam (Keppra) 2006.	2006
D-7789	FDA-Approved U.S. Professional Package Insert for Trileptal (Physician's Desk Reference (2006)).	2006
D-7790	FDA-Approved U.S. Professional Package Insert for Lyrica (Physician's Desk Reference (2006)).	2006
D-7791	FDA-Approved U.S. Professional Package Insert for Gabitril (Physician's Desk Reference (2005)).	2005
D-7792	FDA-Approved U.S. Professional Package Insert for Topamax (Physician's Desk Reference (2007)).	2007

D-7793	FDA-Approved U.S. Professional Package Insert for Depakote (Physician's Desk Reference (2006)).	2006
D-7794	FDA-Approved U.S. Professional Package Insert for Zonegran (Physician's Desk Reference (2007)).	2007
D-7795	FDA-Approved U.S. Professional Package Insert for Tegretol (Physician's Desk Reference (2006)).	2006
D-7796	FDA-Approved U.S. Professional Package Insert for Equetro (Physician's Desk Reference (2005)).	2005
D-7797	FDA-Approved U.S. Professional Package Insert for Felbatol (Physician's Desk Reference (2002)).	2002
D-7798	FDA-Approved U.S. Professional Package Insert for Lamictal (Physician's Desk Reference (2006)).	2006
D-7738	FDA-Approved U.S. Professional Package Insert for Keppra (Physician's Desk Reference (2007)).	2007
D-7799	Amitriptyline Hydrochloride Package Insert.	
D-7800	Nortriptyline Hydrochloride Package Insert.	
D-7801	Desipramine Hydrochloride Package Insert.	
D-7802	Carbamazepine Package Insert.	
D-7803	Valproate Sodium Package Insert.	
D-7804	FDA-Approved U.S. Professional Package Insert for Amitriptyline (Physician's Desk Reference (2001)).	2001
D-7805	FDA-Approved U.S. Professional Package Insert for Bextra (Physician's Desk Reference (2004)).	2004
D-7806	FDA-Approved U.S. Professional Package Insert for Celestone (Physician's Desk Reference (2001)).	2001
D-7807	FDA-Approved U.S. Professional Package Insert for Celestone (Physician's Desk Reference (2002)).	2002
D-7808	FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (1998)).	1998
D-7809	FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (1999)).	1999
D-7810	FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2000)).	2000
D-7811	FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2001)).	2001

D-7812	FDA-Approved U.S. Professional Package Insert for Darvocet N-100 (Physician's Desk Reference (2003)).	2003
D-7813	FDA-Approved U.S. Professional Package Insert for Demerol (Physician's Desk Reference (2003)).	2003
D-7814	FDA-Approved U.S. Professional Package Insert for Desipramine (Physician's Desk Reference (2003)).	2003
D-7815	FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2000)).	2000
D-7816	FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2003)).	2003
D-7817	FDA-Approved U.S. Professional Package Insert for Flexeril (Physician's Desk Reference (2004)).	2004
D-7818	FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (1998)).	1998
D-7819	FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2000)).	2000
D-7820	FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2003)).	2003
D-7821	FDA-Approved U.S. Professional Package Insert for Ibuprofen (Physician's Desk Reference (2004)).	2004
D-7822	FDA-Approved U.S. Professional Package Insert for Imipramine (Physician's Desk Reference (2003)).	2003
D-7823	FDA-Approved U.S. Professional Package Insert for Lexapro (Physician's Desk Reference (2003)).	2003
D-7824	FDA-Approved U.S. Professional Package Insert for Lortab (Physician's Desk Reference (2003)).	2003
D-7825	FDA-Approved U.S. Professional Package Insert for Lortab (Physician's Desk Reference (2004)).	2004
D-7826	FDA-Approved U.S. Professional Package Insert for Marcaine (Physician's Desk Reference (2001)).	2001
D-7827	FDA-Approved U.S. Professional Package Insert for Marcaine (Physician's Desk Reference (2002)).	2002
D-7828	FDA-Approved U.S. Professional Package Insert for Medrol (Physician's Desk Reference (2000)).	2000
D-7829	FDA-Approved U.S. Professional Package Insert for Naprosyn (Physician's Desk Reference (1999)).	1999
D-7830	FDA-Approved U.S. Professional Package Insert for Naprosyn (Physician's Desk Reference (2001)).	2001
D-7831	FDA-Approved U.S. Professional Package Insert for Neurontin (Physician's Desk Reference (2003)).	2003

D-7832	FDA-Approved U.S. Professional Package Insert for Neurontin (Physician's Desk Reference (2004)).	2004
D-7833	FDA-Approved U.S. Professional Package Insert for Percocet (Physician's Desk Reference (1998)).	1998
D-7834	FDA-Approved U.S. Professional Package Insert for Phenergan (Physician's Desk Reference (2003)).	2003
D-7835	FDA-Approved U.S. Professional Package Insert for Tylenol (Physician's Desk Reference (2003)).	2003
D-7836	FDA-Approved U.S. Professional Package Insert for Vioxx (Physician's Desk Reference (2000)).	2000
D-7837	FDA-Approved U.S. Professional Package Insert for Vioxx (Physician's Desk Reference (2001)).	2001

Dated: April 27, 2010

Respectfully submitted,

SKADDEN, ARPS, SLATE, MEAGHER & FLOM
LLP

By: /s/ Mark S. Cheffo
Mark S. Cheffo

Four Times Square
New York, New York 10036
Tel: (212) 735-3000
mark.cheffo@skadden.com

-and-

NEAL & HARWELL, PLC

By: /s/ Gerald D. Neenan
Aubrey B. Harwell, Jr., No. 002559
W. David Bridgers, No. 016603
Gerald D. Neenan, No. 006710

2000 One Nashville Place
150 Fourth Avenue, North
Nashville, TN 37219
(615) 244-1713
(615) 726-0573 (fax)

*Attorneys for Defendants Pfizer Inc and
Warner-Lambert Company LLC*

CERTIFICATE OF SERVICE

I hereby certify that on this the 27th day of April 2010, I electronically filed the foregoing document with the Clerk of the Court, United States District Court for the Middle District of Tennessee, using the CM/ECF system. True and correct copies of the foregoing documents are being served via the Court's CM/ECF system on the following:

Andrew G. Finkelstein, Esq.
Kenneth B. Fromson, Esq.
Finkelstein & Partners, LLP
1279 Route 300
Newburg, NY 12550

Charles F. Barrett, Esq.
Barrett & Associates, P.A.
6718 Highway 100, Suite 210
Nashville, TN 37205

Dara G. Hegar, Esq.
Ken S. Soh, Esq.
Maura Kolb, Esq.
Robert Leone, Esq.
W. Mark Lanier, Esq.
Lanier Law Firm
6810 FM 1960 West
Houston, TX 77069

/s/ Gerald D. Neenan